CONJUGATED PROTEINS AND USES THEREOF

Information

  • Patent Application
  • 20200278355
  • Publication Number
    20200278355
  • Date Filed
    September 27, 2018
    6 years ago
  • Date Published
    September 03, 2020
    4 years ago
Abstract
Disclosed herein, in certain embodiments, are protein-probe adducts and synthetic ligands that inhibit protein-probe adduct formation, in which the proteins are regulated by NRF2. In some instances, also described herein are protein-binding domains that interact with a probe and/or a ligand described herein, in which the proteins are regulated by NRF2.
Description
BACKGROUND OF THE DISCLOSURE

Protein function assignment has been benefited from genetic methods, such as target gene disruption, RNA interference, and genome editing technologies, which selectively disrupt the expression of proteins in native biological systems. Chemical probes offer a complementary way to perturb proteins that have the advantages of producing graded (dose-dependent) gain- (agonism) or loss- (antagonism) of-function effects that are introduced acutely and reversibly in cells and organisms. Small molecules present an alternative method to selectively modulate proteins and to serve as leads for the development of novel therapeutics.


SUMMARY OF THE DISCLOSURE

In certain embodiments, described herein are compositions that comprise cysteine-containing proteins that are regulated by NRF2. In some embodiments, disclosed herein is a protein-probe adduct wherein the probe binds to a cysteine residue illustrated in Tables 1A, 2, 3A, and 4; wherein the probe has a structure represented by Formula (I):




embedded image


wherein,

    • n is 0-8.


In some embodiments, disclosed herein is a synthetic ligand that inhibits a covalent interaction between a protein and a probe, wherein in the absence of the synthetic ligand, the probe binds to a cysteine residue illustrated in Tables 1A, 2, 3A, and 4; and wherein the probe has a structure represented by Formula (I):




embedded image


wherein,

    • n is 0-8


In some embodiments, disclosed herein is a protein binding domain wherein said protein binding domain comprises a cysteine residue illustrated in Tables 1A, 2, 3A, and 4, wherein said cysteine forms an adduct with a compound of Formula I,




embedded image




    • and wherein a compound of Formula IIA or Formula IIB interferes with the formation of the cysteine adduct by the compound of Formula I, wherein Formula (IIA) or Formula (IIB) have the structure:







embedded image




    • wherein,

    • each RA and RB is independently selected from the group consisting of H, D, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6fluoroalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C8cycloalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted C1-C3alkylene-aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted C1-C3alkylene-heteroaryl; or

    • RA and RB together with the nitrogen to which they are attached form a 5, 6, 7 or 8-membered heterocyclic ring A, optionally having one additional heteroatom moiety independently selected from NR1, O, or S; wherein A is optionally substituted; and
      • R1 is independently H, D, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6fluoroalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.








BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:



FIG. 1A-FIG. 1I illustrate chemical proteomic map of NRF2-regulated cysteines in NSCLC cells. FIG. 1A shows proliferation of KEAP1-mutant (H2122) and KEAP1-WT (H1975) cells expressing shRNAs targeting NRF2 (shNRF2) or a control (shGFP), as determined by measuring intracellular ATP concentrations. Data represent mean values+SD (n=6/group). FIG. 1B shows immunoblot of NRF2 in shNRF2- or shGFP-H2122 cells. FIG. 1C shows isoTOP-ABPP (R) ratios for cysteines in shNRF2- or shGFP-H2122 of -H1975 cells. Red data points mark R values≥2.5, which was used as a cutoff for NRF2-dependent changes in cysteine reactivity. Average R values from n=4-5 biological replicates per group are shown. FIG. 1D shows distribution of proteins harboring NRF2-regulated cysteines by functional class. FIG. 1E shows distribution of NRF2-regulated cysteines reflecting changes in reactivity versus protein expression. FIG. 1F shows representative proteins with NRF2-regulated changes in cysteine reactivity. Representative parent mass (MS1) profiles for tryptic peptides with IA-alkyne-reactive cysteines in shNRF2- (red) and shGFP- (blue) H2122 cells. Two cysteines are shown per protein, one with altered and the other with unaltered reactivity between shNRF2- and shGFP-H2122 cells. FIG. 1G shows representative MS1 profiles for cysteine-containing tryptic peptides in SQSTM1 in shNRF2- (red) and shGFP- (blue) H2122 cells (F). FIG. 1H shows immunoblot of GAPDH and PDIA3 expression in shNRF2- and shGFP-H1975 and H2122 cells. FIG. 1I shows GAPDH activity in shNRF2- and shGFP-H2122 and -H1975 cells. Data represent mean values+SD (n=16/group). ****p<0.0001 for shNRF2 versus shGFP groups. FIG. 1J glycolytic flux is impaired in shNRF2-H2122 cells. ECAR=extracellular acidification rate. Data represent mean values+SD (n=20-26/group) from three biological replicates. ***p<0.001, *p<0.05 for shNRF2 versus shGFP groups.



FIG. 2A-FIG. 2E illustrate cysteine ligandability mapping of KEAP1-mutant and KEAP1-WT NSCLC cells. FIG. 2A shows isoTOP-ABPP ratios (R values; DMSO/compound) for cysteines in H2122 cell (KEAP1-mutant) and H358 cell (KEAP1-WT) proteomes treated with DMSO or ‘scout’ fragments 2 or 3 (500 μM, 1 h). Red data points mark R values≥5, which was used as a cutoff for defining liganded cysteines. Average R values from n=3 biological replicates per group are shown. FIG. 2B shows a pie chart of NRF2-regulated genes/proteins in NSCLC cell lines denoting the subset that contain liganded cysteines (red). FIG. 2C shows cysteine ligandability map for representative NRF2 pathways. Blue marks proteins with liganded cysteines in NSCLC cells. ND, not detected. FIG. 2D shows Circos plot showing the overlap in liganded cysteines between KEAP1-mutant (red) and KEAP1-WT (black) NSCLC cells. Gray and blue chords represent liganded cysteines found in both KEAP1-WT and KEAP1-mutant cell lines and selectively in KEAP1-mutant cell lines, respectively. Numbers in parenthesis indicate total liganded cysteines per cell line. FIG. 2E shows immunoblot of AKR1B10, CYP4F11 and NR0B1 in shNRF2- and shGFP-H2122 cells.



FIG. 3A-FIG. 3B illustrate Characterization of liganded proteins selectively expressed in KEAP1-mutant NSCLC cells. FIG. 3A shows Heat map depicting RNAseq data in KEAP1-WT and KEAP1-mutant NSCLC cell lines for genes encoding NRF2-regulated proteins with liganded cysteines. RNAseq data obtained from (Klijn et al., Nat Biotechnol 33, 306-312, 2015) (also see FIG. 9A). FIG. 3B shows NR0B1, AKR1B10, and CYP4F11 expression in lung adenocarcinoma (LUAD) tumors grouped by NRF2/KEAP1 mutational status. Data obtained from TCGA.



FIG. 4A-FIG. 4E illustrate NR0B1 nucleates a transcriptional complex that supports the NRF2 gene-expression program. FIG. 4A shows intersection between NR0B1-regulated genes and transcriptional start sites (TSSs) bound by NR0B1. Outer circle: Chromosomes with cytogenetic bands. Middle circle: Whole genome plot of mapped NR0B1 reads (black) determined by ChIP-Seq corresponding to the transcriptional start sites (TSSs) of genes differentially expressed (up- (blue) or down- (red) regulated >1.5-fold) in shNR0B1-H460 cells compared to shGFP-H460 cells (inner circle). FIG. 4B shows overlap (left) and correlation (right) between genes up- (red) or down- (blue) regulated (>1.5-fold) in shNR0B1- and shNRF2-H460 cells compared to shGFP-H460 control cells. r and p values were determined by Pearson correlation analysis. FIG. 4C shows Heat map depicting RNAseq data for the indicated genes in shNR0B1-, shNRF2-, or shGFP-H460 cells. Expression was normalized by row. FIG. 4D shows Heat map representing NR0B1-interacting proteins in NSCLC cells. FIG. 4E shows endogenous NR0B1 co-immunoprecipitates with FLAG-RBM45 and FLAG-SNW1, but not control protein FLAG-RAP2A, in H460 cells, as determined by immunoblotting (left); right: schematic of NR0B1 protein interactions.



FIG. 5A-FIG. 5G show covalent ligand targeting C274 disrupts NR0B1 protein complexes. FIG. 5A shows co-crystal structure of mouse NR0B1 (white) and LRH1 (burnt orange) from (Sablin et al., 2008) highlighting the location of C274 (orange) at the protein interaction interface that is also flanked by AHC mutations: R267, V269 and L278 (red). FIG. 5B shows a schematic for an NR0B1-SNW1 in vitro-binding assay (Left) and an immunoblot showing that NR0B1 interacts with SNW1, but not a control (METAP2) protein (Right). FIG. 5C shows small molecule screen of electrophilic compounds (50 μM) for disruption of binding of FLAG-SNW1 to NR0B1 as shown in (B). Percentage of NR0B1 bound to SNW1 was normalized to vehicle (DMSO). A hit compound BPK-26 is marked in red. FIG. 5D shows structures of NR0B1 ligands (BPK-26 and BPK-29), clickable probe (BPK-29yne), and inactive control compounds (BPK-9 and BPK-27). FIG. 5E shows BPK-26 and BPK-29, but not BPK-9 and BPK-27, disrupt the in vitro interaction of FLAG-SWN1 with NR0B1. FIG. 5F shows BPK-29yne labels WT-NR0B1, but not an NR0B1-C274V mutant. HEK293T cells expressing the indicated proteins were treated with BPK-29 or vehicle (3 h) prior to treatment with BPK-29yne (30 min). Immunoprecipiated proteins were analyzed by in-gel fluorescence-scanning and immunoblotting. FIG. 5G shows BPK-29 disrupts protein interactions for NR0B1-WT, but not a NR0B1-C274V mutant. HEK293T cells expressing HA-NR0B1-WT or HA-NR0B1-C274V proteins were treated with DMSO or BPK-29, after which lysates were generated and evaluated for binding to FLAG-SNW1, as shown in (B).



FIG. 6A-FIG. 6F show characterization of NR0B1 ligands in KEAP1-mutant NSCLC cells. FIG. 6A shows isoTOP-ABPP of H460 cells treated with NR0B1 ligands and control compounds (40 μM, 3 h). Dashed lines designate R values≥3 (DMSO/compound), which was used as a cutoff to define cysteines liganded by the indicated compounds. Insets show MS1 profiles for C274 in NR0B1 for DMSO (blue) versus compound (red) treatment. Data are from individual experiments representative of at least three biological replicates. FIG. 6B shows a Venn diagram comparing the proteome-wide selectivity of NR0B1 ligands BPK-29 and BPK-26 and control compounds BPK-9 and BPK-27 in H460 cells as determined in (A). (See also Table 5). FIG. 6C shows BPK-29 and BPK-26 block the RBM45-NR0B1 interaction in H460 cells. H460 cells stably expressing FLAG-RBM45 were incubated with indicated compounds for 3 h, whereupon FLAG immunoprecipitates were performed and analyzed by immunoblotting. FIG. 6D shows concentration-dependent blockade of NR0B1 binding to FLAG-RBM45 by BPK-29 (left) and BPK-26 (right) in H460 cells. Experiments performed as described in (C). FIG. 6E shows SILAC ratio plots for light amino acid-labeled cells (pulse phase) switched into media containing heavy amino acids for 3 h (chase phase) followed by proteomic analysis. Dashed line designates R values (light/heavy) of <8, which was used as a cutoff for fast-turnover proteins. Inset shows MS1 peak ratio for NR0B1, which is among the top 5% of fast-turnover proteins. FIG. 6F shows proteins regulated by NRF2 in NSCLC cells are enriched in fast-turnover proteins. Charts comparing fraction of NRF2-regulated genes (as determined by RNAseq) for which the corresponding proteins are designated as fast or slow turnover (as determined in G) further divided into groups showing reduced expression (left) or not (right) on day 1 following NRF2 knockdown (as determined by isoTOP-ABPP).



FIG. 7A-FIG. 7L illustrate chemical proteomic map of NRF2-regulated cysteines in NSCLC cells. FIG. 7A shows immunoblot of NRF2 in H1975 (KEAP1-WT) and H2122 (KEAP1-mutant) cells. FIG. 7B shows immunoblot of NRF2 in H460 and A549 cells expressing shRNAs targeting NRF2 or GFP (control). FIG. 7C shows proliferation rates of KEAP1-mutant NSCLC cells expressing shRNAs targeting NRF2 (shNRF2) or a GFP control (shGFP), as determined by measuring intracellular ATP concentrations. Data represent mean values+SD (n=6/group). FIG. 7D shows proliferation rate of KEAP1-WT NSCLC H2009 cells expressing shRNAs targeting NRF2 (shNRF2) or a GFP control (shGFP), as determined by measuring intracellular ATP concentrations. Data represent mean values+SD (n=6/group). FIG. 7E shows intracellular GSH content in shNRF2- or shGFP-H2122 or -H1975 cells. Data represent mean values+SD (n=11/group), ****p<0.0001 for shNRF2 vs shGFP. FIG. 7F shows cytosolic H2O2 content is increased in shNRF2-H2122, but not shGFP-H2122 cells or shNRF2- or shGFP-H1975 cells. FACS analysis of cells treated with a PF6-AM probe that measures cytosolic H2O2. Data are representative plots from two biological replicates. FIG. 7G shows a schematic for the identification of NRF2-regulated cysteines by isoTOP-ABPP. Proteomes from cells expressing shRNAs as described in FIG. 7A are labeled with an alkynylated iodoacetamide probe (IA-alkyne, compound 1). Cysteines that are oxidized or modified with an electrophile (denoted as X) following NRF2 knockdown cannot further react with IA-alkyne. IA-alkyne-modified cysteines are conjugated by copper-catalyzed azide-alkyne cycloaddition (CuAAC or click) chemistry to isotopically differentiated azide-biotin tags, each containing a TEV cleavage sequence. The light (shNRF2) and heavy (shGFP) samples are mixed, and the IA-alkyne modified peptides are enriched and identified by liquid chromatography tandem mass-spectrometry (LC-MS/MS). The relative reactivity of cysteine residues in shGFP and shNRF2 samples is measured by quantifying the MS1 chromatographic peak ratios (heavy/light). In the theoretical example on the right, two cysteines are identified, with the one residue showing a five-fold quantified decrease in reactivity following NRF2 knockdown. FIG. 7H shows a timeline for measuring changes in cysteine reactivity by isoTOP-ABPP following NRF2 knockdown. FIG. 7I shows changes in cysteine reactivity following NRF2 knockdown at the indicated time points. FIG. 7J shows comparison of cysteine reactivity changes in H2122 or H1975 cells following NRF2 knockdown or treatment with staurosporine or AZD9291. H2122 and H1975 cells were treated with staurosporine (1 μM, 4 h). H1975 cells were treated with AZD9291 (1 μM, 24 h). Changes in cysteine reactivity were determined by isoTOP-ABPP as described in FIG. 7G. FIG. 7K shows analysis of apoptosis induction in NSCLC cells treated with staurosporine and EGFR blockade in H1975 cells treated with AZD9291. H2122 and H1975 cells were treated with staurosporine (1 μM, 4 h). H1975 cells were treated with AZD9291 (1 μM, 24 h). Apoptosis induction was assessed by measuring PARP1 cleavage; EGFR blockade was assessed by measuring autophosphorylation of residue Y1068. Proteins were analyzed by immunoblotting. FIG. 7L shows representative MS1 chromatograms of tryptic peptides containing IA-alkyne-reactive cysteines identified in isoTOP-ABPP experiments comparing shNRF2- (red) and shGFP- (blue) H1975 cells.



FIG. 8A-FIG. 8F illustrate cysteine ligandability landscape of KEAP1-mutant and KEAP1-WT NSCLC cells. FIG. 8A shows identification of liganded cysteines in NSCLC cell lines. isoTOP-ABPP ratios (R values; DMSO/compound) for cysteines in KEAP1-mutant (H460, A549) proteomes treated with DMSO or ‘scout’ fragments 2 or 3 (500 μM, 1 h). Red data points mark R values≥5, which was used as a cutoff for defining 2- or 3-liganded cysteines. Aggregate R values from n=3 biological replicates per group are shown. For cysteines quantified in more than one biological replicate, average ratios are reported. FIG. 8B shows identification of liganded cysteines in NSCLC cell lines. isoTOP-ABPP ratios (R values; DMSO/compound) for cysteines in KEAP1-WT (H1975, H2009 (expressing the luciferase protein)) proteomes treated with DMSO or ‘scout’ fragments 2 or 3 (500 μM, 1 h). Red data points mark R values≥5, which was used as a cutoff for defining 2- or 3-liganded cysteines. Aggregate R values from n=3 biological replicates per group are shown. For cysteines quantified in more than one biological replicate, average ratios are reported. FIG. 8C shows NRF2-regulated proteins and genes, defined as proteins showing reductions in cysteine reactivity (R values≥2.5) in isoTOP-ABPP experiments and genes showing reduction (≥2) in mRNA expression in RNA-seq experiments (see FIG. 1F). Gene expression changes were compiled from shNRF2-H2122 and shNRF2-H460 cells and siNRF2-A549 cells. Genes were defined as NRF2-regulated if they showed a two-fold or greater reduction in expression in two or more data sets. Proteins found to be regulated by NRF2 by both isoTOP-ABPP and RNA-seq are designated as “cysteine reactivity” in the graph. FIG. 8D shows Heat map summarizing liganded cysteines found in NRF2-regulated proteins across KEAP1-mutant and KEAP1-WT NSCLC cell lines. Cysteines were required to be liganded (R values≥5) by fragments 2 and/or 3 in two or more KEAP1-mutant or KEAP1-WT NSCLC lines for inclusion in the heat map. FIG. 8E shows immunoblot of AKR1B10, CYP4F11 and NR0B1 proteins in shNRF2- and shGFP-H460 cells. FIG. 8F shows NRF2 regulates the transcription of NR0B1, AKR1B10, and CYP4F11 genes as determined by RNAseq of H2122 or H460 cells expressing the indicated shRNAs. Data were normalized to shGFP and represent mean values+SD (n=3/group).



FIG. 9A-FIG. 9C illustrate characterization of liganded proteins selectively expressed in KEAP1-mutant NSCLC cells. FIG. 9A shows AKR1B10, CYP4F11 and NR0B1 expression is restricted to KEAP1-mutant cells. RNAseq analysis of genes encoding proteins with cysteine reactivity changes in NSCLC cell lines (see FIG. 8D) was determined across a panel of KEAP1-WT and KEAP1-mutant NSCLC cell lines. The graph displays the ratio of the average expression of the indicated genes (KEAP1-mutant/KEAP1-WT), with genes having a three-fold or greater difference marked in red. Also see FIG. 3A. FIG. 9B shows immunoblot of NR0B1, ARK1B10, and CYP4F11 expression across a representative panel of KEAP1-WT and KEAP1-mutant NSCLC cell lines. FIG. 9C shows expression of NRF2-regulated proteins/genes across normal tissues as measured by RNAseq. Expression was assessed for 53 human tissues from the GTEx portal (gtexportal.org). Genes were considered expressed in a given tissue if they had RPKM values>1. Liganded NRF2-regulated proteins were defined as those showing R values≥2.5 in isoTOP-ABPP experiments of shNRF2-NSCLC cells or reduced by gene expression (e.g., see FIG. 1E and FIG. 2D) and supplemented by NRF2-regulated genes as determined in (Goldstein et al., 2016). The subset of NRF2-regulated proteins/genes that were found to be liganded by scout fragments 2 and/or 3, including AKR1B10, CYP4F11, and NR0B1, are designated.



FIG. 10A-FIG. 10G illustrate NR0B1 nucleates a transcriptional complex that supports the NRF2 gene-expression program. FIG. 10A shows representative top-scoring functional terms enriched in genes down-regulated in shNR0B1-H460 cells compared to shGFP-H460 cells. Scores are calculated based on Benjamini-Hochberg corrected p-values. FIG. 10B shows Myc and E2F gene signatures are enriched in NR0B1-regulated genes. Gene set enrichment analysis (GSEA) was applied to all genes that were differentially expressed between shNR0B1-H460 cells and shGFP-H460 cells. Genes were ranked based on their FDR value. The FDR q-value was computed by GSEA. FIG. 10C shows identification of NR0B1-interacting proteins. FLAG immunoprecipitates were prepared from A549 cells expressing FLAG-NR0B1 or FLAG-METAP2 (control), and the proteins found in these immunoprecipitates were identified by LC-MS/MS. Enrichment of FLAG-NR0B1-interacting proteins was determined by taking the ratio between protein interactions with FLAG-NR0B1 and the control protein FLAG-METAP2. The dashed line marks proteins with a ratio above 20 (red) designated as FLAG-NR0B1 binding partners. FIG. 10D shows endogenous NR0B1 co-immunoprecipitates with FLAG-RBM45 or FLAG-SNW1 in A549 and H2122 cells. FLAG immunoprecipitates were prepared from A549 and H2122 cells stably expressing FLAG-SNW1 (left) or FLAG-RBM45 (right), or FLAG-RAP2A as a control. Cell lysates and immunoprecipitates were analyzed by immunoblotting for the indicated proteins. FIG. 10E shows NR0B1 nucleates a complex with SNW1 and RBM45. Recombinant HA-SNW1 co-immunoprecipitates FLAG-RBM45 in the presence, but not absence, of FLAG-NR0B1. HA immunoprecipitates were prepared from the indicated transfected HEK293T cells. HA immunoprecipitates were analyzed as above (D). FIG. 10F shows NR0B1 and NR0B1-interacting proteins (SNW1 and RBM45) colocalize to the nucleus. Images of A549 cells stably expressing FLAG-SNW1 or FLAG-RBM45 were co-immunostained for NR0B1, FLAG, HOECHST, and NQO1. Insets show selected fields that were magnified five times and their overlays. Scale bar=10 μm. FIG. 10G shows NR0B1 and SNW1-regulated genes in H460 cells are positively correlated as determined by Pearson correlation analysis. Genes in red are co-downregulated (≤1.5 fold) and genes in blue are co-upregulated (≥1.5 fold).



FIG. 11A-FIG. 11F illustrate a covalent ligand targeting Cys274 disrupts NR0B1 protein complexes. FIG. 11A shows structures and activities of BPK-26 and related compounds. See also FIG. 5C. FIG. 11B shows generating an advanced NR0B1 ligand. Top: Structures of screening hit BPK-28 and synthesized derivatives. Middle: Relative inhibition of FLAG-SNW1 binding to NR0B1 by BPK-28 and derivatives identifies BPK-29 as the most potent analogue (red). The In vitro-binding assay was performed as described in FIG. 5B using compounds at a concentration of 50 μM. Bottom: Data represent mean values±SD normalized to DMSO control. n=4/group. FIG. 11C shows concentration-dependent inhibition of the NR0B1-SNW1 interaction by NR0B1 ligands BPK-26 and BPK-29 and control compounds BPK-27 and BPK-9. Top: Compounds were tested as described in FIG. 5B. Bottom: Graph of concentration-dependent inhibition of NR0B1-SNW1 interactions by the indicated compounds. Percent binding was normalized to vehicle (DMSO). Data represent mean values±SD (n=2-5/group). FIG. 11D and FIG. 11E show NR0B1 ligands BPK-26 (D) and BPK-29 (E) covalently modify C274 in NR0B1. Lysate generate from HEK293T cell expressing FLAG-NR0B1 was treated with DMSO or BPK-26 (100 μM, 3 h, D). Alternatively, HEK293T cell expressing FLAG-NR0B1 were treated with DMSO or BPK-29 (50 μM, 3 h) in serum/dye-free RPMI (E) and lysates were generated. FLAG-immunoprecipitates were prepared from each lysate and subjected to proteolytic digestion, whereupon tryptic peptides harboring C274 were analyzed by LC-MS/MS. Extracted ion chromatogram for m/z value of the NR0B1 BPK-26- or BPK-29-modified tryptic peptide (m/z=1228.5992 and 1289.126, respectively) showing signals in BPK-26 or BPK-29-treated (blue), but not DMSO-treated (red) HEK293T cell samples. FIG. 11F shows BPK-29 competition of BPK-29yne labeling of NR0B1. HEK293T cells transiently expressing FLAG-NR0B1 were treated with BPK-29, control compound BPK-27, or vehicle for 3 h prior to treatment with BPK-29yne (30 min). Following cell lysis, FLAG-tagged proteins were immunoprecipiated and conjugated to an azide-TAMRA tag by CuAAC conjugation. Immunoprecipitates were analyzed by in-gel fluorescence-scanning to assess BPK-29yne labeling or by immunoblot for FLAG-NR0B1. C274 is required for BPK-26 inhibition of NR0B1. In a modified in vitro binding assay shown in FIG. 5B, HEK293T cells expressing HA-NR0B1-WT or an HA-NR0B1-C274V mutant were treated with DMSO or BPK-26 (20 μM, 3 h), after which lysates were and interaction with FLAG-SNW1 assessed.



FIG. 12A-FIG. 12G show characterization of NR0B1 ligands in Keap1-mutant NSCLC cells. FIG. 12A shows representative MS1 profiles showing concentration-dependent blockade of IA-alkyne labeling of C274 of NR0B1 (left) or C29 of TXN2 (middle) by BPK-29 and/or BPK-26 (right). Data obtained from isoTOP-ABPP experiments of H460 cells treated with compound (red traces) or DMSO (blue traces) for 3 h. FIG. 12B shows BPK-29 and BPK-26 selectively block IA-alkyne labeling of C274 among several other cysteine residues in NR0B1 quantified by isoTOP-ABPP. Shown are MS1 profiles for quantified cysteines in NR0B1 following treatment with BPK-29 (40 μM, red; top) BPK-26 (40 μM, red; bottom) or DMSO (blue) for 3 h. FIG. 12C shows schematic for BPK-29 competition experiments using the BPK-29yne probe in NSCLC cell lines. FIG. 12D shows CRISPR-generated KEAP1-null and NRF2-null HEK293T cells were analyzed for the expression of the indicated proteins by immunoblotting. FIG. 12 E shows BPK-29 and BPK-26 inhibit NR0B1 interaction with FLAG-RBM45 or FLAG-SNW1 in KEAP1-null HEK293T cells. KEAP1-null HEK293T cells stably expressing FLAG-RBM45 or FLAG-SNW1 were incubated with the indicated compounds for 3 h, after which FLAG immunoprecipitates were prepared from cell lysates. Immunoprecipitates and lysates were analyzed by immunoblotting for the indicated proteins. Dashed lines represent a lane that was cropped from this immunoblot. FIG. 12F shows BPK-29 and BPK-26 block NR0B1 binding to FLAG-RBM45 in H2122 and A549 cells. H2122 or A549 cells stably expressing FLAG-RBM45 were incubated with the indicated compounds for 3 h, after which FLAG immunoprecipitates were prepared. Immunoprecipitates and lysates were analyzed as described in (E). FIG. 12G shows concentration-dependent blockade of NR0B1 binding to its interacting proteins by BPK-29 and BPK-26 in H2122 and A549 cells. H2122 cells stably expressing FLAG-RBM45 or A549 cells stably expressing FLAG-SNW1 were incubated with indicated compounds for 3 h and FLAG immunoprecipitates were prepared and analyzed as described in (E).



FIG. 13A-FIG. 13E illustrate characterization of NR0B1 ligands in Keap1-mutant NSCLC cells. FIG. 13A shows representative genes co-downregulated in BPK-29-treated, shNR0B1, and shNRF2 H460 cells. Top: Heat map depicting changes in gene expression between H460 cells expressing shNRF2, shNR0B1 or a control (shGFP) and those treated with vehicle (DMSO), BPK-29 or BPK-9 (30 μM, 12 h). Expression for each condition was first normalized to appropriate controls (shGFP or DMSO) and then normalized by row. Bottom: Overlap between gene sets regulated in BPK-29-treated vs shNR0B1 H460 cells. Gene set enrichment analysis (GSEA) was applied to all genes that were differentially expressed between shNR0B1-H460 cells and shGFP-H460 cells or between H460 cells treated with BPK-29 or DMSO. Genes were ranked based on their FDR. The FDR q-value was computed by GSEA on the C2.all collection and a cut off of FDR<0.05 was required for a gene set to be considered enriched. FIG. 13B shows BPK-29 alters the expression of representative genes in KEAP1-mutant H460 cells, but not KEAP1-WT H2009 cells. H460 (left) or H2009 (right) cells were treated with vehicle, BPK-29, or BPK-9 (25 μM, 12 h). Gene expression changes for CRY1, DEPDC1, and CPLX2 were determined by qPCR and data represents mean values+SD (n=4-10). FIG. 13C shows BPK-29 alters the expression of representative genes in KEAP1-mutant H2122 cells. Cells were treated with the vehicle, BPK-29, or BPK-9 (30 μM, 12 h). Gene expression changes for Cry1, DEPDC1, and CPLX2 were determined by qPCR and data represents mean values+SD (n=4-6). FIG. 13D shows BPK-29 reduces CRY1 protein content in H460 cells. H460 cells were treated with vehicle or BPK-29 or BPK-9 at the indicated concentrations for 9 h. Protein expression was analyzed by immunoblotting. FIG. 13E shows NR0B1 is a rapidly degraded protein. Top: H460 cells were treated with cycloheximide (100 μg/mL) for the indicated time points and NR0B1 protein content assessed by immunoblotting. Bottom: NR0B1 half-life analysis. NR0B1 protein content was determined following cycloheximide treatment and data were fit into a one-phase exponential decay model. Data represent mean values+SD (n=4-10).



FIG. 14A-FIG. 14D illustrate an exemplary compound library described herein.





DETAILED DESCRIPTION OF THE DISCLOSURE

Cancer cells rewire central metabolic networks to provide a steady source of energy and building blocks needed for cell division and rapid growth. This demand for energy produces toxic metabolic byproducts, including reactive oxygen species (ROS), that, if left unchecked in some cases, promotes oxidative stress and impair cancer cell viability. Many cancers counter a rise in oxidative stress by activating the NRF2 pathway, a master regulator of the cellular antioxidant response. Under basal conditions, the bZip transcription factor NRF2 binds to the negative regulator KEAP1, which directs rapid and constitutive ubiquitination and proteasomal degradation of NRF2. Under conditions of oxidative stress, one or more cysteines in KEAP1 are oxidatively modified to block interaction with NRF2, stabilizing the transcription factor to allow for nuclear translocation and coordination of a gene expression program that induces detoxification and metabolic enzymes to restore redox homeostasis. Cancers stimulate NRF2 function in multiple ways, including genetic mutations in NRF2 and KEAP1 that disrupt their interaction and are found in >20% of non-small cell lung cancers (NSCLCs). Despite maturation in understanding how NRF2 becomes activated and promotes a transcriptional program that responds to oxidative stress, the underlying molecular mechanisms by which stimulation of this pathway imparts a survival and growth advantage to cancer cells remain poorly defined. Moreover, to date, only a handful of early-stage small molecules have been identified that inhibit NRF2 function, and as a consequence, oncogenic mutations in the KEAP1-NRF2 complex remain unactionable from a therapeutic perspective.


In some instances, cysteine plays several roles in protein regulations, including as nucleophiles in catalysis, as metal-binding residues, and as sites for post-translational modification. While low levels of ROS can stimulate cell growth, excessive ROS has damaging effects on many fundamental biochemical processes in cells, including, for instance, metabolic and protein homeostasis pathways. In some cases, activation of NRF2 in cancer cells serves to protect biochemical pathways from ROS-induced functional impairments.


Cysteine residues not only constitute sites for redox regulation of protein function, but also for covalent drug development. Both catalytic and non-catalytic cysteines in a wide range of proteins have been targeted with electrophilic small molecules to create covalent inhibitors for use as chemical probes and therapeutic agents. Some include, for example, ibrutinib, which targets Bruton's tyrosine kinase BTK for treatment of B-cell cancers and afatinib and AZD9291, which target mutant forms of EGFR for treatment of lung cancer.


Described herein, in certain embodiments, are protein-probe adducts and synthetic ligands that inhibit protein-probe adduct formation, in which the proteins are regulated by NRF2. In some instances, also described herein are protein-binding domains that interact with a probe and/or a ligand described herein, in which the proteins are regulated by NRF2.


In some embodiments, further described herein is a method of modulating or altering recruitment of neosubstrates to the ubiquitin proteasome pathway. In some instances, the method comprises covalent binding of a reactive residue on one or more proteins described below for modulation of substrate interaction. In some cases, the method comprises covalent binding of a reactive cysteine residue on one or more proteins described below for substrate modulation.


Small Molecule Compounds

In some embodiments, described herein is a probe with a structure represented by Formula (I):




embedded image


in which n is 0-8. In some instances, n is 1, 2, 3, 4, 5, 6, 7, or 8. In some instances, n is 1. In some instances, n is 2. In some instances, n is 3. In some instances, n is 4. In some instances, n is 5. In some instances, n is 6. In some instances, n is 7. In some instances, n is 8.


In some embodiments, described herein is a synthetic ligand having a structure represented by Formula II:




embedded image


wherein,

    • CRG-L is optional, and when present is a covalent reactive group comprising a Michael acceptor moiety, a leaving group moiety, or a moiety capable of forming a covalent bond to the thiol group of a cysteine residue, and L is a linker;
    • MRE is a molecular recognition element that is capable of interacting with the protein; and
    • RM is optional, and when present comprises a binding element that binds to a second protein or another compound.


In some embodiments, the Michael acceptor moiety comprises an alkene or an alkyne moiety. In some embodiments, the Michael acceptor moiety comprises an alkene moiety. In some embodiments, the Michael acceptor moiety comprises an alkyne moiety.


In some embodiments, L is a cleavable linker.


In some embodiments, L is a non-cleavable linker.


In some embodiments, MRE comprises a small molecule compound, a polynucleotide, a polypeptide or fragments thereof, or a peptidomimetic. In some embodiments, MRE comprises a small molecule compound. In some embodiments, MRE comprises a polynucleotide. In some embodiments, MRE comprises a polypeptide or fragments thereof. In some embodiments, MRE comprises a peptidomimetic.


In some embodiments, the synthetic ligand has a structure represented by Formula (IIA) or Formula (IIB):




embedded image


wherein,

    • each RA and RB is independently selected from the group consisting of H, D, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6fluoroalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C8cycloalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted C1-C3alkylene-aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted C1-C3alkylene-heteroaryl; or
    • RA and RB together with the nitrogen to which they are attached form a substituted or unsubstituted 5, 6, 7 or 8-membered heterocyclic ring A, optionally having one additional heteroatom moiety independently selected from NR1, O, or S; and
    • R1 is H, D, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6fluoroalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.


In some embodiments, RA is substituted or unsubstituted aryl, substituted or unsubstituted C1-C3alkylene-aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted C1-C3alkylene-heteroaryl. In some embodiments, RA is substituted or unsubstituted aryl. In some embodiments, RA is substituted or unsubstituted C1-C3alkylene-aryl. In some embodiments, RA is substituted or unsubstituted heteroaryl. In some embodiments, RA is substituted or unsubstituted C1-C3alkylene-heteroaryl.


In some embodiments, RB is substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In some embodiments, RB is substituted or unsubstituted C2-C7heterocycloalkyl. In some embodiments, RB is substituted or unsubstituted aryl. In some embodiments, RB is substituted or unsubstituted heteroaryl.


In some embodiments, RB is substituted C5-C7heterocycloalkyl, substituted with —C(═O)R2, wherein R2 is substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6fluoroalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl. In some embodiments, R2 is substituted or unsubstituted C1-C6alkyl. In some embodiments, R2 is substituted or unsubstituted C1-C6fluoroalkyl. In some embodiments, R2 is substituted or unsubstituted C1-C6heteroalkyl. In some embodiments, R2 is substituted or unsubstituted aryl. In some embodiments, R2 is substituted or unsubstituted heteroaryl.


In some embodiments, RB is substituted aryl. In some embodiments, RB is substituted or unsubstituted C1-C3alkylene-aryl.


In some embodiments, RA is H or D.


In some embodiments, RA and RB together with the nitrogen to which they are attached form a substituted 6 or 7-membered heterocyclic ring A.


In some embodiments, the heterocyclic ring A is substituted with —Y1—R1, wherein,

    • —Y1— is selected from the group consisting of —O—, —S—, —S(═O)—, —S(═O)2—, —S(═O)(═NR1)—, —CH2—, and —C(═O)—, and
    • R1 is H, D, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6fluoroalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.


Exemplary compounds include the compounds described in the following Tables:









TABLE 6









embedded image















embedded image


          Name







embedded image


3-((N-phenylacrylamido)methyl) benzoic acid







embedded image


3-acrylamido-N-phenyl-5- (trifluoromethyl)benzamide







embedded image


N-(3-(piperidin-1-ylsulfonyl)-5- (trifluoromethyl)phenyl) acrylamide







embedded image


N-(3-(morpholine-4-carbonyl)benzyl)- N-phenylacrylamide







embedded image


N-(2,3-dichlorobenzyl)-N- (4-phenoxy-3- (trifluoromethyl)phenyl) acrylamide







embedded image


5-(N-((6-chloropyridin-2-yl)methyl) acrylamido)-N- phenylpicolinamide









In one aspect, provided herein is an acceptable salt or solvate of a compound described in Table 6.









TABLE 7









embedded image















embedded image


          Name







embedded image


2-chloro-1-(4- ((6-methoxypyridin-3-yl) methyl)piperidin-1- yl)ethan-1-one







embedded image


2-chloro-1-(4-phenoxypiperidin- 1-yl)ethan-1-one







embedded image


2-chloro-1-(4-phenoxyazepan- 1-yl)ethan-1-one







embedded image


methyl 4-acetamido-5- (4-(2-chloro-N- phenylacetamido)piperidin- 1-yl)-5-oxopentanoate







embedded image


N-(1-(3-acetamidobenzoyl) piperidin-4-yl)-2-chloro-N- phenylacetamide







embedded image


2-chloro-N-(1-(3- morpholinobenzoyl) piperidin-4-yl)- N-phenylacetamide







embedded image


2-chloro-N-phenyl-N- (1-(pyrimidine- 4-carbonyl)piperidin- 4-yl)acetamide







embedded image


N-(1-benzoylazepan-4-yl)-2- chloro- N-phenylacetamide







embedded image


2-chloro-N-((1-(4- morpholinobenzoyl) piperidin-4- yl)methyl)-N-(pyrimidin-5-yl) acetamide







embedded image


N-(1-(1H-pyrrolo[2,3-b]pyridine- 2-carbonyl)piperidin-4- yl)-2-chloro-N-phenylacetamide







embedded image


2-chloro-N-(3-(N- phenylsulfamoyl)-5- (trifluoromethyl)phenyl) acetamide







embedded image


N-(1H-benzo[d]imidazol-5-yl)- N-benzyl-2- chloroacetamide







embedded image


N-benzyl-2-chloro-N-(4-oxo-3,4- dihydroquinazolin-6- yl)acetamide







embedded image


N-benzyl-4-((2-chloro-N- phenylacetamido)methyl)benzamide







embedded image


2-chloro-N-(3-fluorobenzyl)- N-(4-phenoxy-3- (trifluoromethyl)phenyl) acetamide







embedded image


2-chloro-N-(2,3-dichlorobenzyl)- N-(4-phenoxy-3- (trifluoromethyl)phenyl) acetamide







embedded image


2-chloro-N-(3-morpholinobenzyl)- N-(4-phenoxy-3- (trifluoromethyl)phenyl) acetamide







embedded image


N-(3-(1H-1,2,4-triazol-1-yl)benzyl)- 2-chloro-N-(4- phenoxy-3-(trifluoromethyl) phenyl)acetamide







embedded image


2-chloro-N-((3,4-dihydro-2H-benzo[b] [1,4]dioxepin-7- yl)methyl)-N-(4-phenoxy-3- (trifluoromethyl)phenyl)acetamide







embedded image


2-chloro-N-(3-chloro-2-fluorobenzyl)- N-(6-chloropyridin- 3-yl)acetamide







embedded image


N-(4-(benzyloxy)-3-methoxybenzyl)- N-(5-(tert-butyl)-2- methoxyphenyl)-2- chloroacetamide







embedded image


N-benzyl-2-chloro-N-(1-(2- methylbenzoyl)azepan-4- yl)acetamide







embedded image


N-benzyl-2-chloro-N-(1- (4-morpholinobenzoyl) azepan-4- yl)acetamide







embedded image


N-benzyl-2-chloro-N-(1- (4-phenoxybenzoyl) azepan-4- yl)acetamide







embedded image


N-benzyl-2-chloro-N-(1- (1-phenylpiperidine-4- carbonyl)azepan-4-yl) acetamide







embedded image


N-(1-(1H-benzo[d]imidazole- 2-carbonyl)azepan-4-yl)-N- benzyl-2-chloroacetamide







embedded image


N-(1-(1-naphthoyl)azepan- 4-yl)-N-benzyl-2- chloroacetamide







embedded image


N-(1-acetylazepan-4-yl)- N-benzyl-2-chloroacetamide







embedded image


2-chloro-N-(3- ethynylbenzyl)-N-(1-(4- morpholinobenzoyl) azepan-4-yl)acetamide









In one aspect, provided herein is an acceptable salt or solvate of a compound described in Table 7.


In some cases, the synthetic ligand is




embedded image


In some cases, the synthetic ligand is




embedded image


Any combination of the groups described above for the various variables is contemplated herein. Throughout the specification, groups and substituents thereof are chosen by one skilled in the field to provide stable moieties and compounds.


Further Forms of Compounds

In one aspect, the compound of Formula (II), Formula (IIA), or Formula (IIB) possesses one or more stereocenters and each stereocenter exists independently in either the R or S configuration. The compounds presented herein include all diastereomeric, enantiomeric, and epimeric forms as well as the appropriate mixtures thereof. The compounds and methods provided herein include all cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers as well as the appropriate mixtures thereof. In certain embodiments, compounds described herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds/salts, separating the diastereomers and recovering the optically pure enantiomers. In some embodiments, resolution of enantiomers is carried out using covalent diastereomeric derivatives of the compounds described herein. In another embodiment, diastereomers are separated by separation/resolution techniques based upon differences in solubility. In other embodiments, separation of stereoisomers is performed by chromatography or by the forming diastereomeric salts and separation by recrystallization, or chromatography, or any combination thereof. Jean Jacques, Andre Collet, Samuel H. Wilen, “Enantiomers, Racemates and Resolutions”, John Wiley And Sons, Inc., 1981. In one aspect, stereoisomers are obtained by stereoselective synthesis.


In another embodiment, the compounds described herein are labeled isotopically (e.g. with a radioisotope) or by another other means, including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.


Compounds described herein include isotopically-labeled compounds, which are identical to those recited in the various formulae and structures presented herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into the present compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, sulfur, fluorine and chlorine, such as, for example, 2H, 3H, 13C, 14C, 15N, 18O, 17O, 35S, 18F, 36Cl. In one aspect, isotopically-labeled compounds described herein, for example those into which radioactive isotopes such as 3H and 14C are incorporated, are useful in drug and/or substrate tissue distribution assays. In one aspect, substitution with isotopes such as deuterium affords certain therapeutic advantages resulting from greater metabolic stability, such as, for example, increased in vivo half-life or reduced dosage requirements.


Compounds described herein may be formed as, and/or used as, acceptable salts. The type of acceptable salts, include, but are not limited to: (1) acid addition salts, formed by reacting the free base form of the compound with an acceptable: inorganic acid, such as, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, metaphosphoric acid, and the like; or with an organic acid, such as, for example, acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, trifluoroacetic acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, 2-naphthalenesulfonic acid, 4-methylbicyclo-[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic acid, 4,4′-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, butyric acid, phenylacetic acid, phenylbutyric acid, valproic acid, and the like; (2) salts formed when an acidic proton present in the parent compound is replaced by a metal ion, e.g., an alkali metal ion (e.g. lithium, sodium, potassium), an alkaline earth ion (e.g. magnesium, or calcium), or an aluminum ion. In some cases, compounds described herein may coordinate with an organic base, such as, but not limited to, ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, dicyclohexylamine, tris(hydroxymethyl)methylamine. In other cases, compounds described herein may form salts with amino acids such as, but not limited to, arginine, lysine, and the like. Acceptable inorganic bases used to form salts with compounds that include an acidic proton, include, but are not limited to, aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like.


It should be understood that a reference to a pharmaceutically acceptable salt includes the solvent addition forms, particularly solvates. Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and may be formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of compounds described herein can be conveniently prepared or formed during the processes described herein. In addition, the compounds provided herein can exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein.


Synthesis of Compounds

In some embodiments, the synthesis of compounds described herein are accomplished using means described in the chemical literature, using the methods described herein, or by a combination thereof. In addition, solvents, temperatures and other reaction conditions presented herein may vary.


In other embodiments, the starting materials and reagents used for the synthesis of the compounds described herein are synthesized or are obtained from commercial sources, such as, but not limited to, Sigma-Aldrich, Fisher Scientific (Fisher Chemicals), and Acros Organics.


In further embodiments, the compounds described herein, and other related compounds having different substituents are synthesized using techniques and materials described herein as well as those that are recognized in the field, such as described, for example, in Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989), March, Advanced Organic Chemistry 4th Ed., (Wiley 1992); Carey and Sundberg, Advanced Organic Chemistry 4th Ed., Vols. A and B (Plenum 2000, 2001), and Green and Wuts, Protective Groups in Organic Synthesis 3rd Ed., (Wiley 1999) (all of which are incorporated by reference for such disclosure). General methods for the preparation of compounds as disclosed herein may be derived from reactions and the reactions may be modified by the use of appropriate reagents and conditions, for the introduction of the various moieties found in the formulae as provided herein. As a guide the following synthetic methods may be utilized.


In the reactions described, it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, in order to avoid their unwanted participation in reactions. A detailed description of techniques applicable to the creation of protecting groups and their removal are described in Greene and Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons, New York, N.Y., 1999, and Kocienski, Protective Groups, Thieme Verlag, New York, N.Y., 1994, which are incorporated herein by reference for such disclosure).


In one aspect, compounds are synthesized as described in the Examples section.


NRF2-Regulated Proteins and Protein-Probe Adducts

In some embodiments, described herein are cysteine-containing proteins that are regulated by NRF2. In some instances, the cysteine-containing proteins are NRF2-regulated proteins illustrated in Tables 1A, 2, 3A, and/or 4. In some cases, the cysteine-containing proteins are NRF2-regulated proteins illustrated in Tables 1A. In some cases, the cysteine-containing proteins are NRF2-regulated proteins illustrated in Tables 2. In some cases, the cysteine-containing proteins are NRF2-regulated proteins illustrated in Table 3A. In some cases, the cysteine-containing proteins are NRF2-regulated proteins illustrated in Table 4.


In some instances, Tables 1A, 2, 3A, and 4 further illustrate one or more cysteine residues of a listed NRF2-regulated protein for interaction with a probe and/or a ligand described herein. In some cases, the cysteine residue number of a NRF2-regulated protein is in reference to the respective UNIPROT identifier.


In some instances, a cysteine residue illustrated in Tables 1A, 2, 3A, and/or 4 is located from 10 Å to 60 Å away from an active site residue of the respective NRF2-regulated protein. In some instances, the cysteine residue is located at least 10 Å, 12 Å, 15 Å, 20 Å, 25 Å, 30 Å, 35 Å, 40 Å, 45 Å, or 50 Å away from an active site residue of the respective NRF2-regulated protein. In some instances, the cysteine residue is located about 10 Å, 12 Å, 15 Å, 20 Å, 25 Å, 30 Å, 35 Å, 40 Å, 45 Å, or 50 Å away from an active site residue of the respective NRF2-regulated protein.


In some embodiments, described herein include a protein-probe adduct wherein the probe binds to a cysteine residue illustrated in Tables 1A, 2, 3A, and 4; wherein the probe has a structure represented by Formula (I):




embedded image


wherein,

    • n is 0-8.


In some instances, n is 1, 2, 3, 4, 5, 6, 7, or 8. In some instances, n is 1. In some instances, n is 2. In some instances, n is 3. In some instances, n is 4. In some instances, n is 5. In some instances, n is 6. In some instances, n is 7. In some instances, n is 8.


In some instances, the probe binds to a cysteine residue illustrated in Table 1A. In some instances, the probe binds to a cysteine residue illustrated in Table 2. In some instances, the probe binds to a cysteine residue illustrated in Table 3A. In some cases, the probe binds to a cysteine residue illustrated in Table 4.


In some embodiments, the protein is ubiquitin carboxyl-terminal hydrolase 7 (USP7). In some cases, the cysteine residue is C223, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier Q93009. In some cases, the probe binds to C223 of USP7.


In some embodiments, the protein is B-cell lymphoma/leukemia 10 (BCL10). In some cases, the cysteine residue is C119 or C122, wherein the numberings of the amino acid positions correspond to the amino acid positions with the UniProt Identifier O95999. In some cases, the probe binds to C119 of BCL10. In other cases, the probe binds to C122 of BCL10.


In some embodiments, the protein is RAF proto-oncogene serine/threonine-protein kinase (RAF1). In some instances, the cysteine residue is C637, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P04049. In some cases, the probe binds to C637 of RAF1.


In some embodiments, the protein is nuclear receptor subfamily 2 group F member 6 (NR2F6). In some instances, the cysteine residue is C203 or C316, wherein the numberings of the amino acid positions correspond to the amino acid positions with the UniProt Identifier P10588. In some cases, the probe binds to C203 of NR2F6. In other cases, the probe binds to C316 of NR2F6.


In some embodiments, the protein is DNA-binding protein inhibitor ID-1 (ID1). In some instances, the cysteine residue is C17, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P41134. In some cases, the probe binds to C17 of ID1.


In some embodiments, the protein is Fragile X mental retardation syndrome-related protein 1 (FXR1). In some instances, the cysteine residue is C99, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P51114. In some cases, the probe binds to C99 or FXR1.


In some embodiments, the protein is Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4). In some instances, the cysteine residue is C883, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier O95819. In some cases, the probe binds to C883 of MAP4K4.


In some embodiments, the protein is Cathepsin B (CTSB). In some instances, the cysteine residue is C105 or C108, wherein the numberings of the amino acid positions correspond to the amino acid positions with the UniProt Identifier P07858. In some cases, the probe binds to C105 of CTSB. In other cases, the probe binds to C108 of CTSB.


In some embodiments, the protein is integrin beta-4 (ITGB4). In some instances, the cysteine residue is C245 or C288, wherein the numberings of the amino acid positions correspond to the amino acid positions with the UniProt Identifier P16144. In some cases, the probe binds to C245 of ITGB4. In other cases, the probe binds to C288 of ITGB4.


In some embodiments, the protein is TFIIH basal transcription factor complex helicase (ERCC2). In some instances, the cysteine residue is C663, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P18074. In some cases, the probe binds to C663 of ERCC2.


In some embodiments, the protein is nuclear receptor subfamily 4 group A member 1 (NR4A1). In some instances, the cysteine residue is C551, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P22736. In some cases, the probe binds to C551 of NR4A1.


In some embodiments, the protein is cytidine deaminase (CDA). In some instances, the cysteine residue is C8, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P32320. In some cases, the probe binds to C8 of CDA.


In some embodiments, the protein is sterol O-acyltransferase 1 (SOAT1). In some instances, the cysteine residue is C92, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P35610. In some cases, the probe binds to C92 of SOAT1.


In some embodiments, the protein is DNA mismatch repair protein Msh6 (MSH6). In some instances, the cysteine residue is C615, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P52701. In some cases, the probe binds to C615 of MSH6.


In some embodiments, the protein is telomeric repeat-binding factor 1 (TERF1). In some instances, the cysteine residue is C118, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P54274. In some cases, the probe binds to C118 of TERF1.


In some embodiments, the protein is NEDD8-conjugating enzyme Ubc12 (UBE2M). In some instances, the cysteine residue is C47, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P61081. In some cases, the probe binds to C47 of UBE2M.


In some embodiments, the protein is E3 ubiquitin-protein ligase TRIP12 (TRIP12). In some instances, the cysteine residue is C535, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier Q14669. In some cases, the probe binds to C535 of TRIP12.


In some embodiments, the protein is ubiquitin carboxyl-terminal hydrolase 10 (USP10). In some instances, the cysteine residue is C94, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier Q14694. In some cases, the probe binds to C94 of USP10.


In some embodiments, the protein is ubiquitin carboxyl-terminal hydrolase 30 (USP30). In some instances, the cysteine residue is C142, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier Q70CQ3. In some cases, the probe binds to C142 of USP30.


In some embodiments, the protein is nucleus accumbens-associated protein 1 (NACC1). In some instances, the cysteine residue is C301, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier Q96RE7. In some cases, the probe binds to C301 of NACC1.


In some embodiments, the protein is lymphoid-specific helicase (HELLS). In some instances, the cysteine residue is C277 or C836, wherein the numberings of the amino acid positions correspond to the amino acid positions with the UniProt Identifier Q9NRZ9. In some cases, the probe binds to C277 of HELLS. In other cases, the probe binds to C836 of HELLS.


In some embodiments, also described herein include a synthetic ligand that inhibits a covalent interaction between a protein and a probe, wherein in the absence of the synthetic ligand, the probe binds to a cysteine residue illustrated in Tables 1A, 2, 3A, and 4; and wherein the probe has a structure represented by Formula (I):




embedded image


wherein,

    • n is 0-8.


In some instances, n is 1, 2, 3, 4, 5, 6, 7, or 8. In some instances, n is 1. In some instances, n is 2. In some instances, n is 3. In some instances, n is 4. In some instances, n is 5. In some instances, n is 6. In some instances, n is 7. In some instances, n is 8.


In some instances, the probe binds to a cysteine residue illustrated in Table 1A. In some instances, the probe binds to a cysteine residue illustrated in Table 2. In some instances, the probe binds to a cysteine residue illustrated in Table 3A. In some instances, the probe binds to a cysteine residue illustrated in Table 4.


In some instances, the protein is ubiquitin carboxyl-terminal hydrolase 7 (USP7) and the cysteine residue is C223, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier Q93009. In some cases, the synthetic ligand inhibits a covalent interaction between C223 of USP7 and the probe.


In some instances, the protein is B-cell lymphoma/leukemia 10 (BCL10) and the cysteine residue is C119 or C122, wherein the numberings of the amino acid positions correspond to the amino acid positions with the UniProt Identifier O95999. In some cases, the synthetic ligand inhibits a covalent interaction between C119 or C122 of BCL10 and the probe.


In some instances, the protein is RAF proto-oncogene serine/threonine-protein kinase (RAF1) and the cysteine residue is C637, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P04049. In some cases, the synthetic ligand inhibits a covalent interaction between C637 of RAF 1 and the probe.


In some instances, the protein is nuclear receptor subfamily 2 group F member 6 (NR2F6) and the cysteine residue is C203 or C316, wherein the numberings of the amino acid positions correspond to the amino acid positions with the UniProt Identifier P10588. In some cases, the synthetic ligand inhibits a covalent interaction between C203 or C316 of NR2F6 and the probe.


In some instances, the protein is DNA-binding protein inhibitor ID-1 (ID1) and the cysteine residue is C17, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P41134. In some cases, the synthetic ligand inhibits a covalent interaction between C17 of ID1 and the probe.


In some instances, the protein is Fragile X mental retardation syndrome-related protein 1 (FXR1) and the cysteine residue is C99, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P51114. In some cases, the synthetic ligand inhibits a covalent interaction between C99 of FXR1 and the probe.


In some instances, the protein is Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) and the cysteine residue is C883, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier O95819. In some cases, the synthetic ligand inhibits a covalent interaction between C883 of MAP4K4 and the probe.


In some instances, the protein is Cathepsin B (CTSB) and the cysteine residue is C105 or C108, wherein the numberings of the amino acid positions correspond to the amino acid positions with the UniProt Identifier P07858. In some cases, the synthetic ligand inhibits a covalent interaction between C108 of CTSB and the probe.


In some instances, the protein is integrin beta-4 (ITGB4) and the cysteine residue is C245 or C288, wherein the numberings of the amino acid positions correspond to the amino acid positions with the UniProt Identifier P16144. In some cases, the synthetic ligand inhibits a covalent interaction between C245 or C288 of ITGB4 and the probe.


In some instances, the protein is TFIIH basal transcription factor complex helicase (ERCC2) and the cysteine residue is C663, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P18074. In some cases, the synthetic ligand inhibits a covalent interaction between C663 of ERCC2 and the probe.


In some instances, the protein is nuclear receptor subfamily 4 group A member 1 (NR4A1) and the cysteine residue is C551, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P22736. In some cases, the synthetic ligand inhibits a covalent interaction between C551 of NR4A1 and the probe.


In some instances, the protein is cytidine deaminase (CDA) and the cysteine residue is C8, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P32320. In some cases, the synthetic ligand inhibits a covalent interaction between C8 of CDA and the probe.


In some instances, the protein is sterol O-acyltransferase 1 (SOAT1) and the cysteine residue is C92, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P35610. In some cases, the synthetic ligand inhibits a covalent interaction between C92 of SOAT1 and the probe.


In some instances, the protein is DNA mismatch repair protein Msh6 (MSH6) and the cysteine residue is C615, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P52701. In some cases, the synthetic ligand inhibits a covalent interaction between C615 of MSH6 and the probe.


In some instances, the protein is telomeric repeat-binding factor 1 (TERF1) and the cysteine residue is C118, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P54274. In some cases, the synthetic ligand inhibits a covalent interaction between C118 of TERF1 and the probe.


In some instances, the protein is NEDD8-conjugating enzyme Ubc12 (UBE2M) and the cysteine residue is C47, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P61081. In some cases, the synthetic ligand inhibits a covalent interaction between C47 of UBE2M and the probe.


In some instances, the protein is E3 ubiquitin-protein ligase TRIP12 (TRIP12) and the cysteine residue is C535, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier Q14669. In some cases, the synthetic ligand inhibits a covalent interaction between C535 of TRIP12 and the probe.


In some instances, the protein is ubiquitin carboxyl-terminal hydrolase 10 (USP10) and the cysteine residue is C94, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier Q14694. In some cases, the synthetic ligand inhibits a covalent interaction between C94 of USP10 and the probe.


In some instances, the protein is ubiquitin carboxyl-terminal hydrolase 30 (USP30) and the cysteine residue is C142, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier Q70CQ3. In some cases, the synthetic ligand inhibits a covalent interaction between C142 of USP30 and the probe.


In some instances, the protein is nucleus accumbens-associated protein 1 (NACC1) and the cysteine residue is C301, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier Q96RE7. In some cases, the synthetic ligand inhibits a covalent interaction between C301 of NACC1 and the probe.


In some instances, the protein is lymphoid-specific helicase (HELLS) and the cysteine residue is C277 or C836, wherein the numberings of the amino acid positions correspond to the amino acid positions with the UniProt Identifier Q9NRZ9. In some cases, the synthetic ligand inhibits a covalent interaction between C277 or C836 of HELLS and the probe.


In some cases, the synthetic ligand comprises a structure represented by Formula II:




embedded image


wherein,

    • CRG-L is optional, and when present is a covalent reactive group comprising a Michael acceptor moiety, a leaving group moiety, or a moiety capable of forming a covalent bond to the thiol group of a cysteine residue, and L is a linker;
    • MRE is a molecular recognition element that is capable of interacting with the protein; and
    • RM is optional, and when present comprises a binding element that binds to a second protein or another compound.


In some cases, the Michael acceptor moiety comprises an alkene or an alkyne moiety.


In some instances, L is a cleavable linker. In other instances, L is a non-cleavable linker.


In some cases, MRE comprises a small molecule compound, a polynucleotide, a polypeptide or fragments thereof, or a peptidomimetic.


In some cases, the synthetic ligand has a structure represented by Formula (IIA) or Formula (IIB):




embedded image


wherein,

    • each RA and RB is independently selected from the group consisting of H, D, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6fluoroalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C8cycloalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted C1-C3alkylene-aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted C1-C3alkylene-heteroaryl; or
    • RA and RB together with the nitrogen to which they are attached form a substituted or unsubstituted 5, 6, 7 or 8-membered heterocyclic ring A, optionally having one additional heteroatom moiety independently selected from NR1, O, or S; and
    • R1 is independently H, D, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6fluoroalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.


In some instances, RA is substituted or unsubstituted aryl, substituted or unsubstituted C1-C3alkylene-aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted C1-C3alkylene-heteroaryl.


In some instances, RB is substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.


In some instances, RB is substituted C5-C7heterocycloalkyl, substituted with —C(═O)R2, wherein R2 is substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6fluoroalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.


In some instances, RB substituted or unsubstituted C1-C3alkylene-aryl.


In some instances, RA is H or D.


In some instances, RB is substituted aryl.


In some instances, RA and RB together with the nitrogen to which they are attached form a substituted 6 or 7-membered heterocyclic ring A.


In some instances, the heterocyclic ring A is substituted with —Y1—R1, wherein,

    • —Y1— is selected from the group consisting of —O—, —S—, —S(═O)—, —S(═O)2—, —S(═O)(═NR1)—, —CH2—, and —C(═O)—, and
    • R1 is independently H, D, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6fluoroalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.


In some cases, the synthetic ligand is: 2-chloro-1-(4-((6-methoxypyridin-3-yl)methyl)piperidin-1-yl)ethan-1-one; 2-chloro-1-(4-phenoxypiperidin-1-yl)ethan-1-one; 2-chloro-1-(4-phenoxyazepan-1-yl)ethan-1-one; methyl 4-acetamido-5-(4-(2-chloro-N-phenylacetamido)piperidin-1-yl)-5-oxopentanoate; N-(1-(3-acetamidobenzoyl)piperidin-4-yl)-2-chloro-N-phenylacetamide; 2-chloro-N-(1-(3-morpholinobenzoyl)piperidin-4-yl)-N-phenylacetamide; 2-chloro-N-phenyl-N-(1-(pyrimidine-4-carbonyl)piperidin-4-yl)acetamide; N-(1-benzoylazepan-4-yl)-2-chloro-N-phenylacetamide; 2-chloro-N-((1-(4-morpholinobenzoyl)piperidin-4-yl)methyl)-N-(pyrimidin-5-yl)acetamide; N-(1-(1H-pyrrolo[2,3-b]pyridine-2-carbonyl)piperidin-4-yl)-2-chloro-N-phenylacetamide; 3-((N-phenylacrylamido)methyl)benzoic acid; 3-acrylamido-N-phenyl-5-(trifluoromethyl)benzamide; N-(3-(piperidin-1-ylsulfonyl)-5-(trifluoromethyl)phenyl)acrylamide; 2-chloro-N-(3-(N-phenylsulfamoyl)-5-(trifluoromethyl)phenyl)acetamide; N-(1H-benzo[d]imidazol-5-yl)-N-benzyl-2-chloroacetamide; N-benzyl-2-chloro-N-(4-oxo-3,4-dihydroquinazolin-6-yl)acetamide; N-(3-(morpholine-4-carbonyl)benzyl)-N-phenylacrylamide; N-benzyl-4-((2-chloro-N-phenylacetamido)methyl)benzamide; 2-chloro-N-(3-fluorobenzyl)-N-(4-phenoxy-3-(trifluoromethyl)phenyl)acetamide; 2-chloro-N-(2,3-dichlorobenzyl)-N-(4-phenoxy-3-(trifluoromethyl)phenyl)acetamide; N-(2,3-dichlorobenzyl)-N-(4-phenoxy-3-(trifluoromethyl)phenyl)acrylamide; 2-chloro-N-(3-morpholinobenzyl)-N-(4-phenoxy-3-(trifluoromethyl)phenyl)acetamide; N-(3-(1H-1,2,4-triazol-1-yl)benzyl)-2-chloro-N-(4-phenoxy-3-(trifluoromethyl)phenyl)acetamide; 2-chloro-N-((3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yl)methyl)-N-(4-phenoxy-3-(trifluoromethyl)phenyl)acetamide; 5-(N-((6-chloropyridin-2-yl)methyl)acrylamido)-N-phenylpicolinamide; 2-chloro-N-(3-chloro-2-fluorobenzyl)-N-(6-chloropyridin-3-yl)acetamide; N-(4-(benzyloxy)-3-methoxybenzyl)-N-(5-(tert-butyl)-2-methoxyphenyl)-2-chloroacetamide; N-benzyl-2-chloro-N-(1-(2-methylbenzoyl)azepan-4-yl)acetamide; N-benzyl-2-chloro-N-(1-(4-morpholinobenzoyl)azepan-4-yl)acetamide; N-benzyl-2-chloro-N-(1-(4-phenoxybenzoyl)azepan-4-yl)acetamide; N-benzyl-2-chloro-N-(1-(1-phenylpiperidine-4-carbonyl)azepan-4-yl)acetamide; N-(1-(1H-benzo[d]imidazole-2-carbonyl)azepan-4-yl)-N-benzyl-2-chloroacetamide; N-(1-(1-naphthoyl)azepan-4-yl)-N-benzyl-2-chloroacetamide; N-(1-acetylazepan-4-yl)-N-benzyl-2-chloroacetamide; or 2-chloro-N-(3-ethynylbenzyl)-N-(1-(4-morpholinobenzoyl)azepan-4-yl)acetamide.


In some embodiments, the synthetic ligand further comprises a second moiety that interacts with a second protein. In some cases, the second protein is not a protein illustrated in Tables 1A, 2, 3A, and 4.


In some embodiments, additionally described herein include a protein binding domain wherein said protein binding domain comprises a cysteine residue illustrated in Tables 1A, 2, 3A, and 4, wherein said cysteine forms an adduct with a compound of Formula I,




embedded image




    • and wherein a compound of Formula IIA or Formula IIB interferes with the formation of the cysteine adduct by the compound of Formula I, wherein Formula (IIA) or Formula (IIB) have the structure:







embedded image




    • wherein,

    • each RA and RB is independently selected from the group consisting of H, D, substituted or unsubstituted C1-C6alkyl, substituted or unsubstituted C1-C6fluoroalkyl, substituted or unsubstituted C1-C6heteroalkyl, substituted or unsubstituted C3-C8cycloalkyl, substituted or unsubstituted C2-C7heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted C1-C3alkylene-aryl, substituted or unsubstituted heteroaryl, and substituted or unsubstituted C1-C3alkylene-heteroaryl; or

    • or RA and RB together with the nitrogen to which they are attached form a 5, 6, 7 or 8-membered heterocyclic ring A, optionally having one additional heteroatom moiety independently selected from NR1, O, or S; wherein A is optionally substituted.





In some instances, n is 1, 2, 3, 4, 5, 6, 7, or 8. In some instances, n is 1. In some instances, n is 2. In some instances, n is 3. In some instances, n is 4. In some instances, n is 5. In some instances, n is 6. In some instances, n is 7. In some instances, n is 8.


In some instances, the cysteine residue is illustrated in Table 1A. In some instances, the cysteine residue is illustrated in Table 2. In some instances, the cysteine residue is illustrated in Table 3A. In some instances, the cysteine residue is illustrated in Table 4.


In some instances, the protein is ubiquitin carboxyl-terminal hydrolase 7 (USP7) and the cysteine residue is C223, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier Q93009. In some cases, the protein binding domain comprises C223.


In some instances, the protein is B-cell lymphoma/leukemia 10 (BCL10) and the cysteine residue is C119 or C122, wherein the numberings of the amino acid positions correspond to the amino acid positions with the UniProt Identifier O95999. In some cases, the protein binding domain comprises C119 or C122.


In some instances, the protein is RAF proto-oncogene serine/threonine-protein kinase (RAF1) and the cysteine residue is C637, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P04049. In some cases, the protein binding domain comprises C637.


In some instances, the protein is nuclear receptor subfamily 2 group F member 6 (NR2F6) and the cysteine residue is C203 or C316, wherein the numberings of the amino acid positions correspond to the amino acid positions with the UniProt Identifier P10588. In some cases, the protein binding domain comprises C203 or C316.


In some instances, the protein is DNA-binding protein inhibitor ID-1 (ID1) and the cysteine residue is C17, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P41134. In some cases, the protein binding domain comprises C17.


In some instances, the protein is Fragile X mental retardation syndrome-related protein 1 (FXR1) and the cysteine residue is C99, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P51114. In some cases, the protein binding domain comprises C99.


In some instances, the protein is Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) and the cysteine residue is C883, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier O95819. In some cases, the protein binding domain comprises C883.


In some instances, the protein is Cathepsin B (CTSB) and the cysteine residue is C105 or C108, wherein the numberings of the amino acid positions correspond to the amino acid positions with the UniProt Identifier P07858. In some cases, the protein binding domain comprises C105 or C108.


In some instances, the protein is integrin beta-4 (ITGB4) and the cysteine residue is C245 or C288, wherein the numberings of the amino acid positions correspond to the amino acid positions with the UniProt Identifier P16144. In some cases, the protein binding domain comprises C245 or C288.


In some instances, the protein is TFIIH basal transcription factor complex helicase (ERCC2) and the cysteine residue is C663, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P18074. In some cases, the protein binding domain comprises C663.


In some instances, the protein is nuclear receptor subfamily 4 group A member 1 (NR4A1) and the cysteine residue is C551, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P22736. In some cases, the protein binding domain comprises C551.


In some instances, the protein is cytidine deaminase (CDA) and the cysteine residue is C8, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P32320. In some cases, the protein binding domain comprises C8.


In some instances, the protein is sterol O-acyltransferase 1 (SOAT1) and the cysteine residue is C92, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P35610. In some cases, the protein binding domain comprises C92.


In some instances, the protein is DNA mismatch repair protein Msh6 (MSH6) and the cysteine residue is C615, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P52701. In some cases, the protein binding domain comprises C615.


In some instances, the protein is telomeric repeat-binding factor 1 (TERF1) and the cysteine residue is C118, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P54274. In some cases, the protein binding domain comprises C118.


In some instances, the protein is NEDD8-conjugating enzyme Ubc12 (UBE2M) and the cysteine residue is C47, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P61081. In some cases, the protein binding domain comprises C47.


In some instances, the protein is E3 ubiquitin-protein ligase TRIP12 (TRIP12) and the cysteine residue is C535, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier Q14669. In some cases, the protein binding domain comprises C535.


In some instances, the protein is ubiquitin carboxyl-terminal hydrolase 10 (USP10) and the cysteine residue is C94, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier Q14694. In some cases, the protein binding domain comprises C94.


In some instances, the protein is ubiquitin carboxyl-terminal hydrolase 30 (USP30) and the cysteine residue is C142, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier Q70CQ3. In some cases, the protein binding domain comprises C142.


In some instances, the protein is nucleus accumbens-associated protein 1 (NACC1) and the cysteine residue is C301, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier Q96RE7. In some cases, the protein binding domain comprises C301.


In some instances, the protein is lymphoid-specific helicase (HELLS) and the cysteine residue is C277 or C836, wherein the numberings of the amino acid positions correspond to the amino acid positions with the UniProt Identifier Q9NRZ9. In some cases, the protein binding domain comprises C277 or C836.


In some embodiments, further described herein is a method for identifying a synthetic ligand that interacts with a protein comprising a cysteine residue illustrated in Tables 1A, 2, 3A, and 4, comprising exposing, in a reaction vessel, the protein to the synthetic ligand and a probe that has a structure represented by Formula (I):




embedded image


wherein,


n is 0-8; and


measuring the amount of the probe that has covalently bound to the cysteine residue relative to the amount of the probe that has covalently bound to the same cysteine residue in the absence of the synthetic ligand.


In some instances, the measuring includes one or more of the analysis methods described below.


In some instances, the cysteine residue is illustrated in Table 1A. In some instances, the cysteine residue is illustrated in Table 2. In some instances, the cysteine residue is illustrated in Table 3A. In some instances, the cysteine residue is illustrated in Table 4.


In some instances, the protein is ubiquitin carboxyl-terminal hydrolase 7 (USP7) and the cysteine residue is C223, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier Q93009. In some cases, the synthetic ligand inhibits a covalent interaction between C223 of USP7 and the probe.


In some instances, the protein is B-cell lymphoma/leukemia 10 (BCL10) and the cysteine residue is C119 or C122, wherein the numberings of the amino acid positions correspond to the amino acid positions with the UniProt Identifier O95999. In some cases, the synthetic ligand inhibits a covalent interaction between C119 or C122 of BCL10 and the probe.


In some instances, the protein is RAF proto-oncogene serine/threonine-protein kinase (RAF1) and the cysteine residue is C637, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P04049. In some cases, the synthetic ligand inhibits a covalent interaction between C637 of RAF1 and the probe.


In some instances, the protein is nuclear receptor subfamily 2 group F member 6 (NR2F6) and the cysteine residue is C203 or C316, wherein the numberings of the amino acid positions correspond to the amino acid positions with the UniProt Identifier P10588. In some cases, the synthetic ligand inhibits a covalent interaction between C203 or C316 of NR2F6 and the probe.


In some instances, the protein is DNA-binding protein inhibitor ID-1 (ID1) and the cysteine residue is C17, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P41134. In some cases, the synthetic ligand inhibits a covalent interaction between C17 of ID1 and the probe.


In some instances, the protein is Fragile X mental retardation syndrome-related protein 1 (FXR1) and the cysteine residue is C99, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P51114. In some cases, the synthetic ligand inhibits a covalent interaction between C99 of FXR1 and the probe.


In some instances, the protein is Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) and the cysteine residue is C883, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier O95819. In some cases, the synthetic ligand inhibits a covalent interaction between C883 of MAP4K4 and the probe.


In some instances, the protein is Cathepsin B (CTSB) and the cysteine residue is C105 or C108, wherein the numberings of the amino acid positions correspond to the amino acid positions with the UniProt Identifier P07858. In some cases, the synthetic ligand inhibits a covalent interaction between C108 of CTSB and the probe.


In some instances, the protein is integrin beta-4 (ITGB4) and the cysteine residue is C245 or C288, wherein the numberings of the amino acid positions correspond to the amino acid positions with the UniProt Identifier P16144. In some cases, the synthetic ligand inhibits a covalent interaction between C245 or C288 of ITGB4 and the probe.


In some instances, the protein is TFIIH basal transcription factor complex helicase (ERCC2) and the cysteine residue is C663, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P18074. In some cases, the synthetic ligand inhibits a covalent interaction between C663 of ERCC2 and the probe.


In some instances, the protein is nuclear receptor subfamily 4 group A member 1 (NR4A1) and the cysteine residue is C551, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P22736. In some cases, the synthetic ligand inhibits a covalent interaction between C551 of NR4A1 and the probe.


In some instances, the protein is cytidine deaminase (CDA) and the cysteine residue is C8, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P32320. In some cases, the synthetic ligand inhibits a covalent interaction between C8 of CDA and the probe.


In some instances, the protein is sterol O-acyltransferase 1 (SOAT1) and the cysteine residue is C92, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P35610. In some cases, the synthetic ligand inhibits a covalent interaction between C92 of SOAT1 and the probe.


In some instances, the protein is DNA mismatch repair protein Msh6 (MSH6) and the cysteine residue is C615, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P52701. In some cases, the synthetic ligand inhibits a covalent interaction between C615 of MSH6 and the probe.


In some instances, the protein is telomeric repeat-binding factor 1 (TERF1) and the cysteine residue is C118, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P54274. In some cases, the synthetic ligand inhibits a covalent interaction between C118 of TERF1 and the probe.


In some instances, the protein is NEDD8-conjugating enzyme Ubc12 (UBE2M) and the cysteine residue is C47, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P61081. In some cases, the synthetic ligand inhibits a covalent interaction between C47 of UBE2M and the probe.


In some instances, the protein is E3 ubiquitin-protein ligase TRIP12 (TRIP12) and the cysteine residue is C535, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier Q14669. In some cases, the synthetic ligand inhibits a covalent interaction between C535 of TRIP12 and the probe.


In some instances, the protein is ubiquitin carboxyl-terminal hydrolase 10 (USP10) and the cysteine residue is C94, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier Q14694. In some cases, the synthetic ligand inhibits a covalent interaction between C94 of USP10 and the probe.


In some instances, the protein is ubiquitin carboxyl-terminal hydrolase 30 (USP30) and the cysteine residue is C142, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier Q70CQ3. In some cases, the synthetic ligand inhibits a covalent interaction between C142 of USP30 and the probe.


In some instances, the protein is nucleus accumbens-associated protein 1 (NACC1) and the cysteine residue is C301, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier Q96RE7. In some cases, the synthetic ligand inhibits a covalent interaction between C301 of NACC1 and the probe.


In some instances, the protein is lymphoid-specific helicase (HELLS) and the cysteine residue is C277 or C836, wherein the numberings of the amino acid positions correspond to the amino acid positions with the UniProt Identifier Q9NRZ9. In some cases, the synthetic ligand inhibits a covalent interaction between C277 or C836 of HELLS and the probe.


Cells, Analytical Techniques, and Instrumentation

In certain embodiments, described herein are methods for profiling one or more of NRF2-regulated proteins to determine a reactive or ligandable cysteine residue. In some instances, the methods comprise profiling the NRF2-regulated proteins in situ. In other instances, the methods comprise profiling the NRF2-regulated proteins in vitro. In some instances, the methods comprising profiling the NRF2-regulated proteins utilize a cell sample or a cell lysate sample. In some embodiments, the cell sample or cell lysate sample is obtained from cells of an animal. In some instances, the animal cell includes a cell from a marine invertebrate, fish, insects, amphibian, reptile, or mammal. In some instances, the mammalian cell is a primate, ape, equine, bovine, porcine, canine, feline, or rodent. In some instances, the mammal is a primate, ape, dog, cat, rabbit, ferret, or the like. In some cases, the rodent is a mouse, rat, hamster, gerbil, hamster, chinchilla, or guinea pig. In some embodiments, the bird cell is from a canary, parakeet or parrots. In some embodiments, the reptile cell is from a turtles, lizard or snake. In some cases, the fish cell is from a tropical fish. In some cases, the fish cell is from a zebrafish (e.g. Danino rerio). In some cases, the worm cell is from a nematode (e.g. C. elegans). In some cases, the amphibian cell is from a frog. In some embodiments, the arthropod cell is from a tarantula or hermit crab.


In some embodiments, the cell sample or cell lysate sample is obtained from a mammalian cell. In some instances, the mammalian cell is an epithelial cell, connective tissue cell, hormone secreting cell, a nerve cell, a skeletal muscle cell, a blood cell, or an immune system cell.


Exemplary mammalian cells include, but are not limited to, 293A cell line, 293FT cell line, 293F cells, 293 H cells, HEK 293 cells, CHO DG44 cells, CHO-S cells, CHO-K1 cells, Expi293F™ cells, Flp-In™ T-REx™ 293 cell line, Flp-In™-293 cell line, Flp-In™-3T3 cell line, Flp-In™-BHK cell line, Flp-In™-CHO cell line, Flp-In™-CV-1 cell line, Flp-In™-Jurkat cell line, FreeStyle™ 293-F cells, FreeStyle™ CHO-S cells, GripTite™ 293 MSR cell line, GS-CHO cell line, HepaRG™ cells, T-REx™ Jurkat cell line, Per.C6 cells, T-REx™-293 cell line, T-REx™-CHO cell line, T-REx™-HeLa cell line, NC-HIMT cell line, and PC12 cell line.


In some instances, the cell sample or cell lysate sample is obtained from cells of a tumor cell line. In some instances, the cell sample or cell lysate sample is obtained from cells of a solid tumor cell line. In some instances, the solid tumor cell line is a sarcoma cell line. In some instances, the solid tumor cell line is a carcinoma cell line. In some embodiments, the sarcoma cell line is obtained from a cell line of alveolar rhabdomyosarcoma, alveolar soft part sarcoma, ameloblastoma, angiosarcoma, chondrosarcoma, chordoma, clear cell sarcoma of soft tissue, dedifferentiated liposarcoma, desmoid, desmoplastic small round cell tumor, embryonal rhabdomyosarcoma, epithelioid fibrosarcoma, epithelioid hemangioendothelioma, epithelioid sarcoma, esthesioneuroblastoma, Ewing sarcoma, extrarenal rhabdoid tumor, extraskeletal myxoid chondrosarcoma, extraskeletal osteosarcoma, fibrosarcoma, giant cell tumor, hemangiopericytoma, infantile fibrosarcoma, inflammatory myofibroblastic tumor, Kaposi sarcoma, leiomyosarcoma of bone, liposarcoma, liposarcoma of bone, malignant fibrous histiocytoma (MFH), malignant fibrous histiocytoma (MFH) of bone, malignant mesenchymoma, malignant peripheral nerve sheath tumor, mesenchymal chondrosarcoma, myxofibrosarcoma, myxoid liposarcoma, myxoinflammatory fibroblastic sarcoma, neoplasms with perivascular epitheioid cell differentiation, osteosarcoma, parosteal osteosarcoma, neoplasm with perivascular epitheioid cell differentiation, periosteal osteosarcoma, pleomorphic liposarcoma, pleomorphic rhabdomyosarcoma, PNET/extraskeletal Ewing tumor, rhabdomyosarcoma, round cell liposarcoma, small cell osteosarcoma, solitary fibrous tumor, synovial sarcoma, telangiectatic osteosarcoma.


In some embodiments, the carcinoma cell line is obtained from a cell line of adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, anaplastic carcinoma, large cell carcinoma, small cell carcinoma, anal cancer, appendix cancer, bile duct cancer (i.e., cholangiocarcinoma), bladder cancer, brain tumor, breast cancer, cervical cancer, colon cancer, cancer of Unknown Primary (CUP), esophageal cancer, eye cancer, fallopian tube cancer, gastroenterological cancer, kidney cancer, liver cancer, lung cancer, medulloblastoma, melanoma, oral cancer, ovarian cancer, pancreatic cancer, parathyroid disease, penile cancer, pituitary tumor, prostate cancer, rectal cancer, skin cancer, stomach cancer, testicular cancer, throat cancer, thyroid cancer, uterine cancer, vaginal cancer, or vulvar cancer.


In some instances, the cell sample or cell lysate sample is obtained from cells of a hematologic malignant cell line. In some instances, the hematologic malignant cell line is a T-cell cell line. In some instances, B-cell cell line. In some instances, the hematologic malignant cell line is obtained from a T-cell cell line of: peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), anaplastic large cell lymphoma, angioimmunoblastic lymphoma, cutaneous T-cell lymphoma, adult T-cell leukemia/lymphoma (ATLL), blastic NK-cell lymphoma, enteropathy-type T-cell lymphoma, hematosplenic gamma-delta T-cell lymphoma, lymphoblastic lymphoma, nasal NK/T-cell lymphomas, or treatment-related T-cell lymphomas.


In some instances, the hematologic malignant cell line is obtained from a B-cell cell line of: acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), acute monocytic leukemia (AMoL), chronic lymphocytic leukemia (CLL), high-risk chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), high-risk small lymphocytic lymphoma (SLL), follicular lymphoma (FL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia, multiple myeloma, extranodal marginal zone B cell lymphoma, nodal marginal zone B cell lymphoma, Burkitt's lymphoma, non-Burkitt high grade B cell lymphoma, primary mediastinal B-cell lymphoma (PMBL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, B cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, splenic marginal zone lymphoma, plasma cell myeloma, plasmacytoma, mediastinal (thymic) large B cell lymphoma, intravascular large B cell lymphoma, primary effusion lymphoma, or lymphomatoid granulomatosis.


In some embodiments, the cell sample or cell lysate sample is obtained from a tumor cell line. Exemplary tumor cell line includes, but is not limited to, 600MPE, AU565, BT-20, BT-474, BT-483, BT-549, Evsa-T, Hs578T, MCF-7, MDA-MB-231, SkBr3, T-47D, HeLa, DU145, PC3, LNCaP, A549, H1299, NCI-H460, A2780, SKOV-3/Luc, Neuro2a, RKO, RKO-AS45-1, HT-29, SW1417, SW948, DLD-1, SW480, Capan-1, MC/9, B72.3, B25.2, B6.2, B38.1, DMS153, SU.86.86, SNU-182, SNU-423, SNU-449, SNU-475, SNU-387, Hs817.T, LMH, LMH/2A, SNU-398, PLHC-1, HepG2/SF, OCI-Ly1, OCI-Ly2, OCI-Ly3, OCI-Ly4, OCI-Ly6, OCI-Ly7, OCI-Ly10, OCI-Ly18, OCI-Ly19, U2932, DB, HBL-1, RIVA, SUDHL2, TMD8, MEC1, MEC2, 8E5, CCRF-CEM, MOLT-3, TALL-104, AML-193, THP-1, BDCM, HL-60, Jurkat, RPMI 8226, MOLT-4, RS4, K-562, KASUMI-1, Daudi, GA-10, Raji, JeKo-1, NK-92, and Mino.


In some embodiments, the cell sample or cell lysate sample is from any tissue or fluid from an individual. Samples include, but are not limited to, tissue (e.g. connective tissue, muscle tissue, nervous tissue, or epithelial tissue), whole blood, dissociated bone marrow, bone marrow aspirate, pleural fluid, peritoneal fluid, central spinal fluid, abdominal fluid, pancreatic fluid, cerebrospinal fluid, brain fluid, ascites, pericardial fluid, urine, saliva, bronchial lavage, sweat, tears, ear flow, sputum, hydrocele fluid, semen, vaginal flow, milk, amniotic fluid, and secretions of respiratory, intestinal or genitourinary tract. In some embodiments, the cell sample or cell lysate sample is a tissue sample, such as a sample obtained from a biopsy or a tumor tissue sample. In some embodiments, the cell sample or cell lysate sample is a blood serum sample. In some embodiments, the cell sample or cell lysate sample is a blood cell sample containing one or more peripheral blood mononuclear cells (PBMCs). In some embodiments, the cell sample or cell lysate sample contains one or more circulating tumor cells (CTCs). In some embodiments, the cell sample or cell lysate sample contains one or more disseminated tumor cells (DTC, e.g., in a bone marrow aspirate sample).


In some embodiments, the cell sample or cell lysate sample is obtained from the individual by any suitable means of obtaining the sample using well-known and routine clinical methods. Procedures for obtaining tissue samples from an individual are well known. For example, procedures for drawing and processing tissue sample such as from a needle aspiration biopsy is well-known and is employed to obtain a sample for use in the methods provided. Typically, for collection of such a tissue sample, a thin hollow needle is inserted into a mass such as a tumor mass for sampling of cells that, after being stained, will be examined under a microscope.


Sample Preparation and Analysis


In some embodiments, a sample solution comprises a cell sample, a cell lysate sample, or a sample comprising isolated proteins. In some instances, the sample solution comprises a solution such as a buffer (e.g. phosphate buffered saline) or a media. In some embodiments, the media is an isotopically labeled media. In some instances, the sample solution is a cell solution.


In some embodiments, the solution sample (e.g., cell sample, cell lysate sample, or comprising isolated proteins) is incubated with a compound of Formula (I) for analysis of protein-probe interactions. In some instances, the solution sample (e.g., cell sample, cell lysate sample, or comprising isolated proteins) is further incubated in the presence of an additional compound probe prior to addition of the compound of Formula (I). In other instances, the solution sample (e.g., cell sample, cell lysate sample, or comprising isolated proteins) is further incubated with a ligand, in which the ligand does not contain a photoreactive moiety and/or an alkyne group. In such instances, the solution sample is incubated with a probe and a ligand for competitive protein profiling analysis.


In some cases, the cell sample or the cell lysate sample is compared with a control. In some cases, a difference is observed between a set of probe protein interactions between the sample and the control. In some instances, the difference correlates to the interaction between the small molecule fragment and the proteins.


In some embodiments, one or more methods are utilized for labeling a solution sample (e.g. cell sample, cell lysate sample, or comprising isolated proteins) for analysis of probe protein interactions. In some instances, a method comprises labeling the sample (e.g. cell sample, cell lysate sample, or comprising isolated proteins) with an enriched media. In some cases, the sample (e.g. cell sample, cell lysate sample, or comprising isolated proteins) is labeled with isotope-labeled amino acids, such as 13C or 15N-labeled amino acids. In some cases, the labeled sample is further compared with a non-labeled sample to detect differences in probe protein interactions between the two samples. In some instances, this difference is a difference of a target protein and its interaction with a small molecule ligand in the labeled sample versus the non-labeled sample. In some instances, the difference is an increase, decrease or a lack of protein-probe interaction in the two samples. In some instances, the isotope-labeled method is termed SILAC, stable isotope labeling using amino acids in cell culture.


In some embodiments, a method comprises incubating a solution sample (e.g. cell sample, cell lysate sample, or comprising isolated proteins) with a labeling group (e.g., an isotopically labeled labeling group) to tag one or more proteins of interest for further analysis. In such cases, the labeling group comprises a biotin, a streptavidin, bead, resin, a solid support, or a combination thereof, and further comprises a linker that is optionally isotopically labeled. As described above, the linker can be about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more residues in length and might further comprise a cleavage site, such as a protease cleavage site (e.g., TEV cleavage site). In some cases, the labeling group is a biotin-linker moiety, which is optionally isotopically labeled with 13C and 15N atoms at one or more amino acid residue positions within the linker. In some cases, the biotin-linker moiety is a isotopically-labeled TEV-tag as described in Weerapana, et al., “Quantitative reactivity profiling predicts functional cysteines in proteomes,” Nature 468(7325): 790-795.


In some embodiments, an isotopic reductive dimethylation (ReDi) method is utilized for processing a sample. In some cases, the ReDi labeling method involves reacting peptides with formaldehyde to form a Schiff base, which is then reduced by cyanoborohydride. This reaction dimethylates free amino groups on N-termini and lysine side chains and monomethylates N-terminal prolines. In some cases, the ReDi labeling method comprises methylating peptides from a first processed sample with a “light” label using reagents with hydrogen atoms in their natural isotopic distribution and peptides from a second processed sample with a “heavy” label using deuterated formaldehyde and cyanoborohydride. Subsequent proteomic analysis (e.g., mass spectrometry analysis) based on a relative peptide abundance between the heavy and light peptide version might be used for analysis of probe-protein interactions.


In some embodiments, isobaric tags for relative and absolute quantitation (iTRAQ) method is utilized for processing a sample. In some cases, the iTRAQ method is based on the covalent labeling of the N-terminus and side chain amines of peptides from a processed sample. In some cases, reagent such as 4-plex or 8-plex is used for labeling the peptides.


In some embodiments, the probe-protein complex is further conjugated to a chromophore, such as a fluorophore. In some instances, the probe-protein complex is separated and visualized utilizing an electrophoresis system, such as through a gel electrophoresis, or a capillary electrophoresis. Exemplary gel electrophoresis includes agarose based gels, polyacrylamide based gels, or starch based gels. In some instances, the probe-protein is subjected to a native electrophoresis condition. In some instances, the probe-protein is subjected to a denaturing electrophoresis condition.


In some instances, the probe-protein after harvesting is further fragmentized to generate protein fragments. In some instances, fragmentation is generated through mechanical stress, pressure, or chemical means. In some instances, the protein from the probe-protein complexes is fragmented by a chemical means. In some embodiments, the chemical means is a protease. Exemplary proteases include, but are not limited to, serine proteases such as chymotrypsin A, penicillin G acylase precursor, dipeptidase E, DmpA aminopeptidase, subtilisin, prolyl oligopeptidase, D-Ala-D-Ala peptidase C, signal peptidase I, cytomegalovirus assemblin, Lon-A peptidase, peptidase Clp, Escherichia coli phage K1F endosialidase CIMCD self-cleaving protein, nucleoporin 145, lactoferrin, murein tetrapeptidase LD-carboxypeptidase, or rhomboid-1; threonine proteases such as ornithine acetyltransferase; cysteine proteases such as TEV protease, amidophosphoribosyltransferase precursor, gamma-glutamyl hydrolase (Rattus norvegicus), hedgehog protein, DmpA aminopeptidase, papain, bromelain, cathepsin K, calpain, caspase-1, separase, adenain, pyroglutamyl-peptidase I, sortase A, hepatitis C virus peptidase 2, sindbis virus-type nsP2 peptidase, dipeptidyl-peptidase VI, or DeSI-1 peptidase; aspartate proteases such as beta-secretase 1 (BACE1), beta-secretase 2 (BACE2), cathepsin D, cathepsin E, chymosin, napsin-A, nepenthesin, pepsin, plasmepsin, presenilin, or renin; glutamic acid proteases such as AfuGprA; and metalloproteases such as peptidase_M48.


In some instances, the fragmentation is a random fragmentation. In some instances, the fragmentation generates specific lengths of protein fragments, or the shearing occurs at particular sequence of amino acid regions.


In some instances, the protein fragments are further analyzed by a proteomic method such as by liquid chromatography (LC) (e.g. high performance liquid chromatography), liquid chromatography-mass spectrometry (LC-MS), matrix-assisted laser desorption/ionization (MALDI-TOF), gas chromatography-mass spectrometry (GC-MS), capillary electrophoresis-mass spectrometry (CE-MS), or nuclear magnetic resonance imaging (NMR).


In some embodiments, the LC method is any suitable LC methods well known in the art, for separation of a sample into its individual parts. This separation occurs based on the interaction of the sample with the mobile and stationary phases. Since there are many stationary/mobile phase combinations that are employed when separating a mixture, there are several different types of chromatography that are classified based on the physical states of those phases. In some embodiments, the LC is further classified as normal-phase chromatography, reverse-phase chromatography, size-exclusion chromatography, ion-exchange chromatography, affinity chromatography, displacement chromatography, partition chromatography, flash chromatography, chiral chromatography, and aqueous normal-phase chromatography.


In some embodiments, the LC method is a high performance liquid chromatography (HPLC) method. In some embodiments, the HPLC method is further categorized as normal-phase chromatography, reverse-phase chromatography, size-exclusion chromatography, ion-exchange chromatography, affinity chromatography, displacement chromatography, partition chromatography, chiral chromatography, and aqueous normal-phase chromatography.


In some embodiments, the HPLC method of the present disclosure is performed by any standard techniques well known in the art. Exemplary HPLC methods include hydrophilic interaction liquid chromatography (HILIC), electrostatic repulsion-hydrophilic interaction liquid chromatography (ERLIC) and reverse phase liquid chromatography (RPLC).


In some embodiments, the LC is coupled to a mass spectroscopy as a LC-MS method. In some embodiments, the LC-MS method includes ultra-performance liquid chromatography-electrospray ionization quadrupole time-of-flight mass spectrometry (UPLC-ESI-QTOF-MS), ultra-performance liquid chromatography-electrospray ionization tandem mass spectrometry (UPLC-ESI-MS/MS), reverse phase liquid chromatography-mass spectrometry (RPLC-MS), hydrophilic interaction liquid chromatography-mass spectrometry (HILIC-MS), hydrophilic interaction liquid chromatography-triple quadrupole tandem mass spectrometry (HILIC-QQQ), electrostatic repulsion-hydrophilic interaction liquid chromatography-mass spectrometry (ERLIC-MS), liquid chromatography time-of-flight mass spectrometry (LC-QTOF-MS), liquid chromatography-tandem mass spectrometry (LC-MS/MS), multidimensional liquid chromatography coupled with tandem mass spectrometry (LC/LC-MS/MS). In some instances, the LC-MS method is LC/LC-MS/MS. In some embodiments, the LC-MS methods of the present disclosure are performed by standard techniques well known in the art.


In some embodiments, the GC is coupled to a mass spectroscopy as a GC-MS method. In some embodiments, the GC-MS method includes two-dimensional gas chromatography time-of-flight mass spectrometry (GC*GC-TOFMS), gas chromatography time-of-flight mass spectrometry (GC-QTOF-MS) and gas chromatography-tandem mass spectrometry (GC-MS/MS).


In some embodiments, CE is coupled to a mass spectroscopy as a CE-MS method. In some embodiments, the CE-MS method includes capillary electrophoresis-negative electrospray ionization-mass spectrometry (CE-ESI-MS), capillary electrophoresis-negative electrospray ionization-quadrupole time of flight-mass spectrometry (CE-ESI-QTOF-MS) and capillary electrophoresis-quadrupole time of flight-mass spectrometry (CE-QTOF-MS).


In some embodiments, the nuclear magnetic resonance (NMR) method is any suitable method well known in the art for the detection of one or more cysteine binding proteins or protein fragments disclosed herein. In some embodiments, the NMR method includes one dimensional (1D) NMR methods, two dimensional (2D) NMR methods, solid state NMR methods and NMR chromatography. Exemplary 1D NMR methods include 1Hydrogen, 13Carbon, 15Nitrogen, 17Oxygen, 19Fluorine, 31Phosphorus, 39Potassium, 23Sodium, 33Sulfur, 87Strontium, 27Aluminium, 43Calcium, 35Chlorine, 37Chlorine, 63Copper, 65Copper, 57Iron, 25Magnesium, 199Mercury or 67Zinc NMR method, distortionless enhancement by polarization transfer (DEPT) method, attached proton test (APT) method and 1D-incredible natural abundance double quantum transition experiment (INADEQUATE) method. Exemplary 2D NMR methods include correlation spectroscopy (COSY), total correlation spectroscopy (TOCSY), 2D-INADEQUATE, 2D-adequate double quantum transfer experiment (ADEQUATE), nuclear overhauser effect spectroscopy (NOSEY), rotating-frame NOE spectroscopy (ROESY), heteronuclear multiple-quantum correlation spectroscopy (HMQC), heteronuclear single quantum coherence spectroscopy (HSQC), short range coupling and long range coupling methods. Exemplary solid state NMR method include solid state 13Carbon NMR, high resolution magic angle spinning (HR-MAS) and cross polarization magic angle spinning (CP-MAS) NMR methods. Exemplary NMR techniques include diffusion ordered spectroscopy (DOSY), DOSY-TOCSY and DOSY-HSQC.


In some embodiments, the protein fragments are analyzed by method as described in Weerapana et al., “Quantitative reactivity profiling predicts functional cysteines in proteomes,” Nature, 468:790-795 (2010).


In some embodiments, the results from the mass spectroscopy method are analyzed by an algorithm for protein identification. In some embodiments, the algorithm combines the results from the mass spectroscopy method with a protein sequence database for protein identification. In some embodiments, the algorithm comprises ProLuCID algorithm, Probity, Scaffold, SEQUEST, or Mascot.


In some embodiments, a value is assigned to each of the protein from the probe-protein complex. In some embodiments, the value assigned to each of the protein from the probe-protein complex is obtained from the mass spectroscopy analysis. In some instances, the value is the area-under- the curve from a plot of signal intensity as a function of mass-to-charge ratio. In some instances, the value correlates with the reactivity of a Lys residue within a protein.


In some instances, a ratio between a first value obtained from a first protein sample and a second value obtained from a second protein sample is calculated. In some instances, the ratio is greater than 2.5, 3, 3.5, 4, 4.5, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20. In some cases, the ratio is at most 20.


In some instances, the ratio is calculated based on averaged values. In some instances, the averaged value is an average of at least two, three, or four values of the protein from each cell solution, or that the protein is observed at least two, three, or four times in each cell solution and a value is assigned to each observed time. In some instances, the ratio further has a standard deviation of less than 12, 10, or 8.


In some instances, a value is not an averaged value. In some instances, the ratio is calculated based on value of a protein observed only once in a cell population. In some instances, the ratio is assigned with a value of 20.


Kits/Article of Manufacture

Disclosed herein, in certain embodiments, are kits and articles of manufacture for use with one or more methods described herein. In some embodiments, described herein is a kit for generating a protein comprising a photoreactive ligand. In some embodiments, such kit includes photoreactive small molecule ligands described herein, small molecule fragments or libraries and/or controls, and reagents suitable for carrying out one or more of the methods described herein. In some instances, the kit further comprises samples, such as a cell sample, and suitable solutions such as buffers or media. In some embodiments, the kit further comprises recombinant proteins for use in one or more of the methods described herein. In some embodiments, additional components of the kit comprises a carrier, package, or container that is compartmentalized to receive one or more containers such as vials, tubes, and the like, each of the container(s) comprising one of the separate elements to be used in a method described herein. Suitable containers include, for example, bottles, vials, plates, syringes, and test tubes. In one embodiment, the containers are formed from a variety of materials such as glass or plastic.


The articles of manufacture provided herein contain packaging materials. Examples of pharmaceutical packaging materials include, but are not limited to, bottles, tubes, bags, containers, and any packaging material suitable for a selected formulation and intended mode of use.


For example, the container(s) include probes, test compounds, and one or more reagents for use in a method disclosed herein. Such kits optionally include an identifying description or label or instructions relating to its use in the methods described herein.


A kit typically includes labels listing contents and/or instructions for use, and package inserts with instructions for use. A set of instructions will also typically be included.


In one embodiment, a label is on or associated with the container. In one embodiment, a label is on a container when letters, numbers or other characters forming the label are attached, molded or etched into the container itself; a label is associated with a container when it is present within a receptacle or carrier that also holds the container, e.g., as a package insert. In one embodiment, a label is used to indicate that the contents are to be used for a specific therapeutic application. The label also indicates directions for use of the contents, such as in the methods described herein.


Certain Terminologies

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the claimed subject matter belongs. It is to be understood that the detailed description are exemplary and explanatory only and are not restrictive of any subject matter claimed. In this application, the use of the singular includes the plural unless specifically stated otherwise. It must be noted that, as used in the specification, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. In this application, the use of “or” means “and/or” unless stated otherwise. Furthermore, use of the term “including” as well as other forms, such as “include”, “includes,” and “included,” is not limiting.


Although various features of the invention may be described in the context of a single embodiment, the features may also be provided separately or in any suitable combination. Conversely, although the invention may be described herein in the context of separate embodiments for clarity, the invention may also be implemented in a single embodiment.


Reference in the specification to “some embodiments”, “an embodiment”, “one embodiment” or “other embodiments” means that a particular feature, structure, or characteristic described in connection with the embodiments is included in at least some embodiments, but not necessarily all embodiments, of the inventions.


As used herein, ranges and amounts can be expressed as “about” a particular value or range. About also includes the exact amount. Hence “about 5 μL” means “about 5 μL” and also “5 μL.” Generally, the term “about” includes an amount that would be expected to be within experimental error.


“Alkyl” refers to a straight or branched hydrocarbon chain radical, having from one to twenty carbon atoms, and which is attached to the rest of the molecule by a single bond. An alkyl comprising up to 10 carbon atoms is referred to as a C1-C10 alkyl, likewise, for example, an alkyl comprising up to 6 carbon atoms is a C1-C6 alkyl. Alkyls (and other moieties defined herein) comprising other numbers of carbon atoms are represented similarly. Alkyl groups include, but are not limited to, C1-C10 alkyl, C1-C9 alkyl, C1-C8 alkyl, C1-C7 alkyl, C1-C6 alkyl, C1-C5 alkyl, C1-C4 alkyl, C1-C3 alkyl, C1-C2 alkyl, C2-C8 alkyl, C3-C8 alkyl and C4-C8 alkyl. Representative alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, 1-methylethyl (i-propyl), n-butyl, i-butyl, s-butyl, n-pentyl, 1,1-dimethylethyl (t-butyl), 3-methylhexyl, 2-methylhexyl, 1-ethyl-propyl, and the like. In some embodiments, the alkyl is methyl or ethyl. In some embodiments, the alkyl is —CH(CH3)2 or —C(CH3)3. Unless stated otherwise specifically in the specification, an alkyl group may be optionally substituted as described below. “Alkylene” or “alkylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group. In some embodiments, the alkylene is —CH2—, —CH2CH2—, or —CH2CH2CH2—. In some embodiments, the alkylene is —CH2—. In some embodiments, the alkylene is —CH2CH2—. In some embodiments, the alkylene is —CH2CH2CH2—.


“Alkoxy” refers to a radical of the formula —OR where R is an alkyl radical as defined. Unless stated otherwise specifically in the specification, an alkoxy group may be optionally substituted as described below. Representative alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, pentoxy. In some embodiments, the alkoxy is methoxy. In some embodiments, the alkoxy is ethoxy.


“Heteroalkylene” refers to an alkyl radical as described above where one or more carbon atoms of the alkyl is replaced with a O, N or S atom. “Heteroalkylene” or “heteroalkylene chain” refers to a straight or branched divalent heteroalkyl chain linking the rest of the molecule to a radical group. Unless stated otherwise specifically in the specification, the heteroalkyl or heteroalkylene group may be optionally substituted as described below. Representative heteroalkyl groups include, but are not limited to —OCH2OMe, —OCH2CH2OMe, or —OCH2CH2OCH2CH2NH2. Representative heteroalkylene groups include, but are not limited to —OCH2CH2O—, —OCH2CH2OCH2CH2O—, or —OCH2CH2OCH2CH2OCH2CH2O—.


“Alkylamino” refers to a radical of the formula —NHR or —NRR where each R is, independently, an alkyl radical as defined above. Unless stated otherwise specifically in the specification, an alkylamino group may be optionally substituted as described below.


The term “aromatic” refers to a planar ring having a delocalized π-electron system containing 4n+2 π electrons, where n is an integer. Aromatics can be optionally substituted. The term “aromatic” includes both aryl groups (e.g., phenyl, naphthalenyl) and heteroaryl groups (e.g., pyridinyl, quinolinyl).


“Aryl” refers to an aromatic ring wherein each of the atoms forming the ring is a carbon atom. Aryl groups can be optionally substituted. Examples of aryl groups include, but are not limited to phenyl, and naphthyl. In some embodiments, the aryl is phenyl. Depending on the structure, an aryl group can be a monoradical or a diradical (i.e., an arylene group). Unless stated otherwise specifically in the specification, the term “aryl” or the prefix “ar-” (such as in “aralkyl”) is meant to include aryl radicals that are optionally substituted.


“Carboxy” refers to —CO2H. In some embodiments, carboxy moieties may be replaced with a “carboxylic acid bioisostere”, which refers to a functional group or moiety that exhibits similar physical and/or chemical properties as a carboxylic acid moiety. A carboxylic acid bioisostere has similar biological properties to that of a carboxylic acid group. A compound with a carboxylic acid moiety can have the carboxylic acid moiety exchanged with a carboxylic acid bioisostere and have similar physical and/or biological properties when compared to the carboxylic acid-containing compound. For example, in one embodiment, a carboxylic acid bioisostere would ionize at physiological pH to roughly the same extent as a carboxylic acid group. Examples of bioisosteres of a carboxylic acid include, but are not limited to:




embedded image


and the like.


“Cycloalkyl” refers to a monocyclic or polycyclic non-aromatic radical, wherein each of the atoms forming the ring (i.e. skeletal atoms) is a carbon atom. Cycloalkyls may be saturated, or partially unsaturated. Cycloalkyls may be fused with an aromatic ring (in which case the cycloalkyl is bonded through a non-aromatic ring carbon atom). Cycloalkyl groups include groups having from 3 to 10 ring atoms. Representative cycloalkyls include, but are not limited to, cycloalkyls having from three to ten carbon atoms, from three to eight carbon atoms, from three to six carbon atoms, or from three to five carbon atoms. Monocyclic cyclcoalkyl radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. In some embodiments, the monocyclic cyclcoalkyl is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. In some embodiments, the monocyclic cyclcoalkyl is cyclopentyl. Polycyclic radicals include, for example, adamantyl, norbornyl, decalinyl, and 3,4-dihydronaphthalen-1(2H)-one. Unless otherwise stated specifically in the specification, a cycloalkyl group may be optionally substituted.


“Fused” refers to any ring structure described herein which is fused to an existing ring structure. When the fused ring is a heterocyclyl ring or a heteroaryl ring, any carbon atom on the existing ring structure which becomes part of the fused heterocyclyl ring or the fused heteroaryl ring may be replaced with a nitrogen atom.


“Halo” or “halogen” refers to bromo, chloro, fluoro or iodo.


“Haloalkyl” refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like. Unless stated otherwise specifically in the specification, a haloalkyl group may be optionally substituted.


“Haloalkoxy” refers to an alkoxy radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethoxy, difluoromethoxy, fluoromethoxy, trichloromethoxy, 2,2,2-trifluoroethoxy, 1,2-difluoroethoxy, 3-bromo-2-fluoropropoxy, 1,2-dibromoethoxy, and the like. Unless stated otherwise specifically in the specification, a haloalkoxy group may be optionally substituted.


“Heterocycloalkyl” or “heterocyclyl” or “heterocyclic ring” refers to a stable 3- to 14-membered non-aromatic ring radical comprising 2 to 10 carbon atoms and from one to 4 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. Unless stated otherwise specifically in the specification, the heterocycloalkyl radical may be a monocyclic, or bicyclic ring system, which may include fused (when fused with an aryl or a heteroaryl ring, the heterocycloalkyl is bonded through a non-aromatic ring atom) or bridged ring systems. The nitrogen, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidized. The nitrogen atom may be optionally quaternized. The heterocycloalkyl radical is partially or fully saturated. Examples of such heterocycloalkyl radicals include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxo-thiomorpholinyl. The term heterocycloalkyl also includes all ring forms of carbohydrates, including but not limited to monosaccharides, disaccharides and oligosaccharides. Unless otherwise noted, heterocycloalkyls have from 2 to 10 carbons in the ring. In some embodiments, heterocycloalkyls have from 2 to 8 carbons in the ring. In some embodiments, heterocycloalkyls have from 2 to 8 carbons in the ring and 1 or 2 N atoms. In some embodiments, heterocycloalkyls have from 2 to 10 carbons, 0-2 N atoms, 0-2 O atoms, and 0-1 S atoms in the ring. In some embodiments, heterocycloalkyls have from 2 to 10 carbons, 1-2 N atoms, 0-1 O atoms, and 0-1 S atoms in the ring. It is understood that when referring to the number of carbon atoms in a heterocycloalkyl, the number of carbon atoms in the heterocycloalkyl is not the same as the total number of atoms (including the heteroatoms) that make up the heterocycloalkyl (i.e. skeletal atoms of the heterocycloalkyl ring). Unless stated otherwise specifically in the specification, a heterocycloalkyl group may be optionally substituted.


“Heteroaryl” refers to an aryl group that includes one or more ring heteroatoms selected from nitrogen, oxygen and sulfur. The heteroaryl is monocyclic or bicyclic. Illustrative examples of monocyclic heteroaryls include pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, pyridazinyl, triazinyl, oxadiazolyl, thiadiazolyl, furazanyl, indolizine, indole, benzofuran, benzothiophene, indazole, benzimidazole, purine, quinolizine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, quinoxaline, 1,8-naphthyridine, and pteridine. Illustrative examples of monocyclic heteroaryls include pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, pyridazinyl, triazinyl, oxadiazolyl, thiadiazolyl, and furazanyl. Illustrative examples of bicyclic heteroaryls include indolizine, indole, benzofuran, benzothiophene, indazole, benzimidazole, purine, quinolizine, quinoline, isoquinoline, cinnoline, phthalazine, quinazoline, quinoxaline, 1,8-naphthyridine, and pteridine. In some embodiments, heteroaryl is pyridinyl, pyrazinyl, pyrimidinyl, thiazolyl, thienyl, thiadiazolyl or furyl. In some embodiments, a heteroaryl contains 0-4 N atoms in the ring. In some embodiments, a heteroaryl contains 1-4 N atoms in the ring. In some embodiments, a heteroaryl contains 0-4 N atoms, 0-1 O atoms, and 0-1 S atoms in the ring. In some embodiments, a heteroaryl contains 1-4 N atoms, 0-1 O atoms, and 0-1 S atoms in the ring. In some embodiments, heteroaryl is a C1-C9heteroaryl. In some embodiments, monocyclic heteroaryl is a C1-C5heteroaryl. In some embodiments, monocyclic heteroaryl is a 5-membered or 6-membered heteroaryl. In some embodiments, a bicyclic heteroaryl is a C6-C9heteroaryl.


The term “optionally substituted” or “substituted” means that the referenced group may be substituted with one or more additional group(s) individually and independently selected from alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, —OH, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, arylsulfone, —CN, alkyne, C1-C6alkylalkyne, halogen, acyl, acyloxy, —CO2H, —CO2alkyl, nitro, and amino, including mono- and di-substituted amino groups (e.g. —NH2, —NHR, —N(R)2), and the protected derivatives thereof. In some embodiments, optional substituents are independently selected from alkyl, alkoxy, haloalkyl, cycloalkyl, halogen, —CN, —NH2, —NH(CH3), —N(CH3)2, —OH, —CO2H, and —CO2alkyl. In some embodiments, optional substituents are independently selected from fluoro, chloro, bromo, iodo, —CH3, —CH2CH3, —CF3, —OCH3, and —OCF3. In some embodiments, substituted groups are substituted with one or two of the preceding groups. In some embodiments, an optional substituent on an aliphatic carbon atom (acyclic or cyclic, saturated or unsaturated carbon atoms, excluding aromatic carbon atoms) includes oxo (═O).


The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.


EXAMPLES

These examples are provided for illustrative purposes only and not to limit the scope of the claims provided herein.


Example 1

Table 1A and Table 1B illustrate proteins and cysteine site residues described herein.












TABLE 1A





UNIPROT
RESIDUES
SYMBOL
DESCRIPTION







Q96RE7
C301
NACC1
NACC1 Nucleus accumbens-associated protein 1


Q14669
C535
TRIP12
TRIP12 E3 ubiquitin-protein ligase TRIP12


Q9NYG5
C7
ANAPC11
ANAPC11 Anaphase-promoting complex subunit 11


Q9UJX4
C203
ANAPC5
ANAPC5 Anaphase-promoting complex subunit 5


O14867
C646
BACH1
BACH1 Transcription regulator protein BACH1


Q9NV06
C87
DCAF13
DCAF13 DDB1- and CUL4-associated factor 13


Q96ME1
C459, C468
FBXL18
FBXL18 F-box/LRR-repeat protein 18


Q8N531
C368
FBXL6
FBXL6 F-box/LRR-repeat protein 6


Q9H2C0
C248
GAN
GAN Gigaxonin


O95714
C1005
HERC2
HERC2 E3 ubiquitin-protein ligase HERC2


Q14145
C319
KEAP1
KEAP1 Kelch-like ECH-associated protein 1


Q9NX47
C188
MARCH5
MARCH5 E3 ubiquitin-protein ligase MARCH5


O60291
C428
MGRN1
MGRN1 E3 ubiquitin-protein ligase MGRN1


Q96BF6
C393
NACC2
NACC2 Nucleus accumbens-associated protein 2


P49792
C206
RANBP2
RANBP2 E3 SUMO-protein ligase RanBP2


Q93009
C223
USP7
USP7 Ubiquitin carboxyl-terminal hydrolase 7


O95999
C122, C119
BCL10
BCL10 B-cell lymphoma/leukemia 10


P51114
C99
FXR1
FXR1 Fragile X mental retardation syndrome-related protein


P41134
C17
ID1
ID1 DNA-binding protein inhibitor ID-1


P10588
C203
NR2F6
NR2F6 Nuclear receptor subfamily 2 group F member 6


P10588
C316
NR2F6
NR2F6 Nuclear receptor subfamily 2 group F member 6


P04049
C637
RAF1
RAF1 RAF proto-oncogene serine/threonine-protein kinase


P32320
C8
CDA
CDA Cytidine deaminase


P07858
C108, C105
CTSB
CTSB Cathepsin B


P18074
C663
ERCC2
ERCC2 TFIIH basal transcription factor complex helicase


Q9NRZ9
C277
HELLS
HELLS Lymphoid-specific helicase


Q9NRZ9
C836
HELLS
HELLS Lymphoid-specific helicase


P16144
C245
ITGB4
ITGB4 Integrin beta-4


P16144
C288
ITGB4
ITGB4 Integrin beta-4


O95819
C883
MAP4K4
MAP4K4 Mitogen-activated protein kinase kinase kinase kin


P52701
C615
MSH6
MSH6 DNA mismatch repair protein Msh6


P22736
C551
NR4A1
NR4A1 Nuclear receptor subfamily 4 group A member 1


P35610
C92
SOAT1
SOAT1 Sterol O-acyltransferase 1


P54274
C118
TERF1
TERF1 Telomeric repeat-binding factor 1


P61081
C47
UBE2M
UBE2M NEDD8-conjugating enzyme Ubc12


Q14694
C94
USP10
USP10 Ubiquitin carboxyl-terminal hydrolase 10


Q70CQ3
C142
USP30
USP30 Ubiquitin carboxyl-terminal hydrolase 30


Q9UHD8
C375
SEPT9
SEPT9 Septin-9


Q9UHD8
C375, C375+
SEPT9
SEPT9 Septin-9


Q9UHD8
C531
SEPT9
SEPT9 Septin-9


Q5JTZ9
C609
AARS2
AARS2 Alanine-tRNA ligase, mitochondrial


O60706
C709
ABCC9
ABCC9 ATP-binding cassette sub-family C member 9


O60706
C788
ABCC9
ABCC9 ATP-binding cassette sub-family C member 9


Q8NE71
C807
ABCF1
ABCF1 ATP-binding cassette sub-family F member 1


Q9UG63
C586
ABCF2
ABCF2 ATP-binding cassette sub-family F member 2


Q9UG63
C388
ABCF2
ABCF2 ATP-binding cassette sub-family F member 2


Q8N2K0
C15, C34
ABHD12
ABHD12 Monoacylglycerol lipase ABHD12


Q9H845
C507
ACAD9
ACAD9 Acyl-CoA dehydrogenase family member 9,





mitochondria


Q9H568
C197
ACTL8
ACTL8 Actin-like protein 8


Q96D53
C285, C285+
ADCK4
ADCK4 Uncharacterized aarF domain-containing protein kin


Q96D53
C335
ADCK4
ADCK4 Uncharacterized aarF domain-containing protein kin


Q9BRR6
C40
ADPGK
ADPGK ADP-dependent glucokinase


Q8N556
C251
AFAP1
AFAP1 Actin filament-associated protein 1


Q96P47
C848
AGAP3
AGAP3 Arf-GAP with GTPase, ANK repeat and PH





domain-containing protein 3


Q53EU6
C306
AGPAT9
AGPAT9 Glycerol-3-phosphate acyltransferase 3


Q8WYP5
C693
AHCTF1
AHCTF1 Protein ELYS


P02765
C132
AHSG
AHSG Alpha-2-HS-glycoprotein


Q13155
C306
AIMP2
AIMP2 Aminoacyl tRNA synthase complex-interacting





multifunctional protein 2


O00170
C121
AIP
AIP AH receptor-interacting protein


Q99996
C3067
AKAP9
AKAP9 A-kinase anchor protein 9


Q99996
C3868
AKAP9
AKAP9 A-kinase anchor protein 9


O60218
C299
AKR1B10
AKR1B10 Aldo-keto reductase family 1 member B10


Q04828
C154
AKR1C1
AKR1C1 Aldo-keto reductase family 1 member C1


P42330
C154
AKR1C3
AKR1C3 Aldo-keto reductase family 1 member C3


P17516
C154
AKR1C4
AKR1C4 Aldo-keto reductase family 1 member C4


P31749
C310
AKT1
AKT1 RAC-alpha serine/threonine-protein kinase


P31751
C311
AKT2
AKT2 RAC-beta serine/threonine-protein kinase


Q9Y243
C307
AKT3
AKT3 RAC-gamma serine/threonine-protein kinase


P54886
C612, C606
ALDH18A1
ALDH18A1 Delta-1-pyrroline-5-carboxylate synthase


P00352
C303, C302
ALDH1A1
ALDH1A1 Retinal dehydrogenase 1


P00352
C303, C302
ALDH1A1
ALDH1A1 Retinal dehydrogenase 1


P47895
C314, C313
ALDH1A3
ALDH1A3 Aldehyde dehydrogenase family 1 member A3


P47895
C467
ALDH1A3
ALDH1A3 Aldehyde dehydrogenase family 1 member A3


Q3SY69
C445
ALDH1L2
ALDH1L2 Mitochondrial 10-formyltetrahydrofolate





dehydrogen


Q3SY69
C472
ALDH1L2
ALDH1L2 Mitochondrial 10-formyltetrahydrofolate





dehydrogen


Q3SY69
C608
ALDH1L2
ALDH1L2 Mitochondrial 10-formyltetrahydrofolate





dehydrogenase


P51648
C241, C237
ALDH3A2
ALDH3A2 Fatty aldehyde dehydrogenase


P51648
C241, C237+,
ALDH3A2
ALDH3A2 Fatty aldehyde dehydrogenase



C249, C241+,



C237


P51648
C249, C241+,
ALDH3A2
ALDH3A2 Fatty aldehyde dehydrogenase



C241


P51648
C241, C237+,
ALDH3A2
ALDH3A2 Fatty aldehyde dehydrogenase



C249, C241+,



C237


P51648
C249, C241+,
ALDH3A2
ALDH3A2 Fatty aldehyde dehydrogenase



C241


P51648
C241, C237
ALDH3A2
ALDH3A2 Fatty aldehyde dehydrogenase


P60006
C24
ANAPC15
ANAPC15 Anaphase-promoting complex subunit 15


Q8IWZ3
C181
ANKHD1
ANKHD1 Ankyrin repeat and KH domain-containing





protein 1


Q86XL3
C674
ANKLE2
ANKLE2 Ankyrin repeat and LEM domain-containing





protein 2


O75179
C210
ANKRD17
ANKRD17 Ankyrin repeat domain-containing protein 17


Q9BTT0
C87
ANP32E
ANP32E Acidic leucine-rich nuclear phosphoprotein 32





family, member E


Q63HQ0
C157
AP1AR
AP1AR AP-1 complex-associated regulatory protein


P61966
C47
AP1S1
AP1S1 AP-1 complex subunit sigma-1A


P56377
C46
AP1S2
AP1S2 AP-1 complex subunit sigma-2


Q9UPM8
C1119
AP4E1
AP4E1 AP-4 complex subunit epsilon-1


Q9UBZ4
C27
APEX2
APEX2 DNA-(apurinic or apyrimidinic site) lyase 2


Q6UXV4
C74
APOOL
APOOL Apolipoprotein O-like


O14497
C336
ARID1A
ARID1A AT-rich interactive domain-containing protein 1A


O14497
C336, C336+
ARID1A
ARID1A AT-rich interactive domain-containing protein 1A


P40616
C80
ARL1
ARL1 ADP-ribosylation factor-like protein 1


Q9NVP2
C201, C189
ASF1B
ASF1B Histone chaperone ASF1B


P00966
C331
ASS1
ASS1 Argininosuccinate synthase


Q76L83
C266
ASXL2
ASXL2 Putative Polycomb group protein ASXL2


Q8NBU5
C137
ATAD1
ATAD1 ATPase family AAA domain-containing protein 1


Q8NBU5
C359
ATAD1
ATAD1 ATPase family AAA domain-containing protein 1


Q6PL18
C635
ATAD2
ATAD2 ATPase family AAA domain-containing protein 2


Q5T9A4
C461+, C461
ATAD3B
ATAD3B ATPase family AAA domain-containing protein





3B


Q7Z3C6
C630
ATG9A
ATG9A Autophagy-related protein 9A


Q7L8W6
C88
ATPBD4
ATPBD4 ATP-binding domain-containing protein 4


Q9UBB4
C283
ATXN10
ATXN10 Ataxin-10


O14965
C33
AURKA
AURKA Aurora kinase A


Q9UIG0
C1045
BAZ1B
BAZ1B Tyrosine-protein kinase BAZ1B


O75815
C360
BCAR3
BCAR3 Breast cancer anti-estrogen resistance protein 3


O75815
C449
BCAR3
BCAR3 Breast cancer anti-estrogen resistance protein 3


P20749
C115
BCL3
BCL3 B-cell lymphoma 3 protein


Q02338
C288
BDH1
BDH1 D-beta-hydroxybutyrate dehydrogenase, mitochondria


O14503
C342
BHLHE40
BHLHE40 Class E basic helix-loop-helix protein 40


P55957
C15
BID
BID BH3-interacting domain death agonist


Q96IK1
C72
BOD1
BOD1 Biorientation of chromosomes in cell division protein


Q8NFC6
C74
BOD1L1
BOD1L1 Biorientation of chromosomes in cell division





protein


Q9Y3E2
C20
BOLA1
BOLA1 BolA-like protein 1


Q6PJG6
C487
BRAT1
BRAT1 BRCA1-associated ATM activator 1


Q6PJG6
C539
BRAT1
BRAT1 BRCA1-associated ATM activator 1


Q9NW68
C49
BSDC1
BSDC1 BSD domain-containing protein 1


O14981
C939, C936
BTAF1
BTAF1 TATA-binding protein-associated factor 172


Q9Y6E2
C97+, C97
BZW2
BZW2 Basic leucine zipper and W2 domain-containing





protein


Q14CZ0
C79
C16orf72
C16orf72 UPF0472 protein C16orf72


Q9HAS0
C204
C17orf75
C17orf75 Protein Njmu-R1


A6NDU8
C244
C5orf51
C5orf51 UPF0600 protein C5orf51


P20810
C413
CAST
CAST Calpastatin


Q96F63
C78
CCDC97
CCDC97 Coiled-coil domain-containing protein 97


O95273
C300
CCNDBP1
CCNDBP1 Cyclin-D1-binding protein 1


Q9UK58
C87
CCNL1
CCNL1 Cyclin-L1


Q8ND76
C238
CCNY
CCNY Cyclin-Y


Q8N7R7
C258
CCNYL1
CCNYL1 Cyclin-Y-like protein 1


Q9UK39
C302
CCRN4L
CCRN4L Nocturnin


P48643
C429
CCT5
CCT5 T-complex protein 1 subunit epsilon


Q00587
C161
CDC42EP1
CDC42EP1 Cdc42 effector protein 1


Q9BXL8
C130
CDCA4
CDCA4 Cell division cycle-associated protein 4


O95674
C286
CDS2
CDS2 Phosphatidate cytidylyltransferase 2


Q9H3R5
C35
CENPH
CENPH Centromere protein H


Q53EZ4
C159
CEP55
CEP55 Centrosomal protein of 55 kDa


Q53EZ4
C236
CEP55
CEP55 Centrosomal protein of 55 kDa


Q76N32
C695
CEP68
CEP68 Centrosomal protein of 68 kDa


Q9H078
C572
CLPB
CLPB Caseinolytic peptidase B protein homolog


P09497
C199
CLTB
CLTB Clathrin light chain B


Q969H4
C42
CNKSR1
CNKSR1 Connector enhancer of kinase suppressor of ras 1


Q99439
C274, C290
CNN2
CNN2 Calponin-2


Q15417
C173+, C173
CNN3
CNN3 Calponin-3


Q6PJW8
C192
CNST
CNST Consortin


Q9Y2Z9
C178
COQ6
COQ6 Ubiquinone biosynthesis monooxygenase COQ6


P31327
C761, C761+
CPS1
CPS1 Carbamoyl-phosphate synthase


P50416
C96
CPT1A
CPT1A Carnitine O-palmitoyltransferase 1, liver isoform


P55060
C939
CSE1L
CSE1L Exportin-2


O43310
C501
CTIF
CTIF CBP80/20-dependent translation initiation factor


O60716
C692
CTNND1
CTNND1 Catenin delta-1


P53634
C258, C255,
CTSC
CTSC Dipeptidyl peptidase 1



C258+


P53634
C258+, C258,
CTSC
CTSC Dipeptidyl peptidase 1



C255, C255+


P07339
C329
CTSD
CTSD Cathepsin D


Q9UBR2
C132, C154,
CTSZ
CTSZ Cathepsin Z



C126


Q9UBR2
C164
CTSZ
CTSZ Cathepsin Z


Q9UBR2
C170
CTSZ
CTSZ Cathepsin Z


Q9UBR2
C179
CTSZ
CTSZ Cathepsin Z


Q9UBR2
C214
CTSZ
CTSZ Cathepsin Z


O43169
C115
CYB5B
CYB5B Cytochrome b5 type B


Q07973
C113
CYP24A1
CYP24A1 1,25-dihydroxyvitamin D(3) 24-hydroxylase,





mitocho


Q07973
C303
CYP24A1
CYP24A1 1,25-dihydroxyvitamin D(3) 24-hydroxylase,





mitocho


Q9HBI6
C45
CYP4F11
CYP4F11 Cytochrome P450 4F11


Q9HBI6
C468+, C468
CYP4F11
CYP4F11 Cytochrome P450 4F11


Q08477
C468
CYP4F3
CYP4F3 Leukotriene-B(4) omega-hydroxylase 2


Q9NPI6
C39
DCP1A
DCP1A mRNA-decapping enzyme 1A


Q13561
C256, C240
DCTN2
DCTN2 Dynactin subunit 2


Q7Z4W1
C138
DCXR
DCXR L-xylulose reductase


Q92499
C406
DDX1
DDX1 ATP-dependent RNA helicase DDX1


Q9NVP1
C435, C435+
DDX18
DDX18 ATP-dependent RNA helicase DDX18


Q9Y6V7
C258
DDX49
DDX49 Probable ATP-dependent RNA helicase DDX49


Q9Y2R4
C536
DDX52
DDX52 Probable ATP-dependent RNA helicase DDX52


Q9NY93
C311, C298
DDX56
DDX56 Probable ATP-dependent RNA helicase DDX56


Q15392
C91
DHCR24
DHCR24 Delta(24)-sterol reductase


Q9BPW9
C203
DHRS9
DHRS9 Dehydrogenase/reductase SDR family member 9


Q14147
C189
DHX34
DHX34 Probable ATP-dependent RNA helicase DHX34


Q6P158
C65
DHX57
DHX57 Putative ATP-dependent RNA helicase DHX57


Q08211
C1029
DHX9
DHX9 ATP-dependent RNA helicase A


Q08211
C1029+, C1029
DHX9
DHX9 ATP-dependent RNA helicase A


Q9UNQ2
C125
DIMT1
DIMT1 Probable dimethyladenosine transferase


Q8TDM6
C1736
DLG5
DLG5 Disks large homolog 5


Q8IXB1
C703, C700
DNAJC10
DNAJC10 DnaJ homolog subfamily C member 10


Q8IXB1
C588
DNAJC10
DNAJC10 DnaJ homolog subfamily C member 10


Q8IXB1
C700
DNAJC10
DNAJC10 DnaJ homolog subfamily C member 10


Q8NBA8
C220
DTWD2
DTWD2 DTW domain-containing protein 2


Q14204
C978
DYNC1H1
DYNC1H1 Cytoplasmic dynein 1 heavy chain 1


Q96F86
C91
EDC3
EDC3 Enhancer of mRNA-decapping protein 3


Q05639
C370, C363
EEF1A2
EEF1A2 Elongation factor 1-alpha 2


P26641
C68
EEF1G
EEF1G Elongation factor 1-gamma


Q12805
C318, C320,
EFEMP1
EFEMP1 EGF-containing fibulin-like extracellular matrix p



C318+


Q12805
C332, C338
EFEMP1
EFEMP1 EGF-containing fibulin-like extracellular matrix p


Q12805
C224
EFEMP1
EFEMP1 EGF-containing fibulin-like extracellular matrix p


Q12805
C365
EFEMP1
EFEMP1 EGF-containing fibulin-like extracellular matrix p


Q7Z2Z2
C124
EFTUD1
EFTUD1 Elongation factor Tu GTP-binding domain-





containing


Q9BQ52
C51
ELAC2
ELAC2 Zinc phosphodiesterase ELAC protein 2


Q15723
C470
ELF2
ELF2 ETS-related transcription factor Elf-2


Q96N21
C52
ENTHD2
ENTHD2 AP-4 complex accessory subunit tepsin


Q9H6S3
C358
EPS8L2
EPS8L2 Epidermal growth factor receptor kinase substrate


O75477
C310
ERLIN1
ERLIN1 Erlin-1


O75477
C310+, C310
ERLIN1
ERLIN1 Erlin-1


Q96HE7
C37, C35
ERO1L
ERO1L ERO1-like protein alpha


Q96HE7
C166
ERO1L
ERO1L ERO1-like protein alpha


Q96HE7
C241
ERO1L
ERO1L ERO1-like protein alpha


Q96HE7
C37
ERO1L
ERO1L ERO1-like protein alpha


Q96HE7
C99
ERO1L
ERO1L ERO1-like protein alpha


Q9UJM3
C146, C142
ERRFI1
ERRFI1 ERBB receptor feedback inhibitor 1


Q9UJM3
C113
ERRFI1
ERRFI1 ERBB receptor feedback inhibitor 1


Q6NXG1
C551
ESRP1
ESRP1 Epithelial splicing regulatory protein 1


Q9H6T0
C581
ESRP2
ESRP2 Epithelial splicing regulatory protein 2


Q9BSJ8
C604, C611
ESYT1
ESYT1 Extended synaptotagmin-1


P38117
C131
ETFB
ETFB Electron transfer flavoprotein subunit beta


P38117
C42
ETFB
ETFB Electron transfer flavoprotein subunit beta


P38117
C42+, C42
ETFB
ETFB Electron transfer flavoprotein subunit beta


Q9NVH0
C109
EXD2
EXD2 Exonuclease 3-5 domain-containing protein 2


Q9NVH0
C133
EXD2
EXD2 Exonuclease 3-5 domain-containing protein 2


Q9NVH0
C227
EXD2
EXD2 Exonuclease 3-5 domain-containing protein 2


Q96KP1
C541
EXOC2
EXOC2 Exocyst complex component 2


Q5RKV6
C117
EXOSC6
EXOSC6 Exosome complex component MTR3


P00734
C391
F2
F2 Prothrombin


Q6P2I3
C215
FAHD2B
FAHD2B Fumarylacetoacetate hydrolase domain-





containing pr


Q5VSL9
C769
FAM40A
FAM40A Protein FAM40A


Q6ZRV2
C550
FAM83H
FAM83H Protein FAM83H


Q9NSD9
C195
FARSB
FARSB Phenylalanine--tRNA ligase beta subunit


Q9NYY8
C283
FASTKD2
FASTKD2 FAST kinase domain-containing protein 2


Q7L8L6
C685, C689
FASTKD5
FASTKD5 FAST kinase domain-containing protein 5


Q7L8L6
C689+, C685,
FASTKD5
FASTKD5 FAST kinase domain-containing protein 5



C689


P37268
C374
FDFT1
FDFT1 Squalene synthase


Q14192
C51, C49
FHL2
FHL2 Four and a half LIM domains protein 2


Q8N6M3
C251
FITM2
FITM2 Fat storage-inducing transmembrane protein 2


P21333
C205, C210
FLNA
FLNA Filamin-A


P21333
C1260
FLNA
FLNA Filamin-A


O75369
C183, C178
FLNB
FLNB Filamin-B


O75369
C660
FLNB
FLNB Filamin-B


P02751
C2367, C2371
FN1
FN1 Fibronectin


P02751
C76, C78
FN1
FN1 Fibronectin


P02751
C2317
FN1
FN1 Fibronectin


Q12841
C113
FSTL1
FSTL1 Follistatin-related protein 1


Q9UI43
C126
FTSJ2
FTSJ2 Putative ribosomal RNA methyltransferase 2


Q8N0W3
C582
FUK
FUK L-fucose kinase


Q9BUM1
C269
G6PC3
G6PC3 Glucose-6-phosphatase 3


O14976
C190
GAK
GAK Cyclin-G-associated kinase


Q8WXI9
C308
GATAD2B
GATAD2B Transcriptional repressor p66-beta


Q8WXI9
C308, C308+
GATAD2B
GATAD2B Transcriptional repressor p66-beta


Q92538
C158
GBF1
GBF1 Golgi-specific brefeldin A-resistance guanine nucl


Q96PP8
C309
GBP5
GBP5 Guanylate-binding protein 5


Q92947
C115
GCDH
GCDH Glutaryl-CoA dehydrogenase, mitochondrial


Q92616
C1275
GCN1L1
GCN1L1 Translational activator GCN1


Q92616
C1362
GCN1L1
GCN1L1 Translational activator GCN1


Q7L5L3
C243, C245
GDPD3
GDPD3 Glycerophosphodiester phosphodiesterase domain-





con


P57678
C210
GEMIN4
GEMIN4 Gem-associated protein 4


Q8TEQ6
C1255
GEMIN5
GEMIN5 Gem-associated protein 5


Q96RP9
C146, C153
GFM1
GFM1 Elongation factor G, mitochondrial


P62873
C294
GNB1
GNB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T)


P62873
C317
GNB1
GNB1 Guanine nucleotide-binding protein G(I)/G(S)/G(T)


P62879
C294
GNB2
GNB2 Guanine nucleotide-binding protein G(I)/G(S)/G(T)


P62879
C317
GNB2
GNB2 Guanine nucleotide-binding protein G(I)/G(S)/G(T)


P63244
C182
GNB2L1
GNB2L1 Guanine nucleotide-binding protein subunit beta-2-


Q9BVP2
C158
GNL3
GNL3 Guanine nucleotide-binding protein-like 3


Q08379
C356
GOLGA2
GOLGA2 Golgin subfamily A member 2


P35052
C401
GPC1
GPC1 Glypican-1


Q3KR37
C210
GRAMD1B
GRAMD1B GRAM domain-containing protein 1B


Q12849
C29
GRSF1
GRSF1 G-rich sequence factor 1


Q12789
C853
GTF3C1
GTF3C1 General transcription factor 30 polypeptide 1


Q9Y5Q9
C607
GTF3C3
GTF3C3 General transcription factor 30 polypeptide 3


Q9NYZ3
C198
GTSE1
GTSE1 G2 and S phase-expressed protein 1


P84243
C111
H3F3B
H3F3B Histone H3.3


P40939
C470
HADHA
HADHA Trifunctional enzyme subunit alpha, mitochondrial


P40939
C550
HADHA
HADHA Trifunctional enzyme subunit alpha, mitochondrial


P53701
C46, C35
HCCS
HCCS Cytochrome c-type heme lyase


P53701
C66
HCCS
HCCS Cytochrome c-type heme lyase


Q9H583
C1899, C1895
HEATR1
HEATR1 HEAT repeat-containing protein 1


Q9H583
C1942
HEATR1
HEATR1 HEAT repeat-containing protein 1


P68431
C97, C111
HIST1H3J
HIST1H3J Histone H3.1


P68431
C97, C111,
HIST1H3J
HIST1H3J Histone H3.1



C111+


Q2TB90
C517
HKDC1
HKDC1 Putative hexokinase HKDC1


P01892
C188
HLA-A
HLA-A HLA class I histocompatibility antigen, A-2 alpha


P01889
C188
HLA-B
HLA-B HLA class I histocompatibility antigen, B-7 alpha


Q29960
C188
HLA-C
HLA-C HLA class I histocompatibility antigen, Cw-16 alph


F8VZB9
C225
HLA-C
HLA-C HLA class I histocompatibility antigen, Cw-14 alph


Q1KMD3
C538
HNRNPUL2
HNRNPUL2 Heterogeneous nuclear ribonucleoprotein U-





like pro


P84074
C185
HPCA
HPCA Neuron-specific calcium-binding protein hippocalcin


Q96IR7
C168
HPDL
HPDL 4-hydroxyphenylpyruvate dioxygenase-like protein


Q96IR7
C82
HPDL
HPDL 4-hydroxyphenylpyruvate dioxygenase-like protein


P15428
C152
HPGD
HPGD 15-hydroxyprostaglandin dehydrogenase


P15428
C182
HPGD
HPGD 15-hydroxyprostaglandin dehydrogenase


Q86YV9
C695
HPS6
HPS6 Hermansky-Pudlak syndrome 6 protein


Q99714
C58
HSD17B10
HSD17B10 3-hydroxyacyl-CoA dehydrogenase type-2


Q6YN16
C218+, C218
HSDL2
HSDL2 Hydroxysteroid dehydrogenase-like protein 2


O43301
C246
HSPA12A
HSPA12A Heat shock 70 kDa protein 12A


O14558
C46
HSPB6
HSPB6 Heat shock protein beta-6


P10809
C237
HSPD1
HSPD1 60 kDa heat shock protein, mitochondrial


A1L0T0
C354
ILVBL
ILVBL Acetolactate synthase-like protein


Q9NV31
C107
IMP3
IMP3 U3 small nucleolar ribonucleoprotein protein IMP3


P20839
C327, C331
IMPDH1
IMPDH1 Inosine-5-monophosphate dehydrogenase 1


Q27J81
C284
INF2
INF2 Inverted formin-2


Q27J81
C898
INF2
INF2 Inverted formin-2


Q8N201
C1833
INTS1
INTS1 Integrator complex subunit 1


Q96HW7
C926
INTS4
INTS4 Integrator complex subunit 4


Q8TEX9
C350
IPO4
IPO4 Importin-4


O00410
C473
IPO5
IPO5 Importin-5


P35568
C436
IRS1
IRS1 Insulin receptor substrate 1


P05556
C301
ITGB1
ITGB1 Integrin beta-1


Q14573
C1558
ITPR3
ITPR3 Inositol 1,4,5-trisphosphate receptor type 3


Q8IWB1
C280+, C280,
ITPRIP
ITPRIP Inositol 1,4,5-trisphosphate receptor-interacting



C288


P14923
C457
JUP
JUP Junction plakoglobin


Q7LBC6
C529
KDM3B
KDM3B Lysine-specific demethylase 3B


Q15004
C99
KIAA0101
KIAA0101 PCNA-associated factor


Q14807
C72
KIF22
KIF22 Kinesin-like protein KIF22


O95239
C153
KIF4A
KIF4A Chromosome-associated kinesin KIF4A


O95239
C190
KIF4A
KIF4A Chromosome-associated kinesin KIF4A


Q2VIQ3
C153
KIF4B
KIF4B Chromosome-associated kinesin KIF4B


Q2VIQ3
C190
KIF4B
KIF4B Chromosome-associated kinesin KIF4B


Q9BW19
C663
KIFC1
KIFC1 Kinesin-like protein KIFC1


P52294
C210
KPNA1
KPNA1 Importin subunit alpha-1


O60684
C208
KPNA6
KPNA6 Importin subunit alpha-7


Q14974
C585
KPNB1
KPNB1 Importin subunit beta-1


Q8N9T8
C537
KRI1
KRI1 Protein KRI1 homolog


P13646
C21
KRT13
KRT13 Keratin, type I cytoskeletal 13


Q04695
C40
KRT17
KRT17 Keratin, type I cytoskeletal 17


Q04695
C60
KRT17
KRT17 Keratin, type I cytoskeletal 17


P19013
C118
KRT4
KRT4 Keratin, type II cytoskeletal 4


P02538
C51
KRT6A
KRT6A Keratin, type II cytoskeletal 6A


P02538
C77
KRT6A
KRT6A Keratin, type II cytoskeletal 6A


Q6KB66
C244
KRT80
KRT80 Keratin, type II cytoskeletal 80


Q6KB66
C49
KRT80
KRT80 Keratin, type II cytoskeletal 80


Q14533
C427, C418
KRT81
KRT81 Keratin, type II cuticular Hb1


Q14533
C273
KRT81
KRT81 Keratin, type II cuticular Hb1


O00515
C428
LAD1
LAD1 Ladinin-1


Q9Y4W2
C469, C474
LAS1L
LAS1L Ribosomal biogenesis protein LAS1L


Q9Y4W2
C699, C706
LAS1L
LAS1L Ribosomal biogenesis protein LAS1L


P80188
C195
LCN2
LCN2 Neutrophil gelatinase-associated lipocalin


P18858
C895
LIG1
LIG1 DNA ligase 1


O14910
C81
LIN7A
LIN7A Protein lin-7 homolog A


Q7L5N7
C223
LPCAT2
LPCAT2 Lysophosphatidylcholine acyltransferase 2


Q96AG4
C277
LRRC59
LRRC59 Leucine-rich repeat-containing protein 59


P83369
C52
LSM11
LSM11 U7 snRNA-associated Sm-like protein LSm11


I3L420
C80
LSM14A
LSM14A Protein LSM14 homolog A


Q8ND56
C85
LSM14A
LSM14A Protein LSM14 homolog A


P43355
C92
MAGEA1
MAGEA1 Melanoma-associated antigen 1


O15479
C301
MAGEB2
MAGEB2 Melanoma-associated antigen B2


P52564
C196, C196+
MAP2K6
MAP2K6 Dual specificity mitogen-activated protein kinase


P52564
C196
MAP2K6
MAP2K6 Dual specificity mitogen-activated protein kinase


O43318
C513
MAP3K7
MAP3K7 Mitogen-activated protein kinase kinase kinase 7


Q3KQU3
C361
MAP7D1
MAP7D1 MAP7 domain-containing protein 1


Q3KQU3
C373
MAP7D1
MAP7D1 MAP7 domain-containing protein 1


Q969Z3
C272
MARC2
MARC2 MOSC domain-containing protein 2, mitochondrial


Q9HCC0
C267
MCCC2
MCCC2 Methylcrotonoyl-CoA carboxylase beta chain,





mitoch


Q9HCC0
C453
MCCC2
MCCC2 Methylcrotonoyl-CoA carboxylase beta chain,





mitoch


O60318
C1377
MCM3AP
MCM3AP 80 kDa MCM3-associated protein


P33992
C207
MCM5
MCM5 DNA replication licensing factor MCM5


Q9NU22
C1358
MDN1
MDN1 Midasin


Q9NU22
C1394
MDN1
MDN1 Midasin


Q9NU22
C333
MDN1
MDN1 Midasin


Q9NU22
C3460
MDN1
MDN1 Midasin


Q9NU22
C43
MDN1
MDN1 Midasin


Q9NU22
C57
MDN1
MDN1 Midasin


Q9NU22
C979
MDN1
MDN1 Midasin


A6NJ78
C172
METTL15
METTL15 Probable methyltransferase-like protein 15


Q6UX53
C203, C202
METTL7B
METTL7B Methyltransferase-like protein 7B


Q99685
C208
MGLL
MGLL Monoglyceride lipase


Q9NYL2
C22
MLTK
MLTK Mitogen-activated protein kinase kinase kinase MLT


Q9NYL2
C571
MLTK
MLTK Mitogen-activated protein kinase kinase kinase MLT


P29372
C56
MPG
MPG DNA-3-methyladenine glycosylase


Q7Z7H8
C180
MRPL10
MRPL10 39S ribosomal protein L10, mitochondrial


Q9NX20
C167
MRPL16
MRPL16 39S ribosomal protein L16, mitochondrial


Q9BZE1
C203
MRPL37
MRPL37 39S ribosomal protein L37, mitochondrial


Q9NYK5
C133
MRPL39
MRPL39 39S ribosomal protein L39, mitochondrial


O15235
C93
MRPS12
MRPS12 28S ribosomal protein S12, mitochondrial


Q9Y399
C250, C230,
MRPS2
MRPS2 28S ribosomal protein S2, mitochondrial



C227


Q96EL2
C103
MRPS24
MRPS24 28S ribosomal protein S24, mitochondrial


P82663
C139, C141
MRPS25
MRPS25 28S ribosomal protein S25, mitochondrial


Q9NZJ7
C385
MTCH1
MTCH1 Mitochondrial carrier homolog 1


P03897
C39
MT-ND3
MT-ND3 NADH-ubiquinone oxidoreductase chain 3


P42345
C423
MTOR
MTOR Serine/threonine-protein kinase mTOR


P98088
C4547, C4534
MUC5AC
MUC5AC Mucin-5AC


P98088
C1643
MUC5AC
MUC5AC Mucin-5AC


P98088
C2220
MUC5AC
MUC5AC Mucin-5AC


P98088
C2714
MUC5AC
MUC5AC Mucin-5AC


P98088
C4071
MUC5AC
MUC5AC Mucin-5AC


P20591
C42
MX1
MX1 Interferon-induced GTP-binding protein Mx1


P35580
C95
MYH10
MYH10 Myosin-10


P35579
C91
MYH9
MYH9 Myosin-9


P35579
C91, C91+
MYH9
MYH9 Myosin-9


O14950
C109
MYL12B
MYL12B Myosin regulatory light chain 12B


Q96H55
C755
MYO19
MYO19 Unconventional myosin-XIX


Q9NZM1
C2013
MYOF
MYOF Myoferlin


Q147X3
C74
NAA30
NAA30 N-alpha-acetyltransferase 30


P43490
C287
NAMPT
NAMPT Nicotinamide phosphoribosyltransferase


Q6XQN6
C385
NAPRT1
NAPRT1 Nicotinate phosphoribosyltransferase


A2RRP1
C1777, C1771
NBAS
NBAS Neuroblastoma-amplified sequence


Q9HCD5
C137
NCOA5
NCOA5 Nuclear receptor coactivator 5


Q9UN36
C321
NDRG2
NDRG2 Protein NDRG2


O00483
C44
NDUFA4
NDUFA4 NADH dehydrogenase


O75306
C146
NDUFS2
NDUFS2 NADH dehydrogenase


O75251
C183
NDUFS7
NDUFS7 NADH dehydrogenase


P25208
C89, C85
NFYB
NFYB Nuclear transcription factor Y subunit beta


Q6KC79
C1754
NIPBL
NIPBL Nipped-B-like protein


Q9BSC4
C16
NOL10
NOL10 Nucleolar protein 10


Q9BSC4
C216
NOL10
NOL10 Nucleolar protein 10


Q9H8H0
C368
NOL11
NOL11 Nucleolar protein 11


Q9H8H0
C455
NOL11
NOL11 Nucleolar protein 11


Q5C9Z4
C661
NOM1
NOM1 Nucleolar MIF4G domain-containing protein 1


O00567
C112
NOP56
NOP56 Nucleolar protein 56


O00567
C384
NOP56
NOP56 Nucleolar protein 56


Q8NDH3
C81
NPEPL1
NPEPL1 Probable aminopeptidase NPEPL1


P51843
C200, C215
NR0B1
NR0B1 Nuclear receptor subfamily 0 group B member 1


P51843
C255
NR0B1
NR0B1 Nuclear receptor subfamily 0 group B member 1


P51843
C274
NR0B1
NR0B1 Nuclear receptor subfamily 0 group B member 1


P51843
C290
NR0B1
NR0B1 Nuclear receptor subfamily 0 group B member 1


P51843
C396
NR0B1
NR0B1 Nuclear receptor subfamily 0 group B member 1


P24468
C200
NR2F2
NR2F2 COUP transcription factor 2


P46459
C599
NSF
NSF Vesicle-fusing ATPase


P78549
C118
NTHL1
NTHL1 Endonuclease III-like protein 1


Q9BSD7
C184
NTPCR
NTPCR Cancer-related nucleoside-triphosphatase


P30990
C62
NTS
NTS Neurotensin/neuromedin N


P53384
C277
NUBP1
NUBP1 Cytosolic Fe-S cluster assembly factor NUBP1


Q9Y5Y2
C196, C199,
NUBP2
NUBP2 Cytosolic Fe-S cluster assembly factor NUBP2



C202


Q9Y5Y2
C54
NUBP2
NUBP2 Cytosolic Fe-S cluster assembly factor NUBP2


P53370
C44
NUDT6
NUDT6 Nucleoside diphosphate-linked moiety X motif 6


O75694
C874, C863
NUP155
NUP155 Nuclear pore complex protein Nup155


O75694
C874
NUP155
NUP155 Nuclear pore complex protein Nup155


Q92621
C877
NUP205
NUP205 Nuclear pore complex protein Nup205


O15381
C431
NVL
NVL Nuclear valosin-containing protein-like


Q6DKJ4
C205
NXN
NXN Nucleoredoxin


P00973
C25
OAS1
OAS1 2-5-oligoadenylate synthase 1


Q9H668
C8
OBFC1
OBFC1 CST complex subunit STN1


Q9NX40
C38
OCIAD1
OCIAD1 OCIA domain-containing protein 1


Q9Y5N6
C88
ORC6
ORC6 Origin recognition complex subunit 6


Q9H4L5
C203
OSBPL3
OSBPL3 Oxysterol-binding protein-related protein 3


O95747
C191
OXSR1
OXSR1 Serine/threonine-protein kinase OSR1


Q13153
C411
PAK1
PAK1 Serine/threonine-protein kinase PAK 1


Q13177
C390
PAK2
PAK2 Serine/threonine-protein kinase PAK 2


O75914
C424
PAK3
PAK3 Serine/threonine-protein kinase PAK 3


O95340
C117
PAPSS2
PAPSS2 Bifunctional 3-phosphoadenosine 5-phosphosulfate


O95340
C73
PAPSS2
PAPSS2 Bifunctional 3-phosphoadenosine 5-phosphosulfate


O95453
C543
PARN
PARN Poly(A)-specific ribonuclease PARN


Q15154
C187
PCM1
PCM1 Pericentriolar material 1 protein


Q99447
C30
PCYT2
PCYT2 Ethanolamine-phosphate cytidylyltransferase


Q8WUM4
C40
PDCD6IP
PDCD6IP Programmed cell death 6-interacting protein


Q29RF7
C327
PDS5A
PDS5A Sister chromatid cohesion protein PDS5 homolog A


Q8IZL8
C191, C191+
PELP1
PELP1 Proline-, glutamic acid- and leucine-rich protein


O00541
C153
PES1
PES1 Pescadillo homolog


O96011
C153
PEX11B
PEX11B Peroxisomal membrane protein 11B


Q92968
C220
PEX13
PEX13 Peroxisomal membrane protein PEX13


Q7Z412
C173
PEX26
PEX26 Peroxisome assembly protein 26


P56589
C251
PEX3
PEX3 Peroxisomal biogenesis factor 3


Q13608
C564
PEX6
PEX6 Peroxisome assembly factor 2


O15067
C1285, C1287
PFAS
PFAS Phosphoribosylformylglycinamidine synthase


P08237
C170
PFKM
PFKM 6-phosphofructokinase, muscle type


P08237
C170+, C170
PFKM
PFKM 6-phosphofructokinase, muscle type


P08237
C709
PFKM
PFKM 6-phosphofructokinase, muscle type


Q01813
C360
PFKP
PFKP 6-phosphofructokinase type C


P35232
C69
PHB
PHB Prohibitin


Q6IE81
C546
PHF17
PHF17 Protein Jade-1


Q8WWQ0
C28
PHIP
PHIP PH-interacting protein


O00443
C514
PIK3C2A
PIK3C2A Phosphatidylinositol 4-phosphate 3-kinase 02





domai


Q03405
C198
PLAUR
PLAUR Urokinase plasminogen activator surface receptor


Q6IQ23
C542
PLEKHA7
PLEKHA7 Pleckstrin homology domain-containing family A





mem


O60664
C341
PLIN3
PLIN3 Perilipin-3


O60664
C60
PLIN3
PLIN3 Perilipin-3


P53350
C544
PLK1
PLK1 Serine/threonine-protein kinase PLK1


Q04941
C12, C16
PLP2
PLP2 Proteolipid protein 2


Q04941
C12
PLP2
PLP2 Proteolipid protein 2


P13797
C104
PLS3
PLS3 Plastin-3


Q9NRX1
C226
PNO1
PNO1 RNA-binding protein PNO1


Q96AD5
C61
PNPLA2
PNPLA2 Patatin-like phospholipase domain-containing prote


Q9NP87
C119
POLM
POLM DNA-directed DNA/RNA polymerase mu


O95602
C613
POLR1A
POLR1A DNA-directed RNA polymerase I subunit RPA1


Q15165
C42
PON2
PON2 Serum paraoxonase/arylesterase 2


Q86W92
C35
PPFIBP1
PPFIBP1 Liprin-beta-1


P50336
C167
PPOX
PPOX Protoporphyrinogen oxidase


P50336
C258
PPOX
PPOX Protoporphyrinogen oxidase


O60831
C28
PRAF2
PRAF2 PRA1 family protein 2


O43663
C531
PRC1
PRC1 Protein regulator of cytokinesis 1


P30048
C229
PRDX3
PRDX3 Thioredoxin-dependent peroxide reductase,





mitochon


P30041
C47
PRDX6
PRDX6 Peroxiredoxin-6


Q9Y478
C223
PRKAB1
PRKAB1 5-AMP-activated protein kinase subunit beta-1


O75400
C39
PRPF40A
PRPF40A Pre-mRNA-processing factor 40 homolog A


O94906
C807
PRPF6
PRPF6 Pre-mRNA-processing factor 6


O94906
C837
PRPF6
PRPF6 Pre-mRNA-processing factor 6


Q9Y520
C177
PRRC2C
PRRC2C Protein PRRC2C


O14818
C63
PSMA7
PSMA7 Proteasome subunit alpha type-7


P62195
C209
PSMC5
PSMC5 26S protease regulatory subunit 8


Q96EY7
C139
PTCD3
PTCD3 Pentatricopeptide repeat-containing protein 3, mit


Q14914
C213
PTGR1
PTGR1 Prostaglandin reductase 1


Q14914
C239
PTGR1
PTGR1 Prostaglandin reductase 1


Q15269
C716
PWP2
PWP2 Periodic tryptophan protein 2 homolog


Q15269
C86
PWP2
PWP2 Periodic tryptophan protein 2 homolog


P32322
C262
PYCR1
PYCR1 Pyrroline-5-carboxylate reductase 1, mitochondrial


Q96C36
C262
PYCR2
PYCR2 Pyrroline-5-carboxylate reductase 2


Q96C36
C95
PYCR2
PYCR2 Pyrroline-5-carboxylate reductase 2


P47897
C456
QARS
QARS Glutamine-tRNA ligase


Q5XKP0
C60
QIL1
QIL1 Protein QIL1


Q9H0R6
C512
QRSL1
QRSL1 Glutamyl-tRNA(Gln) amidotransferase subunit A,





mit


Q6WKZ4
C1007
RAB11FIP1
RAB11FIP1 Rab11 family-interacting protein 1


Q6IQ22
C68
RAB12
RAB12 Ras-related protein Rab-12


P61106
C40, C40+
RAB14
RAB14 Ras-related protein Rab-14


Q9NX57
C70
RAB20
RAB20 Ras-related protein Rab-20


O14966
C120
RAB7L1
RAB7L1 Ras-related protein Rab-7L1


P53611
C40
RABGGTB
RABGGTB Geranylgeranyl transferase type-2 subunit beta


Q92878
C157
RAD50
RAD50 DNA repair protein RAD50


Q9Y3L5
C140
RAP2C
RAP2C Ras-related protein Rap-2c


O75884
C127
RBBP9
RBBP9 Putative hydrolase RBBP9


Q96T37
C926
RBM15
RBM15 Putative RNA-binding protein 15


Q8NDT2
C859
RBM15B
RBM15B Putative RNA-binding protein 15B


A0AV96
C349
RBM47
RBM47 RNA-binding protein 47


Q9Y256
C314
RCE1
RCE1 CAAX prenyl protease 2


Q8IZV5
C288
RDH10
RDH10 Retinol dehydrogenase 10


P35251
C607
RFC1
RFC1 Replication factor C subunit 1


A6NKT7
C206
RGPD3
RGPD3 RanBP2-like and GRIP domain-containing protein 3


Q9HBH0
C162
RHOF
RHOF Rho-related GTP-binding protein RhoF


Q8IXI2
C175
RHOT1
RHOT1 Mitochondrial Rho GTPase 1


Q6R327
C1317
RICTOR
RICTOR Rapamycin-insensitive companion of mTOR


Q5UIP0
C312
RIF1
RIF1 Telomere-associated protein RIF1


Q13671
C223
RIN1
RIN1 Ras and Rab interactor 1


Q6NUQ1
C649
RINT1
RINT1 RAD50-interacting protein 1


Q9BVS4
C449
RIOK2
RIOK2 Serine/threonine-protein kinase RIO2


O14730
C22
RIOK3
RIOK3 Serine/threonine-protein kinase RIO3


P27635
C195
RPL10
RPL10 60S ribosomal protein L10


P27635
C49+, C49
RPL10
RPL10 60S ribosomal protein L10


P62913
C25, C21
RPL11
RPL11 60S ribosomal protein L11


P62913
C25, C21
RPL11
RPL11 60S ribosomal protein L11


P50914
C42
RPL14
RPL14 60S ribosomal protein L14


P46776
C70
RPL27A
RPL27A 60S ribosomal protein L27a


P46779
C13
RPL28
RPL28 60S ribosomal protein L28


P39023
C114
RPL3
RPL3 60S ribosomal protein L3


Q969Q0
C72, C77
RPL36AL
RPL36AL 60S ribosomal protein L36a-like


P36578
C208
RPL4
RPL4 60S ribosomal protein L4


P36578
C250
RPL4
RPL4 60S ribosomal protein L4


P62424
C174
RPL7A
RPL7A 60S ribosomal protein L7a


Q6DKI1
C184
RPL7L1
RPL7L1 60S ribosomal protein L7-like 1


P05388
C27
RPLP0
RPLP0 60S acidic ribosomal protein P0


Q9BUL9
C16
RPP25
RPP25 Ribonuclease P protein subunit p25


Q9BUL9
C16+, C16
RPP25
RPP25 Ribonuclease P protein subunit p25


P62280
C131
RPS11
RPS11 40S ribosomal protein S11


P42677
C40, C37
RPS27
RPS27 40S ribosomal protein S27


P42677
C37
RPS27
RPS27 40S ribosomal protein S27


P42677
C37, C37+
RPS27
RPS27 40S ribosomal protein S27


Q71UM5
C40, C37
RPS27L
RPS27L 40S ribosomal protein S27-like


Q71UM5
C37
RPS27L
RPS27L 40S ribosomal protein S27-like


Q71UM5
C37, C37+
RPS27L
RPS27L 40S ribosomal protein S27-like


Q71UM5
C77
RPS27L
RPS27L 40S ribosomal protein S27-like


P61247
C96+, C96
RPS3A
RPS3A 40S ribosomal protein S3a


P22090
C41
RPS4Y1
RPS4Y1 40S ribosomal protein S4, Y isoform 1


Q8TD47
C41
RPS4Y2
RPS4Y2 40S ribosomal protein S4, Y isoform 2


P62753
C100
RPS6
RPS6 40S ribosomal protein S6


P56182
C198
RRP1
RRP1 Ribosomal RNA processing protein 1 homolog A


P56182
C62
RRP1
RRP1 Ribosomal RNA processing protein 1 homolog A


Q5JTH9
C102
RRP12
RRP12 RRP12-like protein


Q5JTH9
C317
RRP12
RRP12 RRP12-like protein


Q5JTH9
C763
RRP12
RRP12 RRP12-like protein


Q16799
C104, C113
RTN1
RTN1 Reticulon-1


Q16799
C678
RTN1
RTN1 Reticulon-1


P28702
C340
RXRB
RXRB Retinoic acid receptor RXR-beta


P29034
C94
S100A2
S100A2 Protein S100-A2


Q9UPU9
C20
SAMD4A
SAMD4A Protein Smaug homolog 1


Q5PRF9
C20
SAMD4B
SAMD4B Protein Smaug homolog 2


Q9UHR5
C172
SAP30BP
SAP30BP SAP30-binding protein


Q9NVU7
C206
SDAD1
SDAD1 Protein SDA1 homolog


Q9NVU7
C405
SDAD1
SDAD1 Protein SDA1 homolog


P53992
C1083
SEC24C
SEC24C Protein transport protein Sec24C


P05120
C79+, C79
SERPINB2
SERPINB2 Plasminogen activator inhibitor 2


Q9BYW2
C1281
SETD2
SETD2 Histone-lysine N-methyltransferase SETD2


Q587I9
C67
SFT2D3
SFT2D3 Vesicle transport protein SFT2C


Q15464
C139, C141
SHB
SHB SH2 domain-containing adapter protein B


P29353
C248, C248+
SHC1
SHC1 SHC-transforming protein 1


Q14493
C72+, C72
SLBP
SLBP Histone RNA hairpin-binding protein


Q9BXP2
C911
SLC12A9
SLC12A9 Solute carrier family 12 member 9


P43007
C109+, C109
SLC1A4
SLC1A4 Neutral amino acid transporter A


O43772
C283
SLC25A20
SLC25A20 Mitochondrial carnitine/acylcamitine carrier prot


Q9H936
C271
SLC25A22
SLC25A22 Mitochondrial glutamate carrier 1


P12235
C257
SLC25A4
SLC25A4 ADP/ATP translocase 1


P05141
C257
SLC25A5
SLC25A5 ADP/ATP translocase 2


P12236
C257
SLC25A6
SLC25A6 ADP/ATP translocase 3


Q6P1M0
C560
SLC27A4
SLC27A4 Long-chain fatty acid transport protein 4


Q9ULF5
C364
SLC39A10
SLC39A10 Zinc transporter ZIP10


Q15043
C322
SLC39A14
SLC39A14 Zinc transporter ZIP14


Q08AF3
C875
SLFN5
SLFN5 Schlafen family member 5


P51532
C936
SMARCA4
SMARCA4 Transcription activator BRG1


Q96GM5
C460
SMARCD1
SMARCD1 SWI/SNF-related matrix-associated actin-





dependent


Q14683
C1115
SMC1A
SMC1A Structural maintenance of chromosomes protein 1A


O95295
C66
SNAPIN
SNAPIN SNARE-associated protein Snapin


Q9Y5X2
C455
SNX8
SNX8 Sorting nexin-8


P08047
C755
SP1
SP1 Transcription factor Sp1


Q8NB90
C459
SPATA5
SPATA5 Spermatogenesis-associated protein 5


Q9BVQ7
C309
SPATA5L1
SPATA5L1 Spermatogenesis-associated protein 5-like





protein


Q9NUQ6
C536, C533
SPATS2L
SPATS2L SPATS2-like protein


O43278
C331
SPINT1
SPINT1 Kunitz-type protease inhibitor 1


P35270
C159
SPR
SPR Sepiapterin reductase


P11277
C112
SPTB
SPTB Spectrin beta chain, erythrocytic


Q01082
C624, C619
SPTBN1
SPTBN1 Spectrin beta chain, non-erythrocytic 1


O15020
C115+, C115
SPTBN2
SPTBN2 Spectrin beta chain, non-erythrocytic 2


Q9Y6N5
C379
SQRDL
SQRDL Sulfide: quinone oxidoreductase, mitochondrial


Q13501
C290+, C289,
SQSTM1
SQSTM1 Sequestosome-1



C290


P12931
C280+, C280
SRC
SRC Proto-oncogene tyrosine-protein kinase Src


P12931
C280
SRC
SRC Proto-oncogene tyrosine-protein kinase Src


O75044
C357
SRGAP2
SRGAP2 SLIT-ROBO Rho GTPase-activating protein 2


P08240
C621+, C621
SRPR
SRPR Signal recognition particle receptor subunit alpha


Q9Y5M8
C179
SRPRB
SRPRB Signal recognition particle receptor subunit beta


Q9Y5M8
C246
SRPRB
SRPRB Signal recognition particle receptor subunit beta


Q08945
C200
SSRP1
SSRP1 FACT complex subunit SSRP1


Q9Y5Y6
C801
ST14
ST14 Suppressor of tumorigenicity 14 protein


Q9Y5Y6
C830
ST14
ST14 Suppressor of tumorigenicity 14 protein


Q8N1F8
C1064
STK11IP
STK11IP Serine/threonine-protein kinase 11-interacting pro


Q9UEW8
C237
STK39
STK39 STE20/SPS1-related proline-alanine-rich protein ki


P53597
C172, C181
SUCLG1
SUCLG1 Succinyl-CoA ligase


Q8IX01
C540
SUGP2
SUGP2 SURP and G-patch domain-containing protein 2


O94901
C526
SUN1
SUN1 SUN domain-containing protein 1


O94901
C63
SUN1
SUN1 SUN domain-containing protein 1


Q9Y5B9
C574
SUPT16H
SUPT16H FACT complex subunit SPT16


Q8WXH0
C39
SYNE2
SYNE2 Nesprin-2


Q8WXH0
C6161
SYNE2
SYNE2 Nesprin-2


Q12962
C174
TAF10
TAF10 Transcription initiation factor TFIID subunit 10


Q15545
C92
TAF7
TAF7 Transcription initiation factor TFIID subunit 7


Q9BW92
C322
TARS2
TARS2 Threonine-tRNA ligase, mitochondrial


Q8NHU6
C1029
TDRD7
TDRD7 Tudor domain-containing protein 7


Q15582
C97
TGFBI
TGFBI Transforming growth factor-beta-induced protein ig


Q8IXH7
C195
TH1L
TH1L Negative elongation factor C/D


Q07157
C1727
TJP1
TJP1 Tight junction protein ZO-1


Q96SK2
C158
TMEM209
TMEM209 Transmembrane protein 209


Q96SK2
C301
TMEM209
TMEM209 Transmembrane protein 209


Q9BTX1
C468
TMEM48
TMEM48 Nucleoporin NDC1


Q9BTX1
C468+, C468
TMEM48
TMEM48 Nucleoporin NDC1


Q96BY9
C320
TMEM66
TMEM66 Store-operated calcium entry-associated regulatory


Q9NVH6
C167
TMLHE
TMLHE Trimethyllysine dioxygenase, mitochondrial


P42166
C518
TMPO
TMPO Lamina-associated polypeptide 2, isoform alpha


Q9C0C2
C1175
TNKS1BP1
TNKS1BP1 182 kDa tankyrase-1-binding protein


Q8IZW8
C427
TNS4
TNS4 Tensin-4


O96008
C86, C76,
TOMM40
TOMM40 Mitochondrial import receptor subunit TOM40



C74

homolo


O96008
C86, C76,
TOMM40
TOMM40 Mitochondrial import receptor subunit TOM40



C74

homolo


O96008
C86, C76,
TOMM40
TOMM40 Mitochondrial import receptor subunit TOM40



C74

homolo


P11388
C862
TOP2A
TOP2A DNA topoisomerase 2-alpha


Q02880
C426
TOP2B
TOP2B DNA topoisomerase 2-beta


Q02880
C883
TOP2B
TOP2B DNA topoisomerase 2-beta


Q12888
C1933
TP53BP1
TP53BP1 Tumor suppressor p53-binding protein 1


O14773
C365
TPP1
TPP1 Tripeptidyl-peptidase 1


O14773
C537, C522,
TPP1
TPP1 Tripeptidyl-peptidase 1



C526


Q9H4I3
C366
TRABD
TRABD TraB domain-containing protein


O75962
C1713
TRIO
TRIO Triple functional domain protein


Q15654
C54, C47
TRIP6
TRIP6 Thyroid receptor-interacting protein 6


Q15361
C708
TTF1
TTF1 Transcription termination factor 1


Q71U36
C315, C316
TUBA1A
TUBA1A Tubulin alpha-1A chain


Q71U36
C316+, C315,
TUBA1A
TUBA1A Tubulin alpha-1A chain



C316


Q13748
C20, C25, C4
TUBA3D
TUBA3D Tubulin alpha-3C/D chain


Q13748
C347
TUBA3D
TUBA3D Tubulin alpha-3C/D chain


P68366
C213, C200
TUBA4A
TUBA4A Tubulin alpha-4A chain


P68366
C129
TUBA4A
TUBA4A Tubulin alpha-4A chain


P68366
C376
TUBA4A
TUBA4A Tubulin alpha-4A chain


P68366
C376+, C376
TUBA4A
TUBA4A Tubulin alpha-4A chain


Q9NY65
C376
TUBA8
TUBA8 Tubulin alpha-8 chain


Q9NY65
C376+, C376
TUBA8
TUBA8 Tubulin alpha-8 chain


A6NHL2
C323, C322,
TUBAL3
TUBAL3 Tubulin alpha chain-like 3



C322+, C323+


P07437
C201, C211
TUBB
TUBB Tubulin beta chain


P07437
C201, C211
TUBB
TUBB Tubulin beta chain


Q9BVA1
C201, C211
TUBB2B
TUBB2B Tubulin beta-2B chain


Q9BVA1
C201, C211
TUBB2B
TUBB2B Tubulin beta-2B chain


P68371
C201, C211
TUBB4B
TUBB4B Tubulin beta-4B chain


P68371
C201, C211
TUBB4B
TUBB4B Tubulin beta-4B chain


Q9BUF5
C201, C211
TUBB6
TUBB6 Tubulin beta-6 chain


Q9BUF5
C201, C211
TUBB6
TUBB6 Tubulin beta-6 chain


Q2T9J0
C284
TYSND1
TYSND1 Peroxisomal leader peptide-processing protease


Q9GZZ9
C250
UBA5
UBA5 Ubiquitin-like modifier-activating enzyme 5


Q9NPG3
C420
UBN1
UBN1 Ubinuclein-1


Q92575
C144
UBXN4
UBXN4 UBX domain-containing protein 4


Q9BZV1
C125
UBXN6
UBXN6 UBX domain-containing protein 6


Q9NYU1
C1361
UGGT2
UGGT2 UDP-glucose: glycoprotein glucosyltransferase 2


F8VZW7
C77, C74
Uncharacterized
Uncharacterized protein


H7BZ11
C88, C83
Uncharacterized
Uncharacterized protein


H7C455
C156
Uncharacterized
Uncharacterized protein


J3KR12
C188
Uncharacterized
Uncharacterized protein


H7C469
C200
Uncharacterized
Uncharacterized protein


H3BQZ7
C538
Uncharacterized
Uncharacterized protein


F5H5T6
C83
Uncharacterized
Uncharacterized protein


J3KR12
C95
Uncharacterized
Uncharacterized protein


H7BZ11
C99
Uncharacterized
Uncharacterized protein


P22695
C192
UQCRC2
UQCRC2 Cytochrome b-c1 complex subunit 2,





mitochondrial


Q9NVE5
C50
USP40
USP40 Ubiquitin carboxyl-terminal hydrolase 40


P46939
C447
UTRN
UTRN Utrophin


Q9BQE4
C174
VIMP
VIMP Selenoprotein S


A3KMH1
C858
VWA8
VWA8 von Willebrand factor A domain-containing protein


Q9H3P2
C141
WHSC2
WHSC2 Negative elongation factor A


Q9Y4P8
C393
WIPI2
WIPI2 WD repeat domain phosphoinositide-interacting prot


Q9HD64
C33
XAGE1E
XAGE1E G antigen family D member 2


Q9HD64
C43
XAGE1E
XAGE1E G antigen family D member 2


Q9HAV4
C1131
XPO5
XPO5 Exportin-5


P07947
C287
YES1
YES1 Tyrosine-protein kinase Yes


P49750
C1772
YLPM1
YLPM1 YLP motif-containing protein 1


Q9NPG8
C337
ZDHHC4
ZDHHC4 Probable palmitoyltransferase ZDHHC4


P17029
C243
ZKSCAN1
ZKSCAN1 Zinc finger protein with KRAB and SCAN





domains 1




















TABLE 1B







Liganded by

Liganded by


UNIPROT
Compound 3
Compound 3
Compound 2
Compound 2



















Q96RE7


13.585
yes


Q14669
12.06
yes
2.2
no


Q9NYG5
5.243333
yes
14
no


Q9UJX4


8.186667
yes


O14867
20
yes




Q9NV06
7.315
yes
4.845
no


Q96ME1


20
yes


Q8N531
3.54
no
6.286667
yes


Q9H2C0


6.935
yes


O95714
20
yes




Q14145
12.005
yes




Q9NX47
20
yes
2.21
no


O60291


8.625
yes


Q96BF6
9.596667
yes
2.265
no


P49792
6.155
yes




Q93009
1.34
no
5.14
yes


O95999
5.095
yes
8.59
no


P51114
1.095
no
20
yes


P41134
14.63667
yes
5.42
yes


P10588


20
yes


P10588


16.04
yes


P04049
18.11
yes




P32320
5.19
no
20
yes


P07858
18.9
yes
1.31
no


P18074
7.77
yes




Q9NRZ9
20
yes




Q9NRZ9
20
yes
4.63
no


P16144
16.185
yes




P16144


5.16
yes


O95819
2.295
no
6.54
yes


P52701
2.09
no
5.3
yes


P22736


8.636667
yes


P35610
20
yes
3.47
no


P54274
11.525
yes




P61081
3.12
no
5.155
yes


Q14694
2.186667
no
5.22
yes


Q70CQ3
20
yes




Q9UHD8
20
yes
2.71
no


Q9UHD8
13.57
yes
3.2425
no


Q9UHD8
3.25
no
20
yes


Q5JTZ9
2.245
no
5.82
yes


O60706
19.89
yes




O60706
11.915
yes
2.39
no


Q8NE71
20
yes




Q9UG63
6.395
yes
4.4
no


Q9UG63
20
yes




Q8N2K0
20
yes




Q9H845
2.37
no
12.98
yes


Q9H568


20
yes


Q96D53
20
yes
20
yes


Q96D53
20
yes
13.01
yes


Q9BRR6
20
yes
1.55
no


Q8N556
2.095
no
6.465
yes


Q96P47
5.316667
yes




Q53EU6
20
yes
20
yes


Q8WYP5
9.523333
yes
2.673333
no


P02765
6.996667
yes
3.67
no


Q13155
3.643333
no
5.23
yes


O00170
8.18
yes




Q99996
14.825
yes
7.1
yes


Q99996


20
yes


O60218
12.18
yes




Q04828
5.135
yes
4.21
no


P42330
5.135
yes
4.21
no


P17516
5.135
yes




P31749
3.19
no
5.096667
yes


P31751
3.19
no
5.096667
yes


Q9Y243
3.19
no
5.096667
yes


P54886
4.37
no
13.245
yes


P00352
20
yes




P00352
20
yes




P47895
20
yes
20
yes


P47895
20
yes




Q3SY69
16.485
yes
8.89
no


Q3SY69
7.955
yes
8.89
no


Q3SY69
15
yes




P51648
2.853333
no
20
yes


P51648
4.52
no
20
yes


P51648
2.95
no
20
yes


P51648
4.52
no
20
yes


P51648
2.95
no
20
yes


P51648
2.853333
no
20
yes


P60006


20
yes


Q8IWZ3
20
yes




Q86XL3


12.335
yes


O75179
20
yes




Q9BTT0
5.405
yes
3.61
no


Q63HQ0
5.175
yes




P61966


5.655
yes


P56377


5.655
yes


Q9UPM8
20
yes




Q9UBZ4
6.46
yes




Q6UXV4
20
yes
3.19
no


O14497
3.16
no
12.355
yes


O14497
1.854
no
6.095
yes


P40616


6.49
yes


Q9NVP2
3.005
no
5.23
yes


P00966
6.665
yes
5.245
yes


Q76L83
7.09
yes
3.49
no


Q8NBU5
8.825
yes
5.1
yes


Q8NBU5
6.745
yes
2.15
no


Q6PL18


12.365
yes


Q5T9A4
3.51
no
9.27
yes


Q7Z3C6


13.175
yes


Q7L8W6
11.82
yes
3.35
no


Q9UBB4
20
yes
2.876667
no


O14965
3.03
no
6.346667
yes


Q9UIG0
20
yes




O75815
20
yes
3.94
no


O75815
4.19
no
6.51
yes


P20749
17.72
yes
8.75
no


Q02338


20
yes


O14503


5.415
yes


P55957


20
yes


Q96IK1


6.01
yes


Q8NFC6


6.01
yes


Q9Y3E2
1.935
no
6.546667
yes


Q6PJG6
8.08
yes
2.245
no


Q6PJG6
7.386667
yes
1.255
no


Q9NW68
20
yes




O14981
2.47
no
6.07
yes


Q9Y6E2


12.56
yes


Q14CZ0
12.9
yes




Q9HAS0
6.49
no
5.826667
yes


A6NDU8
20
yes




P20810
3.87
no
5.4
yes


Q96F63


5.69
yes


O95273
4.09
no
20
yes


Q9UK58
10.795
yes
4.475
no


Q8ND76


13.49
yes


Q8N7R7
20
yes
13.49
yes


Q9UK39
20
yes
20
yes


P48643
7.65
no
8.645
yes


Q00587


13.405
yes


Q9BXL8
7.61
yes
3.23
no


O95674
3.275
no
18.85333
yes


Q9H3R5
5.53
yes
3.163333
no


Q53EZ4
4.265
no
5.143333
yes


Q53EZ4


5.855
yes


Q76N32
13.895
yes




Q9H078
3.49
no
5.825
yes


P09497
6.413333
yes
4.69
no


Q969H4
20
yes
3.28
no


Q99439
2.665
no
5.27
yes


Q15417
1.893333
no
7.2
yes


Q6PJW8
12.74
yes
6.56
yes


Q9Y2Z9
5.263333
yes
4.33
no


P31327
6.376667
yes
4.113333
no


P50416
20
yes




P55060
1.69
no
6.195
yes


O43310
6.285
yes




O60716
5.983333
yes
3.73
no


P53634
20
yes
1.398333
no


P53634
20
yes
1.963333
no


P07339


12.705
yes


Q9UBR2
4.37
no
7.855
yes


Q9UBR2
3.62
no
6.3
yes


Q9UBR2
3.565
no
8.445
yes


Q9UBR2
4.21
no
7.07
yes


Q9UBR2
7.91
yes




O43169
20
yes
20
yes


Q07973
17.38
yes




Q07973


5.195
yes


Q9HBI6
20
yes
5.06
no


Q9HBI6
13.105
yes
6.06
yes


Q08477
13.105
yes




Q9NPI6
8.89
no
5.22
yes


Q13561
4.205
no
6.05
yes


Q7Z4W1
1.913333
no
5.766667
yes


Q92499
16.63
yes
2.415
no


Q9NVP1
8.4475
yes
20
yes


Q9Y6V7
2.515
no
20
yes


Q9Y2R4
11.42667
yes
2.08
no


Q9NY93
2.375
no
6.19
yes


Q15392
16.06
yes
19.65
yes


Q9BPW9


5.345
yes


Q14147
20
yes




Q6P158


5.125
yes


Q08211
6.6
no
8.403333
yes


Q08211
9.6775
yes
9.976667
yes


Q9UNQ2
20
yes
5.47
yes


Q8TDM6
18.63
yes
18.62
no


Q8IXB1
20
yes
7.305
yes


Q8IXB1
20
yes
10.36
no


Q8IXB1
20
yes




Q8NBA8
20
yes
20
yes


Q14204


8.53
yes


Q96F86


5.58
yes


Q05639
8.55
yes
2.79
no


P26641
16.95667
yes
8.79
yes


Q12805
3.752
no
5.766667
yes


Q12805
3.31
no
9.64
yes


Q12805
3.195
no
6.75
yes


Q12805


15.33333
yes


Q7Z2Z2
20
yes




Q9BQ52
2
no
6.546667
yes


Q15723
2.87
no
6.63
yes


Q96N21


20
yes


Q9H6S3


20
yes


O75477
20
yes
7.31
no


O75477
6.203333
yes
9.825
yes


Q96HE7
20
yes
20
yes


Q96HE7
10.62
yes
6.48
yes


Q96HE7
5.793333
yes
7.845
yes


Q96HE7
20
yes




Q96HE7


5.95
yes


Q9UJM3
6.93
no
7.515
yes


Q9UJM3
14.75667
yes
3.49
no


Q6NXG1


7.326667
yes


Q9H6T0
20
yes
17.715
yes


Q9BSJ8
2.89
no
9.235
yes


P38117
4.29
no
12.115
yes


P38117
20
yes
1.35
no


P38117
19.48667
yes
1.605
no


Q9NVH0
6.8
yes
4.08
no


Q9NVH0
6.443333
yes
2.33
no


Q9NVH0
8.06
no
9.893333
yes


Q96KP1
5.97
no
20
yes


Q5RKV6
2.79
no
5.306667
yes


P00734


14.525
yes


Q6P2I3
12.845
yes
2.08
no


Q5VSL9


20
yes


Q6ZRV2
5.66
no
20
yes


Q9NSD9
1.42
no
5.79
yes


Q9NYY8
20
yes
2.145
no


Q7L8L6
12.32
yes
4.23
no


Q7L8L6
2.456667
no
11.732
yes


P37268


5.315
yes


Q14192
2.25
no
7.116667
yes


Q8N6M3
20
yes
2.82
no


P21333
6.65
yes
4.835
no


P21333
2.02
no
6.833333
yes


O75369
5.275
yes
5.03
yes


O75369
8.96
yes
3.365
no


P02751
7.255
yes
20
yes


P02751


20
yes


P02751
17.76
yes
20
yes


Q12841
5
no
9.7
yes


Q9UI43
14.34
yes
2.415
no


Q8N0W3
2.24
no
20
yes


Q9BUM1
20
yes




O14976
20
yes
13.065
yes


Q8WXI9
3.12
no
10.12
yes


Q8WXI9
2.7225
no
6.716667
yes


Q92538
2.693333
no
7.73
yes


Q96PP8
20
yes
2.33
no


Q92947
9.2
yes
1.54
no


Q92616


12.18
yes


Q92616
13.21
yes
1.51
no


Q7L5L3
20
yes
20
yes


P57678
9.49
yes
5.265
yes


Q8TEQ6
17.185
yes
1.665
no


Q96RP9
4.095
no
6.65
yes


P62873
20
yes




P62873
5.166667
yes
2.455
no


P62879
13.41333
yes
3.63
no


P62879
5.166667
yes
2.455
no


P63244
10.905
yes
0.966667
no


Q9BVP2
6.093333
yes
1.95
no


Q08379
2.28
no
5.595
yes


P35052


13.38333
yes


Q3KR37
20
yes




Q12849
20
yes




Q12789
3.75
no
16.57333
yes


Q9Y5Q9
14.39667
yes
8.09
yes


Q9NYZ3
2.355
no
5.31
yes


P84243
5.79
yes
3.996667
no


P40939
18.85
yes
11.50667
yes


P40939
9.243333
yes
5.39
yes


P53701
3.58
no
6.19
yes


P53701
12.335
yes
6.28
yes


Q9H583
20
yes




Q9H583


9.306667
yes


P68431
5.56
yes
3.88
no


P68431
7.155
yes
2.67
no


Q2TB90
5.34
yes
1.715
no


P01892


15.03333
yes


P01889
20
yes
7.25
yes


Q29960


15.03333
yes


F8VZB9
20
yes




Q1KMD3
14.30667
yes
4.893333
no


P84074
19.54667
yes
8.465
yes


Q96IR7
9.015
yes
5.05
yes


Q96IR7
12.67
yes
1.65
no


P15428
20
yes




P15428
20
yes
20
yes


Q86YV9
7.625
yes
1.555
no


Q99714
3.86
no
5.526667
yes


Q6YN16
13.755
yes
3.07
no


O43301
5.88
no
5.47
yes


O14558
3.885
no
6.1
yes


P10809
4.28
no
5.665
yes


A1L0T0
2.26
no
12.55
yes


Q9NV31
3.32
no
17.03
yes


P20839
15.02667
yes
20
yes


Q27J81
13.695
yes
1.71
no


Q27J81
20
yes
1.34
no


Q8N201


9.043333
yes


Q96HW7
5.46
yes
20
yes


Q8TEX9
8.77
no
6.1
yes


O00410


6.72
yes


P35568
2.39
no
6.09
yes


P05556
15.715
yes
3.74
no


Q14573
2.54
no
5.42
yes


Q8IWB1
10.51333
yes
3.51
no


P14923
10.25
yes
3.33
no


Q7LBC6
5.345
yes
5.92
yes


Q15004
3.59
no
10.085
yes


Q14807


13.11
yes


O95239
20
yes
4.345
no


O95239
7.59
yes
3.54
no


Q2VIQ3
20
yes




Q2VIQ3
7.59
yes
3.54
no


Q9BW19
20
yes
3.73
no


P52294


8.325
yes


O60684


14.41
yes


Q14974
15.66
yes
2.26
no


Q8N9T8
2.08
no
11.34667
yes


P13646
15.88
yes
19.81
yes


Q04695
20
yes
13.84
yes


Q04695
7.755
yes
5.485
yes


P19013


9.7
yes


P02538
12.215
yes
12.3
yes


P02538
17.17
yes
12.92333
yes


Q6KB66
20
yes
6.54
no


Q6KB66
5.26
yes
12.715
yes


Q14533
20
yes




Q14533
11.87667
yes
2.71
no


O00515
20
yes




Q9Y4W2
20
yes




Q9Y4W2
2.47
no
5.06
yes


P80188
1.85
no
8.475
yes


P18858
1.566667
no
5.27
yes


O14910
16.73
yes




Q7L5N7
5.42
yes
2.92
no


Q96AG4
20
yes
11.39
yes


P83369
14.01
yes




I3L420
2.436667
no
5.39
yes


Q8ND56
2.436667
no
5.39
yes


P43355


20
yes


O15479
3.72
no
8.943333
yes


P52564
18.53333
yes
12.715
yes


P52564


18.35
yes


O43318
20
yes




Q3KQU3
7.23
yes
4.935
no


Q3KQU3
11.58333
yes
4.45
no


Q969Z3
20
yes
20
yes


Q9HCC0
1.01
no
5.783333
yes


Q9HCC0
11.68667
yes
2.73
no


O60318


12.385
yes


P33992
20
yes
20
yes


Q9NU22
20
yes




Q9NU22
5.595
yes
2.196667
no


Q9NU22
20
yes
8.745
yes


Q9NU22
6.35
yes




Q9NU22


20
yes


Q9NU22


20
yes


Q9NU22
20
yes
9.35
no


A6NJ78
5.115
yes
6.77
yes


Q6UX53
5.94
yes
0.965
no


Q99685
4.305
no
13.87333
yes


Q9NYL2
2.21
no
20
yes


Q9NYL2
5.21
yes




P29372


5.695
yes


Q7Z7H8
20
yes
2.82
no


Q9NX20
7.91
yes
3.13
no


Q9BZE1
13.17
yes




Q9NYK5
1.39
no
7.216667
yes


O15235
6.01
yes
2.806667
no


Q9Y399
6.415
yes




Q96EL2
5.795
yes
3.46
no


P82663
3.876667
no
5.61
yes


Q9NZJ7


6.7
yes


P03897
7.253333
yes
2.973333
no


P42345
16.705
yes




P98088


7.35
yes


P98088


8.245
yes


P98088


5.08
yes


P98088
4.09
no
6.905
yes


P98088


7.915
yes


P20591
5.43
yes




P35580

no
5.66
yes


P35579


5.66
yes


P35579
10.38
yes
3.36
no


O14950
13.95667
yes
2.5
no


Q96H55


5.55
yes


Q9NZM1
20
yes
18.07
no


Q147X3


6.113333
yes


P43490
9.745
yes
3.26
no


Q6XQN6
5.05
yes
2.32
no


A2RRP1
2.515
no
13.655
yes


Q9HCD5
1.88
no
5.34
yes


Q9UN36
1.7
no
9.465
yes


O00483
12.58
yes
2.19
no


O75306
9.68
yes
3.836667
no


O75251
20
yes
5.99
yes


P25208


13.645
yes


Q6KC79
20
yes




Q9BSC4


7.826667
yes


Q9BSC4


5.435
yes


Q9H8H0
2.6
no
12.765
yes


Q9H8H0
9.025
yes




Q5C9Z4
20
yes
8.315
yes


O00567
14.82333
yes
3.78
no


O00567
20
yes
4.02
no


Q8NDH3
2.1
no
15.38
yes


P51843
10.62
yes




P51843
15.795
yes
3.51
no


P51843
18.19
yes
20
yes


P51843
6.355
yes
2.875
no


P51843
6.073333
yes
3.896667
no


P24468
20
yes




P46459
7.2
yes
2.475
no


P78549
1.775
no
7.966667
yes


Q9BSD7
6.003333
yes
1.81
no


P30990


20
yes


P53384
13.755
yes




Q9Y5Y2
13.26
yes
5.48
yes


Q9Y5Y2
5.196667
yes
1.715
no


P53370
20
yes




O75694
2.56
no
18.19333
yes


O75694
2.04
no
20
yes


Q92621
5.24
yes
2.95
no


O15381
6.22
yes
2.805
no


Q6DKJ4


15.525
yes


P00973
1.583333
no
5.006667
yes


Q9H668
1.295
no
8.325
yes


Q9NX40
8.093333
yes
2.096667
no


Q9Y5N6


6.64
yes


Q9H4L5
3.595
no
6.226667
yes


O95747
20
yes
4.66
no


Q13153
20
yes
2.54
no


Q13177
20
yes
2.54
no


O75914
20
yes
2.54
no


O95340
8.98
yes
2.15
no


O95340
5.383333
yes
3.725
no


O95453


20
yes


Q15154
9.47
yes
3.14
no


Q99447
7.12
yes
1.56
no


Q8WUM4
3.27
no
11.295
yes


Q29RF7
0.82
no
5.735
yes


Q8IZL8
16.06
yes
8.13
no


O00541
5.025
yes
15.65
yes


O96011
4.53
no
17.275
yes


Q92968
20
yes




Q7Z412
16.745
yes
2.35
no


P56589
20
yes
3.41
no


Q13608
5.395
yes
3.52
no


O15067
2.515
no
11.85667
yes


P08237
2.01
no
8.613333
yes


P08237
2.57
no
9.805
yes


P08237


20
yes


Q01813
5.565
yes
3.695
no


P35232
3.39
no
5.545
yes


Q6IE81


20
yes


Q8WWQ0
6.815
yes
1.02
no


O00443
15.945
yes




Q03405


12.615
yes


Q6IQ23
2.77
no
8.39
yes


O60664
5.04
yes
2.005
no


O60664
5.44
yes
1.54
no


P53350
10.11667
yes
11.29
yes


Q04941
8.945
yes
4.125
no


Q04941
16.91
yes
6.99
yes


P13797
1.79
no
8.24
yes


Q9NRX1
6.746667
yes
4.906667
no


Q96AD5
20
yes




Q9NP87


6.95
yes


O95602
9.645
yes
1.05
no


Q15165
20
yes
5.2
no


Q86W92
13.245
yes




P50336


12.61
yes


P50336
7.805
yes
8.3
yes


O60831


6.365
yes


O43663
1.655
no
5.393333
yes


P30048
5.606667
yes
5.41
yes


P30041
7.21
yes
10.51333
yes


Q9Y478


12.485
yes


O75400
3.056667
no
13.87
yes


O94906
8.835
yes
4.255
no


O94906
5.4
yes
3.483333
no


Q9Y520
1.62
no
5.66
yes


O14818
10.85333
yes
2.655
no


P62195
6.26
yes
1.335
no


Q96EY7


20
yes


Q14914
3.71
no
5.365
yes


Q14914
6.245
yes
1.69
no


Q15269
4.245
no
5.46
yes


Q15269
17.935
yes
3.61
no


P32322
14.78333
yes
5.44
no


Q96C36
14.78333
yes
5.44
no


Q96C36
13.155
yes
1.995
no


P47897
20
yes




Q5XKP0
20
yes
2.1
no


Q9H0R6
13.815
yes
20
yes


Q6WKZ4
2.815
no
5.015
yes


Q6IQ22


20
yes


P61106
5.653333
yes
2.316667
no


Q9NX57
6.805
yes




O14966


17.89
yes


P53611
3.22
no
5.105
yes


Q92878
5.35
yes
2.566667
no


Q9Y3L5
20
yes
9.735
yes


O75884


5.405
yes


Q96T37
17.69
yes
2.046667
no


Q8NDT2
20
yes




A0AV96
2.356667
no
5.43
yes


Q9Y256
20
yes
20
yes


Q8IZV5
20
yes
1.135
no


P35251
20
yes




A6NKT7
6.155
yes




Q9HBH0
9.075
yes
1.235
no


Q8IXI2
2.68
no
8.213333
yes


Q6R327
6.673333
yes
4.96
no


Q5UIP0
20
yes
3.68
no


Q13671
20
yes




Q6NUQ1
20
yes




Q9BVS4


20
yes


O14730
6.4
yes
20
yes


P27635
5.34
yes
2.186667
no


P27635
8.11
yes
2.532857
no


P62913
3.116667
no
9.04
yes


P62913
3.116667
no
9.04
yes


P50914
5.38
yes
3.426667
no


P46776
9.643333
yes
2.58
no


P46779
5.136667
yes
2.46
no


P39023
6.95
yes
14.33667
yes


Q969Q0
5.036667
yes
2.356667
no


P36578
12.5
yes
3.746667
no


P36578
10.75333
yes
3.356667
no


P62424
12.87667
yes
6.28
no


Q6DKI1
7.38
yes
0.99
no


P05388
7.093333
yes
7.41
yes


Q9BUL9
2.476667
no
20
yes


Q9BUL9
1.67
no
9.58
yes


P62280
6.4
yes
1.69
no


P42677
12.65333
yes




P42677
16.76
no
9.805
yes


P42677
20
yes
5.713333
yes


Q71UM5
12.65333
yes




Q71UM5
16.76
no
9.805
yes


Q71UM5
20
yes
5.713333
yes


Q71UM5
9.206667
yes
6.12
no


P61247
5.28
yes
3.08
no


P22090
9.32
yes
2.896667
no


Q8TD47
9.32
yes
2.896667
no


P62753
20
yes
2.943333
no


P56182


6.925
yes


P56182
18.565
yes
3.01
no


Q5JTH9
20
yes
2.98
no


Q5JTH9
9.07
yes
6.035
yes


Q5JTH9
14.01
yes
7.15
yes


Q16799
1.975
no
7.6
yes


Q16799
20
yes




P28702


9.585
yes


P29034
6.525
yes
2.125
no


Q9UPU9
7.405
yes




Q5PRF9
7.405
yes




Q9UHR5
5.975
yes
2.62
no


Q9NVU7
5.425
yes
2.19
no


Q9NVU7
20
yes
5.965
yes


P53992


5.3
yes


P05120
2.396667
no
8.8525
yes


Q9BYW2
2.723333
no
6.125
yes


Q587I9


7.625
yes


Q15464
3.98
no
7.886667
yes


P29353
1.85
no
10.335
yes


Q14493
4.85
no
9.3325
yes


Q9BXP2
20
yes




P43007
20
yes
19.885
yes


O43772
5.665
yes
2.115
no


Q9H936


5.105
yes


P12235
1.4
no
16.76
yes


P05141
1.655
no
5.88
yes


P12236
1.4
no
16.76
yes


Q6P1M0
2.273333
no
8.24
yes


Q9ULF5


14.025
yes


Q15043
20
yes
20
yes


Q08AF3
12.085
yes




P51532
17.38333
yes
8.815
yes


Q96GM5
4.02
no
6.95
yes


Q14683
12.73
yes
3.92
no


O95295
3.215
no
8.89
yes


Q9Y5X2
20
yes




P08047
4.775
no
7.703333
yes


Q8NB90
20
yes




Q9BVQ7
20
yes
8.76
no


Q9NUQ6
5.05
yes
5.26
yes


O43278


8.04
yes


P35270
1.9
no
5.375
yes


P11277
17.565
yes
9.79
yes


Q01082
20
yes
16.49
yes


O15020
17.565
yes
9.79
yes


Q9Y6N5
15.29
no
14.265
yes


Q13501
2.505
no
12.91333
yes


P12931
3.311667
no
20
yes


P12931
4.03
no
13.56667
yes


O75044


5.34
yes


P08240
20
yes
2.575
no


Q9Y5M8
11.085
yes
2.73
no


Q9Y5M8
13.595
yes
2.84
no


Q08945
13.82
yes
11.04333
yes


Q9Y5Y6


14.03
yes


Q9Y5Y6
5.053333
yes
5.42
no


Q8N1F8


5.74
yes


Q9UEW8
20
yes
4.66
no


P53597
6.38
yes
2.73
no


Q8IX01
5.73
yes
3.635
no


O94901
8.555
yes
0.84
no


O94901
3.8
no
7.706667
yes


Q9Y5B9
6.263333
yes
7.17
no


Q8WXH0
4.375
no
16.235
yes


Q8WXH0


6.495
yes


Q12962
5.685
yes




Q15545
20
yes




Q9BW92
5.66
yes
4.875
no


Q8NHU6
3.3
no
15.85333
yes


Q15582


12.615
yes


Q8IXH7
1.76
no
20
yes


Q07157
2.62
no
8.59
yes


Q96SK2
2.88
no
11.11
yes


Q96SK2
2.92
no
7.055
yes


Q9BTX1
20
yes
6.01
yes


Q9BTX1
18.74667
yes
6.88
yes


Q96BY9
4.805
no
7.155
yes


Q9NVH6


13.815
yes


P42166
8.52
no
6.213333
yes


Q9C0C2
1.6
no
5.135
yes


Q8IZW8
2.913333
no
5.565
yes


O96008
2.865
no
6.03
yes


O96008
2.865
no
6.03
yes


O96008
2.865
no
6.03
yes


P11388
20
yes
15.39
no


Q02880
5.225
yes
3.765
no


Q02880
17.22
yes
8.34
yes


Q12888
1.973333
no
10.885
yes


O14773
8.6
yes
2.51
no


O14773
11.86333
yes
2.99
no


Q9H4I3
11.29
yes
1.9
no


O75962
20
yes
1.86
no


Q15654
3.663333
no
6.823333
yes


Q15361


6.57
yes


Q71U36
5.156667
yes
2.333333
no


Q71U36
6.163333
yes
2.146667
no


Q13748
6.5
yes




Q13748
5.293333
yes




P68366
9.57
yes
3.75
no


P68366
6.76
yes




P68366
6.98
yes
4.29
no


P68366
9.978
yes
3.958333
no


Q9NY65
6.98
yes




Q9NY65
7.691667
yes
5.003333
yes


A6NHL2
5.156667
yes
2.28
no


P07437
6.94
yes




P07437
6.94
yes




Q9BVA1
6.94
yes
2.56
no


Q9BVA1
6.94
yes
2.56
no


P68371
6.94
yes

no


P68371
6.94
yes

no


Q9BUF5
6.94
yes
2.56
no


Q9BUF5
6.94
yes
2.56
no


Q2T9J0
20
yes
19.22
yes


Q9GZZ9
4.935
no
5.8
yes


Q9NPG3
20
yes




Q92575
1.61
no
13.81667
yes


Q9BZV1
20
yes




Q9NYU1
20
yes
20
yes


F8VZW7
13.375
yes
2.55
no


H7BZ11
5.036667
yes
2.356667
no


H7C455


20
yes


J3KR12
14.78333
yes
5.44
no


H7C469


12.705
yes


H3BQZ7
14.30667
yes
4.893333
no


F5H5T6


20
yes


J3KR12
13.155
yes
1.995
no


H7BZ11
5.08
yes




P22695
12.715
yes
1.99
no


Q9NVE5


20
yes


P46939
2.99
no
13.24
yes


Q9BQE4


8.845
yes


A3KMH1
8.855
yes
1.985
no


Q9H3P2
20
yes




Q9Y4P8
16.115
yes
13.12
no


Q9HD64
6.135
yes




Q9HD64
5.42
yes
2.663333
no


Q9HAV4
2.383333
no
7.993333
yes


P07947
2.66
no
19.3
yes


P49750
2.29
no
20
yes


Q9NPG8
7.84
no
20
yes


P17029
1.75
no
12.05
yes









Table 2, Table 3 (e.g., Table 3A and Table 3B), and Table 4 illustrate additional exemplary lists of NRF2-regulated proteins and their respective cysteine sites of interaction.










Lengthy table referenced here




US20200278355A1-20200903-T00001


Please refer to the end of the specification for access instructions.














Lengthy table referenced here




US20200278355A1-20200903-T00002


Please refer to the end of the specification for access instructions.














Lengthy table referenced here




US20200278355A1-20200903-T00003


Please refer to the end of the specification for access instructions.














Lengthy table referenced here




US20200278355A1-20200903-T00004


Please refer to the end of the specification for access instructions.






Example 2

Cell Lines


All cell lines were obtained from ATCC. All cells were maintained at 37° C. with 5% CO2. HEK-293T cells were grown in DMEM (Corning) supplemented with 10% fetal bovine serum (FBS, Omega Scientific), penicillin (100 U/ml), streptomycin (100 μg/ml) and L-glutamine (2 mM). H2122, H460, A549, H1975, H358, H1792, and H2009 cells were grown in RPMI-1640 (Invitrogen) supplemented as above. H2009 cells were additionally supplemented with Insulin-Transferrin-Selenium (Invitrogen). For SILAC experiments, each cell line was passaged at least six times in SILAC RPMI (Thermo), which lack L-lysine and L-arginine, and supplemented with 10% (v/v) dialyzed FBS (Gemini), penicillin, streptomycin, L-glutamine (as above), and either [13C6, 15N2]-L-lysine and [13C6, 15N4]-L-arginine (100 mg/mL each) or L-lysine and L-arginine (100 mg/mL each). Heavy and light cells were maintained in parallel and cell aliquots were frozen after six passages in SILAC media and stored in liquid N2 until needed. Whenever thawed, cells were passaged at least three times before being used in experiments.


cDNA Cloning and Mutagenesis


cDNAs encoding for NR0B1, SNW1, RBM45 were amplified from a cDNA pool generated from A549 cells and were subcloned into the FLAG-pRK5 or HA-pRK5 expression vectors. These cDNAs were also subcloned into the lentiviral expression vector FLAG-pLJM1 (Bar-Peled et al., Science 340, 1100-1106, 2013). The firefly luciferase gene was cloned into the lentiviral expression vector pLenti-pgk BLAST as described before (Goodwin et al., Mol. Cell 55, 436-450, 2014). Cysteine mutants were generated using QuikChange XLII site-directed mutagenesis (Agilent), using primers containing the desired mutations. All constructs were verified by DNA sequencing.


Mammalian Lentiviral shRNAs Expression


Lentiviral shRNAs targeting the messenger RNA for human NR0B1, SWN1, and AKR1B10 were cloned into pLKO.1 vector at the Age 1, EcoR1 sites.


shRNA-encoding plasmids were co-transfected with ΔVPR envelope and CMV VSV-G packaging plasmids into 2.5×106 HEK-293T cells using the Xtremegene 9 transfection reagent (Sigma-Aldrich). Virus-containing supernatants were collected forty-eight hours after transfection and used to infect target cells in the presence of 10 μg/ml polybrene (Santa Cruz). Twenty-four hours post-infection, fresh media was added to the target cells which were allowed to recover for an additional twenty-four hours. Puromycin was then added to cells, which were analyzed immediately or on the 2nd or 3rd day after selection was added.


Generation of CRISPR-Mediated Knockout HEK-293T Cell Lines


sgRNAs targeting KEAP1 or NRF2 (described below) were designed, amplified, and cloned into transient pSpCas9-2A-Puro (Addgene, PX459). 1×106 HEK-293T cells were transfected with the pSpCa9-2A-Puro plasmid containing sgRNAs targeting KEAP1 or NRF2. Following puromycin selection, clonal cells were isolated by flow cytometry and analyzed for the increased or decreased expression of NRF2 by immunoblot for KEAP1-null or NRF2-null cells, respectively.


Generation of CRISPR-Mediated Knockout H460 Cell Lines


NR0B1-null or CYP4F11-null H460 cells were generated using the protocol described in (Shalem et al., 2014). In brief, sgRNAs targeting NR0B1, CYP4F11 or AKR1B10 were designed, amplified, and cloned into transient Lenti-CRISPR v2 (Addgene). Mammalian lentiviral particles harboring sgRNA-encoding plasmids were generated as described above, with the exception that the viral supernatant was concentrated with LentiX (Clontech) prior to infection of H460 cells. Following 10 days of puromycin selection, clonal cells were isolated by flow cytometry and analyzed for decreased expression of NR0B1, CYP4F11 or AKR1B10 when compared to a parental population expressing a non-targeting sgRNA (CRISPR-CTRL).


Mammalian Lentiviral cDNA Expression


Mammalian lentiviral particles harboring cDNA-encoding plasmids were generated as described above, with the exception that the viral supernatant was concentrated with LentiX (Clontech) prior to infection of target cells. Cells were allowed to recover for 24 h followed by continuous selection with puromycin.


Identification of NR0B1 Interacting Proteins


Confluent 15 cm dishes of A549 stably or transiently expressing FLAG-NR0B1 or FLAG-METAP2, were rinsed with ice-cold PBS and were sonicated in the presence of Chaps IP buffer (0.3% Chaps, 40 mM Hepes pH 7.4, 50 mM KCl, 5 mM MgCl2 and EDTA-free protease inhibitors (Sigma)). Following lysis, samples were clarified by centrifugation for 10 min at 16,000×g. FLAG-M2 beads (100 μL, 50:50 slurry) was added to the clarified supernatant and incubated for 3 h while rotating at 4° C. Beads were washed once with Chaps IP buffer and three times with Chaps IP buffer supplemented with 150 mM NaCl. Proteins were eluted with the FLAG peptide from the FLAG-M2 beads, run on a 4-20% Tris-glycine gel (Invitrogen) and stained with InstantBlue (Expedeon). Each lane was cut into 10 pieces and in-gel trypsin (Promega) digestion was performed. The resulting digests were analyzed by liquid chromatography tandem mass spectrometry (LC-MS/MS). MS2 spectra data were extracted from the raw file using RAW Convertor (version 1.000). MS2 spectra data were searched using the ProLuCID algorithm using a reverse concatenated, non-redundant variant of the Human UniProt database (release-2012_11). Cysteine residues were searched with a static modification for carboxyamidomethylation (+57.02146) and one differential modification for oxidized methionine (+15.9949). Spectral counts for proteins from FLAG-NR0B1 immunoprecipitates were compared to spectral counts for proteins from FLAG-METAP2 immunoprecipitates across 5-6 biological replicates. Interacting proteins were classified as those proteins whose corresponding peptides were enriched by greater that 20-fold in FLAG-NR0B1 immunoprecipitates compared to FLAG-METAP2 immunoprecipitates.


For identification of endogenous NR0B1 interacting proteins, A549, H2122 or H460 cell lysates were prepared as described above. The NR0B1 (Cell Signaling Technology), RagC (Cell Signaling Technology) or GAPDH (Santa Cruz) antibodies were added to each lysate and incubated with rotation at 4° C. for 1.5 h. Subsequently, protein G sepharose beads (50 μL, 50:50 slurry) were added to each sample and incubated for an additional 1.5 h. Beads were washed as described above and proteins were eluted with 8M urea at 30° C. for 1 h. Proteins were reduced by treatment with DTT (10 mM for 30 min at 65° C.) and cysteines were alkylated with iodoacetamide (20 mM for 30 min at 37° C.). Urea was diluted to 2M and proteins were digested with 2 μg of Trypsin (Promega). The resulting digests were analyzed by mass spectrometry as described below.


Co-Transfection Based Interaction Experiments


For transfection experiments, 4×106 HEK-293T cells were plated in a 10 cm dish. The next day, cells were transfected with the pRK5-based cDNA expression plasmids indicated in the figures in the following amounts. Figure S4: 25 ng FLAG-RBM45, 100 ng FLAG-NR0B1, 200 ng HA-SNW1; FIG. 5 and FIG. 11: for in-vitro binding experiments: 5000 ng FLAG-SNW1; for in vitro binding experiments with transiently transfected NR0B1: 25 ng HA-NR0B1 or HA-NR0B1-C274V; for fluorescence experiments: 5000 ng Flag-NR0B1 or 5000 ng FLAG-NR0B1-C274V; FIG. 5S: for site of labeling experiments, 5000 ng FLAG-NR0B1. Following transfections, cells were grown for 48 h and processed as described below.


Compound Treatment for Assessment of Protein-Protein Interactions


Confluent 10 cm plates of indicated cell lines were rinsed once with warm PBS and incubated in serum/dye-free RPMI with indicated compounds or vehicle for 3 h at 37° C. Cells were washed once ice-cold PBS and snap frozen.


Cell Lysis and Immunoprecipitations


Cells were rinsed once with ice-cold PBS, and lysed by sonication in Triton IP buffer. Lysates were clarified by centrifugation at 16,000×g for 10 min. Samples were normalized to 1 mg ml−1 and boiled following the addition of sample buffer. For FLAG- or HA-immunoprecipitations, FLAG or HA resins (30 μL, 50:50 slurry) were added to the pre-cleared lysates and incubated with rotation for 3 hours at 4° C. Following immunoprecipitation, the beads were washed once with IP buffer followed by 3 times with IP buffer containing 500 mM NaCl. Loading buffer (40 μL) was added to the immunoprecipitated proteins which were subsequently denatured by boiling. Proteins were resolved by SDS-PAGE, analyzed by immunoblotting and relative band intensities were quantified using ImageJ software.


In Vitro Binding Assay


H2122 clarified cell lysate (100 μL, 1 mg ml−1) in IP-buffer were incubated with the indicated compounds or vehicle (DMSO) for 3 hours at 4° C. with rotation. Following treatment, 3 volumes of IP-buffer was added along with immobilized FLAG-SNW1 beads (30 μL, 50:50 slurry), which was incubated for an additional hour at 4° C. Beads were washed three times with IP-buffer supplemented with 500 mM NaCl. Immunoprecipitated proteins were resolved by SDS-PAGE and analyzed by immunoblotting. NR0B1 and HA-NR0B1 levels were determined by using the NR0B1 antibody (Cell Signaling). IC50 curves were determined using Prism 6 (Graphpad) software, with maximum and minimum values set at 100% NR0B1 bound 0% NR0B1 bound respectively.


Immunofluorescence


Samples were prepared as follows. In brief, 1×105 A549 cells stably expressing FLAG-RBM45 or FLAG-SNW1 were plated on poly-lysine coated glass coverslips in 12-well tissue culture plates. Forty-eight hours later, the culture media was removed and cells were fixed with 4% paraformaldehyde (Electron microscopy services). The slides were rinsed three times with PBS and cells were permeabilized with 0.05% Triton X-100 in PBS for 1 min. The slides were rinsed four times with PBS and incubated with primary antibodies in 5% normal donkey serum (Thermo) overnight at 4° C. After rinsing four times with PBS, the slides were incubated with secondary antibodies conjugated to the indicated fluorophores (Invitrogen) for 1 h at room temperature. Following an additional four washes with PBS, the slides were stained with Hoechst (Invitrogen) following the manufacturer's protocol. Slides were mounted on glass coverslips using Prolong Gold® Antifade reagent (Invitrogen) and imaged on Zeiss LSM 780 laser scanning confocal microscope. Images were processed using ImageJ software.


Measurement of Glycolytic Flux


Cells were plated on poly-L-lysine coated 96-well Seahorse plates (Seahorse Biosciences) after lentiviral infection with shNRF2 or shGFP and equilibrated for 1 h in DMEM (Sigma D6030) containing 2 mM glutamine in the absence of serum and glucose. Basal extracellular acidification rate (ECAR) was then analyzed in the Seahorse XFe96 flux analyzer (Seahorse Biosciences), followed by ECAR measurements after sequential injections of 10 mM glucose, 2 μM oligomycin and 100 mM 2-deoxyglucose (2-DG).


Measurement of Intracellular Glutathione Levels


H2122 or H1975 cells expressing shRNAs targeting a control or NRF2 were cultured in 6-well plates and total cellular glutathione content was determined using the Glutathione Assay Kit (Cayman Chemical) following the manufacturer's protocol. Absorbance from GSH reaction with DTNB was measured using a Biotek Synergy 2 microplate reader (Biotek).


Measurement of GAPDH Activity


2.5×105 H2122 or H1975 cells expressing shRNAs targeting a control or NRF2 were cultured in 6-well plates and GAPDH activity was determined using Ambion KDalert GAPDH Assay Kit (Fisher) following the manufacture's protocol. This assay measures the conversion of NAD+ to NADH by GAPDH in the presence of glyceraldehyde-3-phosphate. The rate of NADH production correlated to an increase in fluorescence was measured by using a Biotek Synergy 2 microplate reader (Biotek).


Measurement of Cytosolic Hydrogen Peroxide Levels


Cytosolic hydrogen peroxide was measured using the Peroxyfluor-6 acetoxymethyl ester (PF6-AM) fluorescent probe as described in (Dickinson et al., Nat Chem Biol 7, 106-112, 2011). In brief, cells were washed twice with warm PBS and incubated with 250 nM of PF6-AM in serum-free RPMI for 20 min at 37° C. Cells were allowed to recover in complete RPMI for 1 h and were subsequently harvested and resuspended in sorting buffer (PBS+1% FBS). Flow cytometry acquisition was performed with BD FACSDiva™-driven BD™ LSR II flow cytometer (Becton, Dickinson and Company) which measured the increase in PF6-AM fluorescence. Data was analyzed with FlowJo software (Treestar Inc.)


Monolayer Proliferation Assay


Cells were cultured in 96-well plates at 3×103 cells per well in 100 μl of RPMI. At the indicated time points 50 μl of Cell Titer Glo reagent (Promega) was added to each well and the luminescence read on a Biotek Synergy 2 microplate reader (Biotek).


qPCR Analysis


2.5×105 cells/well of a 6-well plate were seeded the night before treatment. Cells were treated with the indicated concentrations of compound as denoted in the figure legends for 12 h. Total RNA was isolated using the RNeasy Kit (Qiagen) according to the manufacturer's protocol. cDNA amplification was preformed using iScript Reverse Transcription Supermix kit (Bio-Rad). qPCR primer sequences were obtained from PrimerBank and are listed below. qPCR analysis was performed on a ABI Real Time PCR System (Applied Biosystems) with the SYBR green Mastermix (Applied Biosystems). Relative gene expression was normalized to the 18S gene.


Gel-Based Competition of BPK-29Yne Labeling of NR0B1


4×106 HEK-293T cells were seeded in poly-L-lysine coated 10 cm plates and transfected the next day with 5 μg of FLAG-NR0B1, FLAG-NR0B1-C274V, or FLAG-METAP2 cDNA in a pRK5-based expression vector. 48 h after transfection, cells were treated with indicated concentrations of BPK-29 or control compound BPK-27 for 3 h at 37° C. in DMEM containing 10% FBS and supplements as described in Cell Culture. BPK-29yne (5 μM) was then added and incubated for an additional 30 min at 37° C. FLAG immunoprecipitates were prepared as described above and following washes, the FLAG resin was resuspended in PBS (100 μL). To each sample, 12 μL of a freshly prepared “click” reagent mixture was added to conjugate the fluorophore to probe-labeled proteins. CuAAC reaction mixture consisted of TAMRA azide (1 μL of 12.5 mM stocks in DMSO, final concentration=125 μM), 1 mM tris(2-carboxyethyl)phosphine hydrochloride (TCEP; 2 μL of fresh 50× stock in water, final concentration=1 mM), ligand (6 μL 17× stock in DMSO:t-butanol 1:4, final concentration=100 μM) and 1 mM CuSO4 (2 μL of 50× stock in water, final concentration=1 mM). Upon addition of the click mixture, each reaction was immediately mixed by vortexing and then allowed to react at ambient temperature for 1 h before quenching the reactions with 100 μL of loading buffer. Samples were boiled for 5 min and proteins were resolved by SDS-PAGE (10% acrylamide), and visualized by in-gel fluorescence on a Bio-Rad ChemiDoc MP flatbed fluorescence scanner. Samples were also analyzed by immunoblotting. Recombinantly expressed FLAG-tagged protein levels were determined with the FLAG antibody (Sigma). Gel fluorescence and imaging was processed using Image Lab (v 5.2.1) software.


Measurement of NR0B1 Degradation


7.5-8×105 H460 cells were seeded the night before per well of a 6-well plate. Cells were treated with cycloheximide (100 μg/mL) for the indicated time points. Cells were rinsed in ice-cold PBS, scraped on ice and processed for immunoblot analysis as described above. Proteins were resolved by SDS-PAGE, analyzed by immunoblotting and NR0B1 band intensities were quantified using ImageJ software and compared to a loading control (Beta-actin or GAPDH).


RNA Sequencing


RNA was isolated by RNeasy Kit (Qiagen) and digested with DNase (Qiagen) from n=3 samples per condition (cells expressing shGFP, shNRF2_1, shNR0B1_1 or shSNW1_1 or treated with DMSO, 30 μM BPK-29 or 30 μM BPK-9). RNA integrity (RIN) numbers were determined using the Agilent TapeStation prior to library preparation. mRNA-seq libraries were prepared using the TruSeq RNA library preparation kit (version 2) according to the manufacturer's instructions (Illumina). Libraries were then quantified, pooled, and sequenced by single-end 50 base pairs using the Illumina HiSeq 2500 platform at the Salk Next-Generation Sequencing Core. Raw sequencing data were demultiplexed and converted into FASTQ files using CASAVA (version 1.8.2). Libraries were sequenced at an average depth of 15 million reads per sample.


The spliced read aligner STAR (Dobin et al., 2013) was used to align sequencing reads to the human hg19 genome. Gene-level read counts were obtained based on UCSC hg19 gene annotation. DESeq2 (Love et al., 2014) was used to calculate differential gene expression based on uniquely aligned reads, and p-values were adjusted for multiple hypothesis testing with the Benjamini-Hochberg method.


ChIP-seq Analysis


ChIP was conducted as previously described (Komashko et al., Genome Res 18, 521-532, 2008). H460 cells were fixed in 1% formaldehyde (Sigma) for 15 minutes at 25° C. After lysis, samples were sonicated using a biorupter sonicator (Diagenode) for 60 cycles (30 seconds per cycle/30 seconds cooling) at a high power level. Chromatin sheering was optimized to a size range of 200 to 600 bp. Chromatin (100 μg) was immunoprecipitated with the NR0B1 antibody (Cell Signaling Technology). For DNA sequencing, samples were prepared for library construction, flow cell preparation and sequencing were performed according to Illumina's protocols. Sequencing was accomplished on Illumina HiSeq 2500 using PE 2×125 bp reads with over 14 million clusters per sample.


Sequencing reads were aligned to the hg19 genome using bowtie2 (Langmead and Salzberg, Nat Methods 9, 357-359, 2012). Peak detection was carried out using HOMER, comparing the NR0B1 IP sample against a whole-cell extract (WCE) with default parameters for transcription factor-style analysis. This requires relevant peaks to be significantly enriched over WCE and the local region with an uncorrected Poisson distribution-based p-value threshold of 0.0001 and false discovery rate threshold of 0.001. These peaks were further restricted to a 2 kb window around annotated transcription start sites.


Correlation Analysis:


For shRNA gene expression analysis data, the correlation of gene expression levels between the shNR0B1-cells and shNRF2-cells and shNR0B1-cells and shSNW1-cells was calculated using Pearson's correlation coefficient, and a correlation analysis was performed to calculate the p-value.


Circos Plot


A graphical summary of NR0B1 genome-wide effects. The inner track shows the change in gene expression following NR0B1 knockdown (red indicates an increase, blue a decrease). The middle track shows the normalized peak height of the NR0B1 ChIP. Only genes with both significantly altered expression (adjusted p-value threshold of 0.01 and 1.5-fold expression threshold) and an NR0B1 peak near a TSS are shown.


A graphical summary of liganded cysteines in KEAP1-WT and KEAP1-mutant cell lines. The outer track denotes total liganded cysteines in a given cell line (cysteines were defined as liganded if they had an average R≥5 and were quantified in two or more replicates). Grey chords connect liganded cysteines that are found in two or more cell lines.


GSEA


GSEA (Subramanian et al., PNAS 102, 15545-15550, 2005) was carried out using pre-ranked lists from FDR or fold change values, setting gene set permutations to 1000 and using either c1 collection in MSigDB version 4.0 (FIG. 10C).


Functional Gene Enrichment Analysis


Functional enrichment in gene sets was determined using the DAVID functional annotation tool (version 6.7) with “FAT” Gene Ontology terms (Huang da et al., Nat Protoc 4, 44-57, 2009).


isoTOP-ABPP Sample Preparation


Sample preparation and analysis were based on (Backus et al. Nature 534, 570-574, 2016) with modifications noted below.


For analysis of NR0B1 ligands or control compound reactivity, H460 cells or H460 cells expressing luciferase in a 10 cm plate were incubated with indicated compounds in serum/dye-free RPMI for 3 hours at 37° C. Cells were washed once ice-cold PBS and lysed in 1% Triton X-100 dissolved in PBS with protease inhibitors (Sigma) by sonication. Samples were clarified by centrifugation for 10 min at 16,000×g. Lysate was adjusted to 1.5 mg ml−1 in 500 μL.


For analysis of cysteines regulated by NRF2, H2222 or H1975 cells expressing shGFP or shNRF2 were lysed and processed as described above. Lysate was adjusted to 1.5 mg ml−1 in 500 μL.


For analysis of cysteines that change following induction of apoptosis, H2122 and H1975 cells were treated with DMSO or staurosporine (1 μM, 4 h) in full RPMI. H1975 cells were treated with DMSO or AZD9291 (1 μM, 24 h) in full RPMI. Cells were lysed as described above.


For analysis of ligandable cysteines in KEAP1-WT (H2122, H460 and A549) cells and KEAP1-mutant (H1975, H2009 (expressing the luciferase protein) and H358) cells, lysate was prepared as described in (Backus et al., 2016). Samples were treated with 500 μM of compound 2, 3 or vehicle for 1 h at room temperature.


isoTOP-ABPP IA-Alkyne Labeling and Click Chemistry


Samples were labeled for 1 h at ambient temperature with 100 μM iodoacetamide alkyne (1, IA-alkyne, 5 μL of 10 mM stock in DMSO). Samples were conjugated by copper-catalyzed azide-alkyne cycloaddition (CuAAC) to isotopically labeled, TEV-cleavable tags (TEV-tags). Heavy CuAAC reaction mixtures was added to the DMSO-treated or shGFP control samples and light CuAAC reaction mixture was added to compound-treated or shNRF2 samples. The CuAAC reaction mixture consisted of TEV tags (light or heavy, 10 μL of 5 mM stocks in DMSO, final concentration=100 μM), 1 mM tris(2-carboxyethyl)phosphine hydrochloride (TCEP; fresh 50× stock in water, final concentration=1 mM), ligand (17× stock in DMSO:t-butanol 1:4, final concentration=100 μM) and 1 mM CuSO4 (50× stock in water, final concentration=1 mM). The samples were allowed to react for 1 h at which point the samples were centrifuged (16,000×g, 5 min, 4° C.). The resulting pellets were sonicated in ice-cold methanol (500 μL) and the resuspended light- and heavy-labeled samples were then combined pairwise and centrifuged (16,000×g, 5 min, 4° C.). The pellets were solubilized in PBS containing 1.2% SDS (1 mL) with sonication and heating (5 min, 95° C.) and any insoluble material was removed by an additional centrifugation step at ambient temperature (14,000×g, 1 min).


isoTOP-ABPP Streptavidin Enrichment


For each sample, 100 μL of streptavidin-agarose beads slurry (Fisher) was washed in 10 mL PBS and then resuspended in 6 mL PBS (final concentration 0.2% SDS in PBS). The SDS-solubilized proteins were added to the suspension of streptavidin-agarose beads and the bead mixture was rotated for 3 h at ambient temperature. After incubation, the beads were pelleted by centrifugation (1,400×g, 3 min) and were washed (2×10 mL PBS and 2×10 mL water).


isoTOP-ABPP Trypsin and TEV Digestion


The beads were transferred to eppendorftubes with 1 mL PBS, centrifuged (1,400×g, 3 min), and resuspended in PBS containing 6 M urea (500 μL). To this was added 10 mM DTT (25 μL of a 200 mM stock in water) and the beads were incubated at 65° C. for 15 mins. 20 mM iodoacetamide (25 μL of a 400 mM stock in water) was then added and allowed to react at 37° C. for 30 mins with shaking. The bead mixture was diluted with 900 μL PBS, pelleted by centrifugation (1,400×g, 3 min), and resuspended in PBS containing 2 M urea (200 μL). To this was added 1 mM CaCl2 (2 μL of a 200 mM stock in water) and trypsin (2 μg, Promega, sequencing grade) and the digestion was allowed to proceed overnight at 37° C. with shaking. The beads were separated from the digest with Micro Bio-Spin columns (Bio-Rad) by centrifugation (1,000×g, 1 min), washed (2×1 mL PBS and 2×1 mL water) and then transferred to fresh eppendorf tubes with 1 mL water. The washed beads were washed once further in 140 μL TEV buffer (50 mM Tris, pH 8, 0.5 mM EDTA, 1 mM DTT) and then resuspended in 140 μL TEV buffer. 5 μL TEV protease (80 μM) was added and the reactions were rotated overnight at 29° C. The TEV digest was separated from the beads with Micro Bio-Spin columns by centrifugation (1,400×g, 3 min) and the beads were washed once with water (100 μL). The samples were then acidified to a final concentration of 5% (v/v) formic acid and stored at −80° C. prior to analysis.


isoTOP-ABPP Liquid-Chromatography-Mass-Spectrometry (LC-MS) Analysis


Samples processed for multidimensional liquid chromatography tandem mass spectrometry (MudPIT) were pressure loaded onto a 250 μm (inner diameter) fused silica capillary columns packed with C18 resin (Aqua 5 μm, Phenomenex). Samples were analyzed using an LTQVelos Orbitrap mass spectrometer (Thermo Scientific) coupled to an Agilent 1200-series quaternary pump. The peptides were eluted onto a biphasic column with a 5 μm tip (100 μm fused silica, packed with C18 (10 cm) and bulk strong cation exchange resin (3 cm, SCX, Phenomenex)) in a 5-step MudPIT experiment, using 0%, 30%, 60%, 90%, and 100% salt bumps of 500 mM aqueous ammonium acetate and using a gradient of 5-100% buffer B in buffer A (buffer A: 95% water, 5% acetonitrile, 0.1% formic acid; buffer B: 5% water, 95% acetonitrile, 0.1% formic acid) as has been described in (Weerapana et al., 2007). Data were collected in data-dependent acquisition mode with dynamic exclusion enabled (20 s, repeat of 2). One full MS (MS1) scan (400-1800 m/z) was followed by 30 MS2 scans (ITMS) of the nth most abundant ions.


isoTOP-ABPP Peptide and Protein Identification


The MS2 spectra data were extracted from the raw file using RAW Convertor (version 1.000). MS2 spectra data were searched using the ProLuCID algorithm (publicly available at http://fields.scripps.edu/downloads.php) using a reverse concatenated, non-redundant variant of the Human UniProt database (release-2012_11). Cysteine residues were searched with a static modification for carboxyamidomethylation (+57.02146) and up to two differential modification for either the light or heavy TEV tags or oxidized methionine (+464.28595, +470.29976, +15.9949 respectively).


MS2 spectra data were also searched using the ProLuCID algorithm using a custom database containing only selenocysteine proteins, which was generated from a reverse concatenated, nonredundant variant of the Human UniProt database (release-2012_11). In the database, selenocysteine residues (U) were replaced with cysteine (C) and were searched with a static modification for carboxyamidomethylation (+57.02146) and up to two differential modification for either the light or heavy TEV tags or oxidized methionine (+512.2304+ or +518.2442+15.9949). Peptides were required to have at least one tryptic terminus and to contain the TEV modification. ProLuCID data was filtered through DTASelect (version 2.0) to achieve a peptide false-positive rate below 1%.


isoTOP-ABPP R Value Calculation and Processing


The isoTOP-ABPP ratios (R values) of heavy/light for each unique peptide (DMSO/compound treated or shGFP/shNRF2) were quantified with in-house CIMAGE software (Weerapana et al., Nature 468, 790-795, 2010) using default parameters (3 MS1 acquisitions per peak and signal to noise threshold set to 2.5). Site-specific engagement of cysteine residues was assessed by blockade of IA-alkyne probe labelling. A maximal ratio of 20 was assigned for peptides that showed a ≥95% reduction in MS1 peak area from the experimental proteome (light TEV tag) when compared to the control proteome (DMSO, shGFP; heavy TEV tag). Ratios for unique peptide sequences entries were calculated for each experiment; overlapping peptides with the same modified cysteine (for example, different charge states, MudPIT chromatographic steps or tryptic termini) were grouped together and the median ratio is reported as the final ratio (R). Additionally, ratios for peptide sequences containing multiple cysteines were grouped together. Biological replicates of the same treatment and cell line were averaged if the standard deviation was below 60% of the mean; otherwise, for cysteines with at least one R value<4 per treatment, the lowest value of the ratio set was taken. For cysteines where all R values were ≥4, the average was reported. The peptide ratios reported by CIMAGE were further filtered to ensure the removal or correction of low-quality ratios in each individual data set. The quality filters applied were the following: removal of half tryptic peptides; removal of peptides which were detected only once across all data sets reported herein; removal of peptides with R=20 and only a single MS2 event triggered during the elution of the parent ion; manual annotation of all the peptides with ratios of 20, removing any peptides with low-quality elution profiles that remained after the previous curation steps.


For selenocysteines, the ratios of heavy/light for each unique peptide (DMSO/compound treated; isoTOP-ABPP ratios, R values) were quantified with in-house CIMAGE software using the default parameters described above, with the modification to allow the definition of selenocysteine (amino acid atom composition and atomic weights). Extracted ion chromatograms were manually inspected to ensure the removal of low quality ratios and false calls.


Cysteine residues were deemed to have significantly changed following NRF2 knockdown if they had R-values≥2.5. Changes in cysteine reactivity were considered reactivity based if a cysteine for a given protein had an R-value≥2.5 and all the remaining cysteines in that protein had R-values<1.5. If only one cysteine was identified per protein with an R value≥2.5, and if the corresponding change in the mRNA transcript was <1.5 (shGFP/shNRF2) then that change was also considered reactivity based. Changes in cysteine reactivity were considered expression based if a cysteine for a given protein had an R-value≥2.5 and all the remaining cysteines in that protein had R-values≥1.5. If only one cysteine was identified per protein with an R-value≥2.5, and if the corresponding change in the mRNA transcript was ≥1.5 (shGFP/shNRF2) then than change was also considered expression based. For datasets corresponding to changes in cysteine reactivity in H2122 cells expressing shNRF2 or shGFP at ‘Day 1/2’ two replicates were taken from the ‘Day 1’ time point and three replicates were taken from the ‘Day 2 time point’ (Tables 2 and 3). For datasets corresponding to changes in cysteine reactivity in H1975 cells expressing shNRF2 or shGFP at ‘Day 1/2’ two replicates were taken from the ‘Day 1’ time point and two replicates were taken from the ‘Day 2 time point’ (Tables 2 and 3). For datasets corresponding to changes in cysteine reactivity in H2122 cells expressing shNRF2 or shGFP at ‘Day1’ three replicates were used. Cysteine residues were designated as expression-based changes for this experiment if following NRF2 knockdown they had R-values≥2.5 and were considered unchanged if they had R-values<1.5 (Tables 2 and 3). Cysteines were considered significantly changed following staurosporine or AZD9291 treatment if they had R values≥2.5.


Cysteine residues were considered liganded in vitro by electrophilic fragments (compounds 2 or 3) if they had an average R-value≥5 and were quantified in at least 2 out of 3 replicates. Targets of NR0B1 ligands or control compounds were defined as those cysteine residues that had R-values≥3 in more than one biological replicate following ligand treatment in cells.


Protein Turnover


For analysis of protein turnover in H460 cells, confluent 10 cm plates were washed twice with warm PBS, then incubated in “heavy” RPMI for 3 h. Cells were washed once ice-cold PBS and lysed in 1% Triton 100-X dissolved in PBS with protease inhibitors (Sigma) by sonication. Lysate was adjusted to 1.5 mg ml−1 in 2×500 μL. Samples were processed identically to other samples (lysates were adjusted to 1.5 mg ml−1 in 2×500 μL), with the following modification: only isotopically light TEV tag was used. After the “click” reaction, both 2×500 μL were centrifuged (16,000×g, 5 min, 4° C.) and resuspended by sonication in ice-cold methanol (500 μL). Aliquots were then combined and resolubilized in PBS containing 1.2% SDS (1 mL) as detailed in isoTOP-ABPP IA-alkyne labeling and click chemistry. Samples were further processed and analyzed as detailed in: isoTOP-ABPP streptavidin enrichment, isoTOP-ABPP trypsin and TEV digestion, isoTOP-ABPP liquid-chromatography-mass-spectrometry (LC-MS) analysis, isoTOP-ABPP peptide and protein identification and isoTOP-ABPP R value calculation and processing with the following exceptions: Samples processed for protein turnover were searched with ProLuCID with mass shifts of SILAC labeled amino acids (+10.0083 R, +8.0142 K) in addition to carboxyamidomethylation modification (+57.02146) and two differential modification for either the light TEV tag or oxidize methionine (+464.28595, +15.9949 respectively). 1 peptide identification was required for each protein. ProLuCID data was filtered through DTASelect (version 2.0) to achieve a peptide false-positive rate below 1%. Ratios of light/heavy peaks were calculated using in-house CIMAGE software. Median SILAC ratios from one or more unique peptides were combined to generate R values. Proteins were required to be quantified in at least two biological replicates. The mean R values and standard deviation for multiple biological experiments were calculated from the average ratios from each replicate. Proteins were designated as rapid turnover if they had R-values≤8.


ABPP-SILAC Sample Preparation and LC-MS Analysis.


Isotopically labeled H460 cell lines were generated as described above. Light and heavy cells were treated with compounds (20 μM) or DMSO, respectively, for 3 h, followed by labeling with the BPK-29yne (5 μM) for 30 min. Cells were washed once ice-cold PBS and lysed in 1% Triton 100-X dissolved in PBS with protease inhibitors (Sigma) by sonication. Lysate was adjusted to 1.5 mg ml−1 in 500 μL. Samples were conjugated by CuAAC to Biotin-PEG4-azide (5 μL of 10 mM stocks in DMSO, final concentration=100 μM). CuAAC “click” mix contained TCEP, TBTA ligand and CuSO4 as detailed for isoTOP-ABPP sample preparation. Samples were further processed as detailed in: isoTOP-ABPP streptavidin enrichment and isoTOP-ABPP trypsin TEV digestion with the following exception: after overnight incubation at 37° C. with trypsin, tryptic digests were separated from the beads with Micro Bio-Spin columns (Bio-Rad) by centrifugation (1,000×g, 1 min). Beads were rinsed once with water (200 μL) and combined with tryptic digests. The samples were then acidified to a final concentration of 5% (v/v) formic acid and stored at −80° C. prior to analysis. Samples were processed for multidimensional liquid chromatography tandem mass spectrometry (MudPIT) as described in isoTOP-ABPP liquid-chromatography-mass-spectrometry (LC-MS) with the exception that peptides were eluted using the 5-step MudPIT protocol with conditions: 0%, 25%, 50%, 80%, and 100% salt bumps of 500 mM aqueous ammonium acetate and using a gradient of 5-100% buffer B in buffer A (buffer A: 95% water, 5% acetonitrile, 0.1% formic acid; buffer B: 5% water, 95% acetonitrile, 0.1% formic acid).


ABPP-SILAC Peptide and Protein Identification and R Value Calculation and Processing


The MS2 spectra data were extracted and searched using RAW Convertor and ProLuCID algorithm as described in isoTOP-ABPP peptide and protein quantification. Briefly, cysteine residues were searched with a static modification for carboxyamidomethylation (+57.02146 C). Searches also included methionine oxidation as a differential modification (+15.9949 M) and mass shifts of SILAC labeled amino acids (+10.0083 R, +8.0142 K) and no enzyme specificity. Peptides were required to have at least one tryptic terminus and unlimited missed cleavage sites. 2 peptide identifications were required for each protein. ProLuCID data was filtered through DTASelect (version 2.0) to achieve a peptide false-positive rate below 1%. Ratios of heavy/light (DMSO/test compound) peaks were calculated using in-house CIMAGE software. Median SILAC ratios from two or more unique peptides were combined to generate R values. The mean R values and standard deviation for multiple biological experiments were calculated from the average ratios from each replicate. Targets of NR0B1 ligands or control compounds were defined as those proteins that had R-values≥2.5 in two or more biological replicates following ligand treatment in cells.


Site of Labeling


For site of labeling with BPK-29, 4×106 HEK-293T cells were seeded in a 10 cm plate and transfected the next day with 5 μg of FLAG-NR0B1 cDNA in a pRK5-based expression vector. 48 hours after transfection, cells were treated with vehicle, BPK-29 (50 μM) in serum-free RPMI for 3 h at 37° C. FLAG immunoprecipitates were prepared as described above in Identification of NR0B1 interacting proteins. FLAG-NR0B1 was eluted from FLAG-M2 beads with 8M urea and subjected to proteolytic digestion, whereupon tryptic peptides harboring C274 were analyzed by LC-MS/MS. The resulting mass spectra were extracted using the ProLuCID algorithm designating a variable peptide modification (+252.986 and +386.1851 for BPK-26 and BPK-29, respectively) for all cysteine residues. For site of labeling with BPK-26, HEK-293T cell lysate transfected with FLAG-NR0B1 as described above was treated with vehicle or BPK-26 (100 μM) for 3 h at 4° C. FLAG immunoprecipitates were processed for proteomic analysis as described above.


Quantification and Statistical Analysis


Statistical analysis was preformed using GraphPad Prism version 6 or 7 for Mac, GraphPad Software, La Jolla Calif. USA, or the R statistical programming language. Statistical values including the exact n and statistical significance are also reported in the Figures. Inhibition curves of the NR0B1-SNW1 interactions by NR0B1-ligand are fit as using log(inhibitor) vs % normalized remaining of NR0B1-SNW1 interaction and data points are plotted as the mean±SD (n=2-5 per group). NR0B1 half-life was calculated from a one-phase exponential decay curve plotted as mean±SD (4-10 per group). Statistical significance was defined as p<0.05 and determined by 2-tailed Student's t-test (FIG. 1I, FIG. 3B), two-way Anova with Bonferroni post-test analysis (FIG. 1J) or correlation analysis using Pearson product-moment correlation coefficient (FIG. 4B, FIG. 10G).


Mapping Cysteine Reactivity in KEAP1-WT and KEAP1-Mutant NSCLC Cells


Several human NSCLC cell lines were identified that contain inactivating mutations in the gene encoding KEAP1 (H2122, H460, A549 and H1792), as well as additional NSCLC lines that were wild type (WT) for this gene (H1975 and H2009) (Tables 2 and 3). Small hairpin RNA (shRNA)-mediated knockdown of NRF2 in NSCLC cell lines with KEAP1 mutations, where NRF2 protein levels are stabilized (FIG. 7A), and impaired cell proliferation in conjunction with lowering NRF2 protein content (FIG. 1A, FIG. 1B, and FIGS. 7B-7C). In contrast, KEAP1-WT NSCLC lines were only marginally affected by NRF2-knockdown (FIG. 1A and FIG. 7D). Depletion of NRF2 in the KEAP1-mutant NSCLC line H2122 also led to a marked reduction in glutathione and a concomitant rise in cytosolic H2O2 compared to KEAP1-WT H1975 cells (FIGS. 7E-7F).


Cysteine reactivities in KEAP1-mutant (H2122) and KEAP1-WT (H1975) NSCLC lines were mapped following shRNA-mediated knockdown of NRF2 (shNRF2) using the isoTOP-ABPP platform, which employs a broadly reactive iodoacetamide alkyne (IA-alkyne, 1) probe for labeling, enriching, and quantifying cysteine residues in proteomes (FIG. 7G). Cells were evaluated at early (24, 48 h) time points following NRF2 knockdown (FIG. 7H) to minimize changes in cysteine reactivity that may have been indirectly caused by proliferation defects. NRF2-regulated cysteines were defined as those showing ≥2.5-fold changes in reactivity in shNRF2 cells compared to control shRNA (shGFP) cells (i.e., isoTOP-ABPP Ratio (R)≥2.5 for shGFP/shNRF2) and found that 156 cysteines of >3000 total quantified cysteines in H2122 cells satisfied this criterion (FIG. 1C and Tables 2 and 3). Approximately three times as many NRF2-regulated cysteines were observed on day 2 versus day 1 post-NRF2 knockdown in H2122 cells (FIG. 7I), which may reflect a proportional increase in changes caused by NRF2-regulated gene/protein expression (see below). In contrast, NRF2 depletion had minimal effects on cysteine reactivity in H1975 cells (FIG. 1C and Tables 2 and 3). It was also noted that several cysteines with prominent changes in shNRF2-H2122 cells were not detected in H1975 cells, likely reflecting that the proteins harboring these cysteines are themselves regulated by NRF2 (see below). It was further evaluated changes in cysteine reactivity in NSCLC cells caused by other anti-proliferative mechanisms—specifically treatment with the general kinase inhibitor staurosporine or the EGFR inhibitor AZD9291—neither of which caused substantive changes in cysteine reactivity in KEAP1-mutant or KEAP1-WT cells (FIGS. 7J-L and Tables 2 and 3). These results indicate that NRF2 disruption produces specific and widespread alterations in cysteine reactivity in KEAP1-mutant NSCLC cells.


NRF2-regulated cysteines were found in proteins from many different functional classes (FIG. 1D). In instances where all quantified cysteines for a given protein were altered in shNRF2-H2122 cells, it was concluded that the changes reflected an alteration in protein expression. In contrast, if only one of multiple cysteines for a given protein had a substantial reduction in IA-alkyne-reactivity (R≥2.5), with the other quantified cysteines remaining constant (R<1.5), it was noted that the change was reactivity-based. This analysis was supplemented by determining changes in gene expression in shNRF2-versus shGFP-H2122 cells by RNA sequencing (RNA-seq), which provided an expression estimate for proteins that contained only one quantified IA-alkyne-reactive cysteine. By combining the proteomic and gene expression analysis, it was determined that ˜80% of all changes in cysteine reactivity reflected alterations in protein abundance following NRF2-knockdown, with the remaining ˜20% identified as alterations in reactivity (FIG. 1E). Proteins harboring cysteines that underwent specific reactivity changes in shNRF2-H2122 cells were found in central pathways that include glycolysis (GAPDH), protein folding (PDIA3), protein translation (EEF2), and mitochondrial respiration (UQCRC1) (FIG. 1F). An example of a protein showing expression changes in shNRF2-H2122 cells was the canonical NRF2-regulated protein SQSTM1 (FIG. 1G). None of these cysteines were affected by NRF2 knockdown in H1975 cells (FIG. 7L).


A recent cysteine proteomics study performed in Kras-mutated mouse pancreatic cancer organoids deleted for NRF2 expression identified several redox-regulated cysteines (Chio et al., Cell 166, 963-976, 2016). It was noted, however, a minimal overall overlap (˜3%) in NRF2-regulated cysteines in the results compared to the study of Chio et al., which may reflect differences in the mode of NRF2 activation (KEAP1 mutations versus Kras/p53 mutations) tumor of origin (NSCLC versus pancreatic), species (human versus mouse), and/or method of assigning changes in cysteine reactivity (fold-change versus statistical).


The NRF2-regulated cysteines in PDIA3 (C57) and GAPDH (C152) are catalytic residues, designating them as candidate sites for NRF2 control over fundamental biochemical pathways in cancer cells. Another quantified cysteine outside of the GAPDH active site—C247 (FIG. 1F)—was unaltered in reactivity by NRF2 knockdown (FIG. 1F), and it was confirmed that GAPDH protein expression was unaffected in shNRF2 cells by immunoblotting (FIG. 1H). C152 in GAPDH is a redox-sensitive residue that is subject to S-sulphenylation and S-sulfhydration and in some instances is affected by pharmacologically induced forms of oxidative stress. Consistent with the conserved catalytic function performed by C152, shNRF2-H2122 cells, but not shNRF2-H1975 cells, showed decrease in GAPDH activity (FIG. 1I). NRF2 knockdown also produced reductions in basal glycolysis and maximal glycolytic rate that were more substantial in magnitude in H2122 cells compared to H1975 cells (FIG. 1J).


Mapping Cysteine Ligandability in KEAP1-WT and KEAP1-Mutant NSCLC Cells


The ligandability of cysteines in NRF2-regulated proteins was investigated by performing competitive isoTOP-ABPP of proteomes from three KEAP1-mutant (H2122, H460 and A549) and three KEAP1-WT (H1975, H2009 and H358) NSCLC lines with two electrophilic fragments—2 and 3 (FIG. 2A)—that showed broad cysteine reactivity in previous studies (Backus et al., 2016). These compounds were referred to as ‘scout’ fragments capable of providing a global portrait of covalent small molecule-cysteine interactions in native biological systems.


From a total of ˜9700 cysteines quantified across the proteomes of six NSCLC lines, ˜1100 scout fragment-sensitive, or ‘liganded’, cysteines were identified (FIG. 2A and FIGS. 8A-8B). Next this ligandability map was overlayed with the fraction of proteins showing changes in cysteine reactivity and/or gene expression in shNRF2 cells (FIG. 8C), resulting in the identification of ˜120 NRF2-regulated proteins with liganded cysteines (FIG. 2B). These proteins populated diverse metabolic and signaling pathways known to be modulated by NRF2 (FIG. 2C), but most were observed in both KEAP1-mutant and KEAP1-WT cells (FIG. 2D and FIG. 8D), indicating that NRF2 influenced, but did not strictly control the expression of these proteins in NSCLCs. Opposing this general profile was a much more restricted subset of liganded proteins that were exclusive to KEAP1-mutant cells (FIG. 2D and FIG. 8D). These proteins included NR0B1 (liganded at C274), CYP4F11 (liganded at C45), and AKR1B10 (liganded at C299) (FIG. 2D and FIG. 8D), which was confirmed by RNA-seq and western blotting were all decreased following knockdown of NRF2 in KEAP1-mutant NSCLC cells (FIG. 2E and FIGS. 8E-8F).


A broader survey of gene expression across >30 NSCLC lines confirmed the remarkably restricted expression of NR0B1, CYP4F11, and AKR1B10 to KEAP1-mutant cells (FIG. 3A and FIG. 9A). This expression profile was confirmed by western blotting (FIG. 9B) and was also observed in primary human lung adenocarcinoma (LUAD) tumors (FIG. 3B). NR0B1 and AKR1B10 have been shown to be important for the proliferation of certain cancers, including KEAP1-mutant NSCLC cells. The role of CYP4F11 in cancer cell growth has not been examined. Consistent with past work, it was found that shRNA knockdown of NR0B1 and AKR1B10 impaired the three-dimensional growth of H460 and H2122 cells. Similar effects were observed for CYP4F11. It was also found that CRISPR-mediated knockout of NR0B1 or CYP4F11 in H460 cells strongly reduced colony formation. Efforts to generate CRISPR knockout cells lacking AKR1B10 were unsuccessful.


NR0B1 Nucleates a Transcriptional Complex that Supports the NRF2 Gene Network


It was noted that most of these enzymes, as well as other NRF2-regulated genes and proteins, were expressed broadly across many human tissues. NR0B1, however, stood out as a striking contrast, being an atypical orphan nuclear receptor with very limited normal tissue expression. Structural studies have shown that NR0B1 possesses a very shallow pocket in place of the typical ligand-binding domain found in other nuclear receptors, indicating that NR0B1 may function as a “ligandless” adaptor or coregulatory protein. Consistent with this premise, NR0B1 acts as a transcriptional repressor of the nuclear receptors SF1 and LRH1 and supports development of Lydig and Serotoli cells in mice. Mutations in the NR0B1 gene lead to adrenal hypoplasia congenita (AHC) in human males. The biochemical and cellular functions of NR0B1 in human cancer and in particular, KEAP1-mutant cancer cells, however, remain poorly understood.


It was first assessed whether NR0B1 acts as a transcriptional regulator in KEAP1-mutant NSCLC cells. RNAseq analysis identified more than >2500 genes that were substantially altered (1.5-fold) in expression in shNR0B1 H460 cells, and ˜30% of these genes were located near transcriptional start sites (TSSs) bound by NR0B1 as determined by chromatin immunoprecipitation sequencing (ChIP-seq) (FIG. 4A). These results suggest that many of the NR0B1-regulated genes in NSCLC cells are in open chromatin under direct transcriptional control of NR0B1. Unbiased functional enrichment analysis (Huang da et al., 2009) revealed an overrepresentation of cell cycle-related and pro-proliferation functions in genes reduced in expression in shNR0B1 NSCLC cells (FIG. 10A) that included, for instance, strong E2F and Myc gene signatures (FIG. 10B). RNAseq analyses further revealed a substantial correlation in global gene expression changes induced by knockdown of NR0B1 or NRF2 in NSCLC cells (FIG. 4B), with >50% of the genes with substantially altered (>1.5 fold) expression in shNR0B1 cells showed a similar magnitude directional change in shNRF2 cells (FIG. 4B). Among the most co-downregulated genes were those involved in proliferation and DNA metabolism/replication (FIG. 4C), consistent with the enrichment of these terms in the NR0B1-regulated gene set (FIG. 10B).


Considering the established function of NR0B1 as a coregulatory protein that participates in nuclear receptor complexes, it was hypothesized that NR0B1 may interact with other proteins to regulate transcriptional pathways in KEAP1-mutant cancer cells. It was expressed a FLAG epitope-tagged form of NR0B1 in KEAP1-mutant NSCLC cells, immunoprecipitated NR0B1 from these cells, and identified associated proteins by mass spectrometry (MS)-based proteomics. Eleven proteins were substantially co-enriched (>20-fold) with NR0B1 compared to a control protein METAP2 (FIG. 10C). A subset of these proteins, including RBM45 and SNW1, were also confirmed by MS-based proteomics to interact with endogenous NR0B1 (FIG. 4D). Stably expressed FLAG-SNW1 and FLAG-RBM45, but not a control protein (FLAG-RAP2A), interacted with NR0B1 in multiple NSCLC cells (FIG. 4E and FIG. 10D), and both SNW1 and RBM45, like NR0B1, were localized to the nucleus of NSCLC cells (FIG. 10F). SNW1 did not directly interact with RBM45 in the absence of NR0B1 (FIG. 10E), indicating that NR0B1 bridges these two proteins to nucleate a multimeric protein complex (FIG. 4E). While very little is known about RBM45, SNW1 has been implicated as a transcriptional activator and found to interact with multiple nuclear receptors, including NR0B1, in large-scale yeast two-hybrid assays. Consistent with this role and with a coordinated function for SNW1 and NR0B1 in KEAP1-mutant cancer cells, RNAi-mediated knockdown of SNW1 produced a similar set of gene expression changes to those observed in shNR0B1 cells (FIG. 10G). SNW1 knockdown also blocked the anchorage independent growth of KEAP1-mutant NSCLC cells.


Covalent Small Molecules that Disrupt NR0B1 Protein Interactions


The liganded cysteine in NR0B1-C274—is located within a conserved “repression helix” that commonly possesses a LXXLL sequence in other nuclear receptors, but, in NR0B1, has been replaced by a PCFXXLP sequence, where the “C” is C274. Missense mutations within this general region of NR0B1 have been found to cause AHC (FIG. 5A), pointing to an important functional role for the repression helix. The hydrophobic residues in the repression helix of NR0B1, including C274, are solvent-exposed and appear to contribute to protein-protein interactions (FIG. 5A), suggesting that ligands targeting C274 might disrupt NR0B1 protein complexes.


Next, a chemical probe targeting C274 of NR0B1 was developed. Using an in vitro binding assay (FIG. 5B), an ˜80-member library of cysteine-reactive electrophilic compounds was screened at 50 μM for blockade of interactions between endogenous NR0B1 and recombinant FLAG-SNW1 in cell lysates (FIG. 5C). Among the hits (>50% blockade) were a series of N-disubstituted chloroacetamides (CAs), including BPK-26 (FIGS. 5D, 5E), that were selected for further investigation. The initial structure-activity relationship indicated more tolerance to substitution of the N-aryl compared to N-benzyl group of BPK-26, including a hit BPK-28 where the N-aryl group was replaced with an azepane group with only modest reductions in potency (FIG. 11A). Modifications to BPK-28, including installation of a morpholine group, generated compound BPK-29 (FIG. 5D) that recovered potency (FIG. 5E and FIG. 11B). Both BPK-26 and BPK-29 inhibited the NR0B1-SNW1 interaction with IC50 values between 10-20 μM in vitro (FIG. 11C). The initial screen also identified structurally related, inactive control compounds—BPK-9 and BPK-27 (FIGS. 5C, 5D)—that did not inhibit the NR0B1-SNW1 interaction across a tested concentration range of 1-50 μM (FIG. 5E and FIG. 11C). Finally, it was confirmed by LC-MS/MS analysis that BPK-26 and BPK-29 covalently modified C274 of NR0B1 (FIGS. 11D, 11E).


An alkyne analogue of BKP-29 (BPK-29yne) was synthesized and found that this probe labeled WT-NR0B1, but not a C274V mutant (FIG. 5G), and this labeling was blocked by pre-treatment with BPK-29 in a concentration dependent manner (FIG. 5G and FIG. 11F). The C274V-NR0B1 mutant maintained binding to SNW1, but this protein-protein interaction was not sensitive to BPK-26 or BPK-29, supporting that these ligands disrupt the NR0B1 protein-protein interactions by covalently modifying C274 (FIG. 5G and FIG. 11G).


Cellular Studies with NR0B1 Ligands


IsoTOP-ABPP confirmed the cellular engagement of C274 of NR0B1 by BPK-26 and BPK-29 in NSCLC cells (FIG. 6A and Table 5), with both compounds achieving ˜70% target occupancy when tested at 40 μM for 3 h (FIG. 6A and FIG. 12A). In contrast, the inactive control compounds BPK-9 and BPK-27 did not engage C274 (FIG. 6A and Table 5). Nine additional cysteines among the >1500 total cysteines quantified by isoTOP-ABPP cross-reacted with BPK-26 and/or BPK-29 in NSCLC cell proteomes (FIGS. 6A, 6B and Table 5), and most of these cysteines also reacted with the control compounds (FIG. 6B and Table 5). NR0B1 was the only target shared between BPK-26 and BPK-29 that did not cross-react with the control compounds (FIG. 6B and Table 5). C274 was also the only cysteine in NR0B1 engaged by BPK-26 and BPK-29 among several other quantified cysteines (FIG. 12B). BPK-29 displayed superior potency compared to BPK-26, achieving >50% engagement of C274 at 5 μM in NSCLC cells (FIG. 12A). The BPK-29yne probe was employed to further characterize the protein targets of BPK-29 in NSCLC cells following the chemical proteomic workflow outlined in FIG. 12C, which verified most of the targets mapped by isoTOP-ABPP and revealed another seven proteins engaged by BPK-29, all of which also cross-reacted with the control compounds (Table 5). Taken together, these data indicate that BPK-26 and BPK-29 substantially engage NR0B1 with good overall proteomic selectivity in KEAP1-mutant NSCLCs.


Next it was asked whether BPK-26 and BPK-29 inhibited NR0B1 protein interactions in cells using two complementary systems. First, KEAP1-null HEK293T cells were generated and found that these cells show elevated expression of NR0B1 (FIG. 12D). KEAP1-null HEK293T cells, or KEAP1-mutant NSCLC cells, were then engineered to stably express FLAG-tagged RMB45 or SNW1 and treated with BPK-26 and BPK-29 or inactive control compounds. In both cell systems, BPK-26 and BPK-29, but not control compounds, blocked the interactions of FLAG-tagged RMB45 or SNW1 with endogenous NR0B1 (FIG. 6C and FIG. 12E-F). BPK-29 blocked NR0B1-protein interactions with better potency than BPK-26 (FIG. 6D and FIG. 12G).


Based on its in situ activity (FIG. 6D and FIG. 12A, 12G) and selectivity (FIGS. 6A, 6B), BPK-29 was chosen for additional biological studies. Treatment of KEAP1-mutant NSCLC cells with BPK-29 (5 μM) blocked colony formation in soft agar. Control compounds BPK-9 and BPK-27 had much less of an effect. Exogenous expression of WT or a C274V mutant of NR0B1 albeit partially rescued the growth inhibition caused by BPK-29. In contrast, BPK-29 (5 μM), or NR0B1 knockdown, minimally affected the anchorage-independent growth of KEAP1-WT NSCLC cells.


BPK-29 (30 μM, 12 h) also produced some of the gene expression changes caused by shRNA-mediated disruption of NR0B1 or NRF2 in KEAP1-mutant NSCLC cells (FIG. 13A), including reductions in CRY1, DEPDC1, and CPLX2 (FIG. 13B-C), which were not observed in KEAP1-WT NSCLC cells treated with BPK-29 (FIG. 13B). It was further confirmed that BPK-29-treated cells also showed a substantial reduction in CRY1 protein content (FIG. 13D). These gene and protein expression changes were not observed in KEAP1-mutant NSCLC cells treated with control compound BPK-9 (FIG. 13A-D).


In the course of studying the cellular activity of BPK-29, the concentration-dependent change in engagement of C274 of NR0B1 was less relative to other targets of the compound (FIG. 12A). Covalent ligands like BPK-29 engage proteins in a time-dependent manner, which led to speculate that differences in protein turnover rate in cells could affect the maximal absolute engagement of NR0B1 by BPK-29. Accordingly SILAC pulse-chase chemical proteomics experiments was performed in Keap1-mutant NSCLC cells, which revealed that NR0B1 was among a select subset of NRF2-regulated proteins that exhibit rapid turnover in NSCLC cells (FIG. 6G). These fast-turnover proteins generally corresponded to those that displayed early time point changes in protein abundance in our original isoTOP-ABPP analysis of shNRF2 cells (FIG. 6H). Similar results were obtained in KEAP1-mutant NSCLC cells treated with cycloheximide, which provided a half-life estimate for NR0B1 of ˜4.8 h (FIG. 13E). These findings demonstrate that NR0B1 is a short half-life protein in KEAP1-mutant NSCLC cells, possibly explaining its rapid decrease following NRF2 disruption and substantive, but incomplete engagement by BPK-29 in cells (FIG. 6A and FIG. 12A).









TABLE 5







Proteome-wide selectivity of NR0B1 ligand BPK-29














BPK-29-
BPK-29-






competed
competed
Competed
Competed by




isoTOP-ABPP
BPK-29yne
residues
control ligands


UniProt ID
Protein
analysis#
analysis*
(peptide)
BPK-9/27*,#





P51843
NR0B1
Yes
Yes
C274
No


Q8WV74
NUDT8
Yes
Yes
C207
Yes


P22307
SCP2
Yes
Yes
C94
Yes


P10599
TXN
Yes
Yes
C35
Yes


Q16881
TXNRD1{circumflex over ( )}
Yes
Yes
U648
Yes


O95881
TXNDC12
Yes
Yes
C66
No


Q99757
TXN2
Yes

C90
Yes


P00352
ALDH1A1

Yes

Yes


Q9BRX8
FAM213A

Yes

Yes


Q9BVL4
SELO{circumflex over ( )}

Yes

Yes


P78417
GSTO1

Yes

Yes


Q5TFE4
NT5DC1

Yes

Yes


Q9H7Z7
PTGES2

Yes

Yes





{circumflex over ( )}Contains conserved functional (seleno)cysteine residue


*Competed defined as showing R value ≥ 2.5 at 20 μM of test compound



#Competed defined as showing R value ≥ 3.0 at 40 μM of test compound



— BPK-29-competed protein or peptide not detected






Example 3
Synthetic Methodology
Example S-1: Synthesis of 2-chloro-1-(4-((6-methoxypyridin-3-yl)methyl)piperidin-1-yl)ethan-1-one (BPK-1)



embedded image


Step 1.

Under an atmosphere of nitrogen, 9-BBN (0.5 M in THF, 5.1 mL, 2.53 mmol, 1.0 eq) was added to a solution tert-butyl 4-methylenepiperidine-1-carboxylate (500.0 mg, 2.53 mmol, 1.0 eq) in THF (12 mL) at 20° C. and the reaction was heated at reflux for 3 h. The mixture was then cooled down to 20° C., followed by the addition of CsF (769.0 mg, 5.06 mmol, 2.0 eq), 4-bromo-2-methoxy-pyridine (333.0 mg, 1.77 mmol, 0.7 eq), water (6 mL), and bis(tri-tert-butylphosphine)palladium(0) (38.8 mg, 0.076 mmol, 0.03 eq). The reaction was heated at reflux for 12 h and the progress was monitored by TLC (Petroleum ether: EtOAc=10: 1). Upon completion, the mixture was allowed to cool down and extracted with EtOAc (15 mL×3). The combined organic layers were washed with brine (50 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (Petroleum ether: EtOAc=50: 1 to 20: 1) to afford compound SI-1 (350.0 mg, 45%) as light-yellow oil, which was used in the next step without further purification. Step 2.


A mixture of compound SI-1 (250.0 mg, 0.82 mmol, 1.0 eq) in HCl/MeOH (4 M, 5 mL) was stirred at 15° C. for 2 h. Upon completion, the reaction was concentrated in vacuo to afford compound SI-2 (220.0 mg, HCl salt) as yellow oil, which was used in the next step without further purification. Step 3.


2-chloroacetyl chloride (57.0 μL, 0.72 mmol, 2.0 eq) was added to a solution of compound SI-2 (100.0 mg, 0.36 mmol, 1.0 eq, HCl salt) and NEt3 (49.9 μL, 0.36 mmol, 1.0 eq) in DCM (5 mL) at 0° C. and the resulting mixture was stirred at 15° C. for 1 h. Upon completion, the reaction mixture was concentrated in vacuo and purified by prep. HPLC (TFA conditions) to afford the title compound (11.6 mg, 11%) as a light yellow solid. 1H NMR (D2O, 400 MHz) δ 8.32 (dd, J=9.1, 2.3 Hz, 1H), 8.09 (d, J=2.2 Hz, 1H), 7.44 (d, J=9.1 Hz, 1H), 4.38-4.21 (m, 3H), 4.16 (s, 3H), 3.93-3.84 (m, 1H), 3.18-3.09 (m, 1H), 2.77-2.64 (m, 3H), 2.01-1.86 (m, 1H), 1.78-1.66 (m, 2H), 1.29 (qd, J=12.6, 4.3 Hz, 1H), 1.17 (qd, J=12.7, 4.3 Hz, 1H). HRMS electrospray (m/z): [M+H]+ calcd for C14H20C1N2O2: 283.1208, found: 283.1210.


Example S-2: Synthesis of 2-chloro-1-(4-phenoxypiperidin-1-yl)ethan-1-one (BPK-2)



embedded image


Step 1.

DIAD (2.2 g, 10.9 mmol, 1.1 eq) was added to a solution of compound tert-butyl 4-hydroxypiperidine-1-carboxylate (2.0 g, 9.9 mmol, 1.0 eq), PPh3 (2.9 g, 10.9 mmol, 1.1 eq.) and phenol (935.2 mg, 9.9 mmol, 1.0 eq) in THF (20 mL) at 0° C. The resulting mixture was stirred at 15° C. for 1 h, after which the solvent was removed under vacuum and the residue was purified by prep. HPLC (basic conditions) to afford tert-butyl 4-phenoxypiperidine-1-carboxylate (SI-3) as yellow oil.


Step 2.

In a round-bottom flask HCl in dioxane (4 M, 3.6 mL, 4.0 eq) was added dropwise to a solution of compound SI-3 (1.0 g, 3.6 mmol, 1.0 eq) in dioxane (10 mL) at 0° C. The mixture was stirred at 15° C. for 1 h. Upon completion, the reaction mixture was concentrated under vacuum to afford compound SI-4 (500.0 mg) as an off-white solid, which was used in Step 3 without additional purification.


Step 3.

Under an atmosphere of nitrogen, 2-chloroacetyl chloride (74 μL, 0.94 mmol, 2.0 eq) was added dropwise to a solution of compound SI-4 (100.0 mg, 0.47 mmol, 1.0 eq) and NEt3 (261 μL, 1.87 mmol, 4.0 eq) in anhydrous DCM (1 mL) at 0° C. The mixture was stirred at 15° C. for 1 h. Upon completion, the reaction was quenched by the addition of water (50 mL) at 15° C., extracted with DCM (3×75 mL) and washed with brine (25 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated under vacuum. The residue was purified by prep. HPLC (HCl conditions) to give compound the title compound as an off-white solid (49.5 mg, 42%). 1H NMR (CDCl3, 400 MHz) δ 7.33-7.27 (m, 2H), 6.97 (tt, J=7.4, 1.1 Hz, 1H), 6.94-6.90 (m, 2H), 4.63-4.56 (m, 1H), 4.10 (m, 2H), 3.86-3.63 (m, 3H), 3.50 (dt, J=13.8, 5.2 Hz, 1H), 2.05-1.83 (m, 4H). HRMS electrospray (m/z): [M+H]+ calcd for C13H17ClNO2: 254.0942, found: 254.0941.


Example S-3: Synthesis of 2-chloro-1-(4-phenoxyazepan-1-yl)ethan-1-one (BPK-3)



embedded image


Step 1.

DIAD (413.7 mg, 2.1 mmol, 1.1 eq) was added to a solution of tert-butyl 4-hydroxyazepane-1-carboxylate (400.4 mg, 1.9 mmol, 1.0 eq), PPh3 (536.7 mg, 2.1 mmol, 1.1 eq) and phenol (175.0 mg, 1.9 mmol, 1.0 eq) in THF (4 mL) at 0° C. The resulting mixture was stirred at 15° C. for 16 h. Reaction progress was monitored by TLC (Petroleum ether: EtOAc=50: 1). Upon completion, the mixture was concentrated under vacuum and the residue was purified by silica gel chromatography to afford intermediate SI-5 as colorless oil (400.0 mg, 72%).


Step 2.

In a round-bottom flask HCl in dioxane (4 M, 4.1 mL, 12.0 eq) was added dropwise to a solution of intermediate SI-5 (400.0 mg, 1.4 mmol, 1.0 eq) in dioxane (1 mL) at 0° C. The mixture was stirred at 15° C. for 1 h. Upon completion, the reaction mixture was concentrated under vacuum to afford compound SI-6 (300.0 mg, 94%) as a white solid, which was used in Step 3 without additional purification.


Step 3.

Under an atmosphere of nitrogen, 2-chloroacetyl chloride (69.9 μL, 0.88 mmol, 2.0 eq) was added dropwise to a solution of amine SI-6 (100.0 mg, 0.44 mmol, 1.0 eq) and NEt3 (245.0 μL, 1.76 mmol, 4.0 eq) in anhydrous DCM (1 mL) at 0° C. The mixture was stirred at 15° C. for 1 h. Upon completion, the reaction was quenched by the addition of water (50 mL) at 15° C., extracted with DCM (3×75 mL) and washed with brine (25 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated under vacuum. The residue was purified by prep. HPLC (HCl conditions) to give compound the title compound as colorless oil (51.0 mg, 43%). 1H NMR (CDCl3, 400 MHz) δ 7.25-7.16 (m, 2H), 6.92-6.82 (m, 1H), 6.80 (d, J=8.1 Hz, 2H), 4.54-4.40 (m, 1H), 4.10-3.98 (m, 2H), 3.76-3.36 (m, 4H), 2.14-1.87 (m, 4H), 1.85-1.74 (m, 1H), 1.74-1.58 (m, 1H). HRMS electrospray (m/z): [M+H]+ calcd for C14H19C1NO2: 268.1099, found: 268.1100.


Compounds of Examples S-4-S-7 were synthesized from a common intermediate SI-8, which was obtained from compound SI-7 (Backus et al. 2016) as follows:




embedded image


TFA (34.7 mL, 453.5 mmol, 10.0 eq) was added to a solution of compound SI-7 (16.0 g, 45.4 mmol, 1.0 eq) in DCM (20 mL) at 18° C. The resulting mixture was stirred at 18° C. for 3 h. Upon completion, the reaction mixture was concentrated in vacuo to give crude intermediate SI-8 (23.0 g) as yellow oil, which was used without further purification in the syntheses of Compounds of Examples S-4-S-7.


Example S-4: Synthesis of methyl 4-acetamido-5-(4-(2-chloro-N-phenylacetamido)piperidin-1-yl)-5-oxopentanoate (BPK-4)



embedded image


Step 1.

Acetic anhydride (95.0 mg, 0.93 mmol, 1.5 eq) was added to a solution of 2-amino-5-methoxy-5-oxo-pentanoic acid (100.0 mg, 0.62 mmol, 1.0 eq) in DCM (2.0 mL) at room temperature and the resulting mixture was stirred at 30° C. for 16 h. Upon completion, the mixture was concentrated in vacuo to afford crude compound SI-9 (120.0 mg), which was used in the next step without additional purification.


Step 2.

HATU (269.5 mg, 0.71 mmol, 1.2 eq) and DIEA (229.0 mg, 1.77 mmol, 3.0 eq) were added to a suspension of SI-9 (120.0 mg, 0.59 mmol, 1.0 eq) in DMF (2.0 mL). Intermediate SI-8 (238.3 mg, 0.68 mmol, 1.2 eq) was then added and the resulting mixture was stirred at 0° C. for 1 h. Upon completion, the reaction was acidified to pH 3 with HCl (0.5 M, 2 mL) and diluted with CH3CN (1 mL). Purification by prep. HPLC (HCl conditions) afforded the title compound (16.0 mg, 6%) as a white solid. 1H NMR (CDCl3, 400 MHz) δ 7.50-7.41 (m, 3H), 7.18-7.06 (m, 2H), 6.51 (br, 1H), 4.99-4.73 (m, 2H), 4.62 (d, J=13.0 Hz, 1H), 4.26-4.10 (m, 1H), 3.70 (s, 2H), 3.67 (s, 2H), 3.64 (s, 1H), 3.25-3.11 (m, 1H), 2.76-2.61 (m, 1H), 2.45-2.20 (m, 3H), 2.08-1.85 (m, 6H), 1.42-1.16 (m, 2H). HRMS electrospray (m/z): [M+H]+ calcd for C21H29C1N3O5: 438.1790, found: 438.1793.


Example S-5: Synthesis of N-(1-(3-acetamidobenzoyl)piperidin-4-yl)-2-chloro-N-phenylacetamide (BPK-5)



embedded image


Step 1.

Acetic anhydride (148.9 mg, 1.46 mmol, 2.0 eq) was added in one portion to a mixture of 3-aminobenzoic acid (100.0 mg, 0.73 mmol, 1.0 eq) in DCM (1 mL) at 15° C. The mixture was stirred at 15° C. for 16 h. Upon completion, the mixture was filtered and the filter cake was washed with DCM (3 mL), then dried in vacuo to afford 3-acetamidobenzoic acid (120.0 mg) as a white solid, which was used in the next step without further purification.


Step 2.

To a suspension of 3-acetamidobenzoic acid (225.2 mg, 0.61 mmol, 1.1 eq, TFA) in DMF (2 mL) were added HATU (254.7 mg, 0.67 mmol, 1.2 eq) and DIEA (216.4 mg, 1.7 mmol, 3.0 eq) followed by Intermediate SI-8 (100.0 mg, 0.56 mmol, 1.0 eq). The resulting mixture was stirred at 0° C. for 2 h. Upon completion, the mixture was quenched with water (5 mL) and extracted with EtOAc (3×3 mL). The combined organic layers were washed with hydrochloric acid (3 mL, 0.5 M) and concentrated in vacuo. The residue was diluted with CH3CN (5 mL) and purified by prep. HPLC (basic conditions) to afford the title compound (45.1 mg, 20%) as a white solid. 1H NMR (CDCl3, 400 MHz) δ 7.77 (s, 1H), 7.60-7.53 (m, 1H), 7.51-7.44 (m, 3H), 7.41-7.35 (m, 1H), 7.27 (t, J=7.7 Hz, 1H), 7.14 (br, 2H), 6.97 (d, J=7.7 Hz, 1H), 4.87-4.68 (m, 2H), 3.87-3.75 (m, 1H), 3.71 (s, 2H), 3.21-3.05 (m, 1H), 2.91-2.75 (m, 1H), 2.13 (s, 3H), 1.99-1.75 (m, 2H), 1.45-1.17 (m, 2H). HRMS electrospray (m/z): [M+H]+ calcd for C22H25C1N3O3: 414.1579, found: 414.1580.


Example S-6: Synthesis of 2-chloro-N-(1-(3-morpholinobenzoyl)piperidin-4-yl)-N-phenylacetamide (BPK-6)



embedded image


HATU (137.6 mg, 0.36 mmol, 1.5 eq) and DIEA (93.6 mg, 0.72 mmol, 3.0 eq) were added to a solution of intermediate SI-8 (100.0 mg, 0.27 mmol, 1.1 eq, TFA salt) in DMF (2 mL). 3-morpholinobenzoic acid (50.0 mg, 0.24 mmol, 1.0 eq) was then added and the resulting mixture was stirred at 15° C. for 16 h. Upon completion, the reaction mixture was diluted with CH3CN (3 mL) and purified by prep. HPLC (HCl conditions) to afford the title compound (37.0 mg, 34%) as a white solid. 1H NMR (CDCl3, 400 MHz) δ 7.93-7.88 (m, 2H), 7.56 (t, J=7.7 Hz, 1H), 7.51-7.43 (m, 4H), 7.18 (s, 2H), 4.87-4.69 (m, 2H), 4.34 (s, 4H), 3.71 (s, 3H), 3.51 (s, 4H), 3.22 (br, 1H), 2.86 (br, 1H), 1.92 (br, 2H), 1.42 (br, 2H). HRMS electrospray (m/z): [M+H]+ calcd for C24H29C1N3O3: 442.1892, found: 442.1892.


Example S-7: Synthesis of 2-chloro-N-phenyl-N-(1-(pyrimidine-4-carbonyl)piperidin-4-yl)acetamide (BPK-7)



embedded image


HATU (257.4 mg, 0.68 mmol, 1.2 eq) and DIEA (218.7 mg, 1.69 mmol, 3.0 eq) were added to a suspension of pyrimidine-4-carboxylic acid (70.0 mg, 0.56 mmol, 1.0 eq) in DMF (2 mL). Intermediate SI-8 (227.6 mg, 0.63 mmol, 1.1 eq, TFA salt) was then added and the resulting mixture was stirred at 0° C. for 2 h. Upon completion, the mixture was acidified to pH 3 with HCl (0.5 M, 2 mL), diluted with CH3CN (1 mL) and purified by prep. HPLC (HCl conditions) to afford the title compound (74.9 mg, 34%, HCl salt) as a red solid. 1H NMR (CDCl3, 400 MHz) δ 9.31 (s, 1H), 9.00 (d, J=4.6 Hz, 1H), 7.77 (d, J=4.4 Hz, 1H), 7.51-7.43 (m, 3H), 7.15 (s, 2H), 4.92-4.82 (m, 1H), 4.75 (d, J=13.2 Hz, 1H), 3.93 (d, J=12.2 Hz, 1H), 3.71 (s, 2H), 3.23 (t, J=12.8 Hz, 1H), 2.91 (t, J=12.0 Hz, 1H), 1.95 (dd, J=37.9, 12.2 Hz, 2H), 1.50-1.36 (m, 2H). HRMS electrospray (m/z): [M+H]+ calcd for C18H20ClN4O2: 359.1269, found: 359.1272.


Example S-8: Synthesis of N-(1-benzoylazepan-4-yl)-2-chloro-N-phenylacetamide (BPK-8)



embedded image


Step 1.

A solution of tert-butyl 4-oxoazepane-1-carboxylate (1.00 g, 4.7 mmol, 1.0 eq) in HCl/MeOH (4 M, 10.0 mL, 8.5 eq) was stirred at 15° C. for 12 h. Upon completion, the reaction mixture was concentrated in vacuo to give crude azepan-4-one (750.0 mg, HCl salt) as a white solid, which was used in Step 2 without further purification.


Step 2.

Benzoyl chloride (1.17 mL, 10.0 mmol, 2.0 eq) was added dropwise to a solution of azepan-4-one (0.75 g, 5.0 mmol, 1.0 eq, HCl salt) and NEt3 (2.10 mL, 15.0 mmol, 3.0 eq) in DCM (50 mL) at 0° C. The resulting mixture was stirred at 15° C. for 3 h, quenched with water (10 mL) and extracted with DCM (3×15 mL). The combined organic layers were washed with brine (5 mL), dried with anhydrous Na2SO4, filtered and concentrated to afford crude compound SI-10 (0.50 g) as colorless oil, which was used in step 3 without additional purification.


Step 3.

Under an atmosphere of nitrogen, AcOH (79.0 μL, 1.4 mmol, 1.0 eq) was added to a solution of compound SI-10 (300.0 mg, 1.4 mmol, 1.0 eq) and aniline (135.0 mg, 1.5 mmol, 1.05 eq) in anhydrous DCM (5 mL) at 15° C. The reaction was then stirred at 15° C. for 3 h. Subsequently, NaBH(OAc)3 (585.3 mg, 2.8 mmol, 2.0 eq) was added and the reaction was stirred at 15° C. for an additional 12 h. After this time, LCMS showed that half of the starting material was consumed. The reaction was quenched by the addition of water (5 mL) and extracted with DCM (3×10 mL). The combined organic layers were washed with brine (5 mL), dried with anhydrous Na2SO4, filtered and concentrated. The residue was purified by prep. HPLC (basic conditions) to afford compound SI-11 (230.0 mg) as a yellow solid.


Step 4.

Under an atmosphere of nitrogen, 2-chloroacetyl chloride (53 μL, 0.66 mmol, 2.0 eq) was added dropwise to a solution of compound SI-11 (150.0 mg, 0.51 mmol, 1.5 eq) and NEt3 (92 μL, 0.66 mmol, 2.0 eq) in anhydrous DCM (3 mL) at 0° C. The mixture was stirred at 15° C. for 12 h. Upon completion, the reaction was concentrated in vacuo and the residue was purified by prep. HPLC (HCl conditions) to afford the title compound as an off-white solid (50.0 mg, 41%). The compound was analyzed and further used as the racemate (R:S=1:1). 1H NMR (CDCl3, 400 MHz) δ 7.51-7.42 (m, 6H), 7.39-7.31 (m, 6H), 7.26 (br, 4H), 7.22-7.07 (m, 4H), 4.66 (q, J=12.3 Hz, 2H), 4.17-4.06 (m, 1H), 3.84-3.74 (m, 1H), 3.70 (dd, J=9.3, 2.2 Hz, 4H), 3.57-3.18 (m, 6H), 2.15-1.33 (m, 12H). HRMS electrospray (m z): [M+H]+ calcd for C21H24C1N2O2: 371.1521, found: 371.1519.


Example S-9: Synthesis of 2-chloro-N-((1-(4-morpholinobenzoyl)piperidin-4-yl)methyl)-N-(pyrimidin-5-yl)acetamide (BPK-9)



embedded image


Step 1.

HATU (6.10 g, 16.0 mmol, 1.2 eq) and DIEA (5.2 g, 40.1 mmol, 3.0 eq) were added to a solution of 4-morpholinobenzoic acid (3.05 g, 14.7 mmol, 1.1 eq) in DMF (30.0 mL). The resulting mixture was stirred at 20° C. for 1 h, after which piperidine-4-carbaldehyde (2.00 g, 13.4 mmol, 1.0 eq, HCl salt) was added to the mixture at 0° C. in several portions. The mixture was stirred at 20° C. for 16 h. Upon completion, the reaction was poured into water (300 mL) and extracted with DCM (3×100 mL). The combined organic layers were washed with brine (2×50 mL), dried over Na2SO4, filtered and concentrated in vacuo. Purification by prep. HPLC (TFA conditions) afforded compound SI-12 (1.15 g, 28%) as yellow oil.


Step 2.

A solution of pyrimidin-5-amine (113.2 mg, 1.2 mmol, 1.2 eq), AcOH (68 μL, 1.2 mmol, 1.2 eq), and compound SI-12 (300.0 mg, 1.0 mmol, 1.0 eq) in anhydrous MeOH (3.0 mL) was stirred at 63° C. for 30 h. NaBH3CN (187.0 mg, 3.0 mmol, 3.0 eq) was then added and the reaction mixture was stirred at 25° C. for additional 16 h. Upon completion, the reaction mixture was concentrated in vacuo, diluted with saturated aqueous NaHCO3 (2 mL) and extracted with DCM (3×3 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated. Purification by prep. HPLC (basic conditions) afforded compound SI-13 (185.0 mg, 48%) as colorless oil.


Step 3.

NaH (21.0 mg, 0.5 mmol, 60% in oil, 5.0 eq) was added to a solution of compound SI-13 (40.0 mg, 0.1 mmol, 1.0 eq) in anhydrous THF (1.0 mL) at 0° C. and the resulting suspension was stirred at 25° C. for 30 min. The reaction mixture was then cooled to 0° C. and 2-chloroacetylchloride (17 μL, 0.21 mmol, 2.0 eq) was added dropwise. The reaction was stirred at 25° C. for additional 20 h and subsequently quenched by dropwise addition of HCl (3 M, 3 mL). The resulting mixture was then neutralized to pH 3-5 with saturated aqueous NaHCO3 and extracted with DCM (3×2 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. Purification by prep. HPLC (HCl conditions) afforded the title compound (23.0 mg, 44%, HCl salt) as a light yellow solid. 1H NMR (DMSO-d6, 400 MHz) δ 9.19 (s, 1H), 8.95 (s, 2H), 7.34 (d, J=8.7 Hz, 2H), 7.28 (d, J=8.5 Hz, 2H), 4.13 (s, 2H), 3.89-3.81 (m, 4H), 3.71-3.59 (m, 2H), 3.35-3.26 (m, 4H), 2.81 (s, 2H), 1.69 (d, J=17.3 Hz, 3H), 1.20-1.01 (m, 2H). Note: peak at 5.00 ppm (2H) overlaps with a broad signal of HCl. HRMS electrospray (m/z): [M+H]+ calcd for C23H29C1N5O3: 458.1953, found: 458.1952.


Example S-10: Synthesis of N-(1-(1H-pyrrolo[2,3-b]pyridine-2-carbonyl)piperidin-4-yl)-2-chloro-N-phenylacetamide (BPK-10)



embedded image


Step 1.

Aniline (4.58 mL 50.2 mmol, 1.0 eq) and tert-butyl 3-oxopiperidine-1-carboxylate (10.0 g, 50.2 mmol, 1.0 eq) were added to a solution of AcOH (2.87 mL, 50.2 mmol, 1.0 eq) in anhydrous DCM (150 mL) and the mixture was stirred for 16 h. NaBH(OAc)3 (21.3 g, 100 mmol, 2.0 eq) was then added and the reaction was stirred for an additional 3 h. Upon completion, the mixture was washed with saturated aqueous NaHCO3 (50 mL) and brine (50 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuo to afford the intermediate SI-14 (15.0 g) as yellow oil, which was used in the next step without further purification.


Step 2.

2-chloroacetyl chloride (8.63 mL, 109.0 mmol, 2.0 eq) was added dropwise to a solution of intermediate SI-14 (15.0 g, 54.3 mmol, 1.0 eq) and NEt3 (30.0 mL, 217.0 mmol, 4.0 eq) in DCM (1 mL) at 0° C. The mixture was warmed to ambient temperature and stirred for 2 h. Upon completion, the reaction was quenched with water (15 mL) and extracted with DCM (3×5 mL). The combined organic layers were washed with brine (3×5 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give intermediate SI-15 (13.0 g) as yellow oil, which was used directly in the next step.


Step 3.

TFA (1.51 mL, 20.4 mmol, 3.0 eq) was added dropwise to a solution of intermediate SI-15 (2.40 g, 6.8 mmol, 1.0 eq) in DCM (2 mL) at 0° C. The mixture was then warmed to ambient temperature and stirred for 2 h. Upon completion, the reaction was quenched with water (2 mL) and extracted with DCM (3×2 mL). The combined organic layers were washed with brine (3×2 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to afford intermediate SI-16 (1.30 g) as yellow oil, which was used in the next step without additional purification.


Step 4.

A solution of HATU (281.4 mg, 0.74 mmol, 1.2 eq) and DIEA (323.0 μL, 1.9 mmol, 3.0 eq) in DMF (2 mL) was added to a solution of 1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid (100.0 mg, 0.62 mmol, 1.0 eq) in DMF and the resulting mixture was stirred for 30 min. Intermediate SI-16 (187.0 mg, 0.74 mmol, 1.2 eq) was then added and the mixture was stirred at 0° C. for another 1.5 h. Upon completion, the reaction was quenched with water (1 mL) and extracted with DCM (3×1 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The resulting residue was re-dissolved in CH3CN (1 mL) and water (0.5 mL) and purified by prep. HPLC (HCl conditions) to afford the title compound (70.0 mg, 25%, HCl salt) as yellow oil. 1H NMR (DMSO-d6, 400 MHz) δ 13.15 (s, 1H), 8.51-8.42 (m, 2H), 8.11 (s, 1H), 7.51-7.41 (m, 4H), 7.35 (d, J=5.9 Hz, 2H), 4.60-4.43 (m, 2H), 4.18 (s, 1H), 3.83 (s, 2H), 2.82-2.56 (m, 2H), 1.87 (d, J=10.7 Hz, 1H), 1.67 (d, J=12.6 Hz, 1H), 1.60-1.46 (m, 1H), 1.16-1.02 (m, 1H). HRMS electrospray (m/z): [M+H]+ calcd for C21H22C1N4O2: 397.1426, found: 397.1425.


Example S-11: Synthesis of 3-((N-phenylacrylamido)methyl)benzoic acid (BPK-11)



embedded image


Step 1.

A solution of acrylic acid (1.10 mL, 16.11 mmol, 1.5 eq), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (3.09 g, 16.11 mmol, 1.5 eq), DIEA (5.6 mL, 32.22 mmol, 3.0 eq), and 1-hydroxybenzotriazole (1.45 g, 10.74 mmol, 1.0 eq) in DCM (20 mL) was stirred at 20° C. for 1 h, after which aniline (1.00 g, 10.74 mmol, 1.0 eq) was added dropwise at 0° C. The reaction was stirred at 20° C. for 11 hours and the reaction progress was monitored by TLC (Petroleum ether:EtOAc=1:3). Upon completion, the mixture was diluted with water (20 mL) and extracted with dichloromethane (20 mL×2). The combined organic layers were washed with brine (50 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (Petroleum ether:EtOAc=10:1) to afford compound SI-17 (300.0 mg, 7%) as an off-white solid.


Step 2.

A mixture of compound SI-17 (150.0 mg, 1.02 mmol, 1.0 eq), methyl 3-(bromomethyl)benzoate (233.0 mg, 1.02 mmol, 1.0 eq) and cesium carbonate (665.0 mg, 2.04 mmol, 2.0 eq) in DMF (3 mL) was stirred at 20° C. for 12 hours. Upon completion, the reaction was quenched with water (15 mL) and extracted with EtOAc (10 mL×2). The combined organic layers were washed with water (15 mL×3) and brine (15 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo to afford compound SI-18 (120 mg) as yellow oil.


Step 3.

A solution of lithium hydroxide monohydrate (28.4 mg, 0.68 mmol, 2.0 eq) in water (3 mL) was added dropwise to a solution of compound SI-18 (100.0 mg, 0.34 mmol, 1.0 eq) in THF (3 mL) at 20° C. and the mixture was stirred at 20° C. for 12 hours. Upon completion, the mixture was concentrated in vacuo and the crude product was purified by prep. HPLC (HCl conditions) to afford the target product the title compound (28.0 mg, 29%) as an off-white solid. 1H NMR (CDCl3, 400 MHz) δ 7.99 (d, J=7.7 Hz, 1H), 7.92 (s, 1H), 7.54 (d, J=7.6 Hz, 1H), 7.43-7.29 (m, 4H), 7.02 (d, J=7.1 Hz, 2H), 6.47 (d, J=16.7 Hz, 1H), 6.05 (dd, J=16.8, 10.3 Hz, 1H), 5.58 (d, J=10.4 Hz, 1H), 5.05 (s, 2H). HRMS electrospray (m/z): [M+H]+ calcd for C23H26C1N4O2: 282.1125, found: 282.1124.


Example S-12: Synthesis of 3-acrylamido-N-phenyl-5-(trifluoromethyl)benzamide (BPK-12)



embedded image


Step1.

Oxalyl dichloride (140.0 mg, 1.1 mmol, 1.3 eq) and DMF (50 μL) were added to a solution of 3-nitro-5-(trifluoromethyl)benzoic acid (200.0 mg, 0.85 mmol, 1.0 eq) in DCM (2.0 mL). The mixture was stirred at 40° C. for 3 h. The reaction was then concentrated in vacuo to afford compound SI-19 (250.0 mg) as light yellow oil, which was used in the next step without additional purification.


Step2.

NEt3 (71.8 mg, 0.71 mmol, 3.0 eq) and aniline (22.0 mg, 0.24 mmol, 1.0 eq) were added to a solution of SI-19 (60.0 mg, 0.24 mmol, 1.0 eq) in DCM (1.0 mL) and the resulting mixture was stirred at 15° C. for 18 h. Upon completion, the reaction was concentrated in vacuo to afford compound SI-20 (80.0 mg) as a light yellow solid, which was used in the next step without additional purification.


Step 3.

SnCl2.2H2O (215.3 mg, 0.95 mmol, 4.0 eq) and DMF (174 μg, 2.4 μmol, 0.01 eq) were added to a solution of compound SI-20 (74.0 mg, 0.24 mmol, 1.0 eq) in EtOH (1.0 mL) and the resulting mixture was stirred at 80° C. for 2 h. Upon completion, the reaction was quenched with aqueous NaHCO3 (2 mL), stirred for 5 min and extracted with DCM (3×2 mL). The combined organic layers were dried with Na2SO4, filtered and concentrated in vacuo to afford SI-21 (90.0 mg) as light yellow oil, which was used in the next step without additional purification.


Step 4.

Acryloyl chloride (23.6 mg, 0.26 mmol, 0.8 eq) and DMF (0.2 mg, 3.1 μmol, 0.01 eq) were added to a solution of compound SI-21 (90.0 mg, 0.32 mmol, 1.0 eq) in DCM (1.0 mL) and the resulting mixture was stirred at 15° C. for 18 h. Upon completion, the mixture was concentrated in vacuo and the resulting residue was purified by prep. HPLC (FA conditions) to afford the title compound (20.0 mg, 18%) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.77-10.72 (m, 1H), 10.50 (s, 1H), 8.42 (s, 1H), 8.37 (s, 1H), 8.03 (s, 1H), 7.76 (d, J=7.9 Hz, 2H), 7.38 (t, J=7.9 Hz, 2H), 7.14 (t, J=7.4 Hz, 1H), 6.46 (dd, J=17.0, 9.9 Hz, 1H), 6.34 (dd, J=17.0, 2.0 Hz, 1H), 5.86 (dd, J=9.9, 1.9 Hz, 1H). HRMS electrospray (m/z): [M+H]+ calcd for C17H14F3N2O2: 335.1002, found: 335.1002


Example S-13: Synthesis of N-(3-(piperidin-1-ylsulfonyl)-5-(trifluoromethyl)phenyl)acrylamide (BPK-13)



embedded image


Step 1.

Under an atmosphere of nitrogen, a two-neck round-bottom flask was charged with 1-bromo-3-nitro-5-(trifluoromethyl)benzene (11.50 g, 42.6 mmol, 1.0 eq), Pd2(dba)3 (1.17 g, 1.3 mmol, 0.03 eq), Xantphos (1.23 g, 2.1 mmol, 0.05 eq), DIEA (14.9 mL, 85.2 mmol, 2.0 eq), and 1,4-dioxane (90 mL). The flask was fitted with a reflux condenser and stirred at 80° C. for 10 min, after which benzylthiol (5.5 mL, 46.9 mmol, 1.1 eq) was added. The mixture was stirred at 80° C. for an additional 20 min and monitored by TLC (Petroleum ether: EtOAc=20: 1). Upon completion, the reaction was quenched with aqueous NaHCO3 (100 mL) and extracted with ethyl acetate (3×100 mL). The combined organic layers were washed with brine (50 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuo. The resulting residue was passed through a short silica gel plug (Petroleum ether) to afford crude SI-22 (15.0 g) as a yellow liquid, which was used in the next step without additional purification.


Step 2.

NCS (17.05 g, 127.7 mmol, 4.0 eq) was added to a solution of compound SI-22 (10.0 g, 31.9 mmol, 1.0 eq) in HCl (12 M, 12.5 mL, 4.7 eq) and AcOH (60 mL) at 0° C. The mixture was stirred at 25° C. for 16 h and monitored by TLC (Petroleum ether: EtOAc=20: 1). Upon completion, the reaction was poured into ice water (500 mL) and extracted with ethyl acetate (3×50 mL). The combined organic layers were washed with brine (500 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuo to afford crude compound SI-23 (13.0 g), which was used without additional purification for the synthesis of compounds of Examples S-13 and S-14.


Step 3.

A solution of intermediate SI-23 (180.0 mg, 0.62 mmol, 1.0 eq) in THF (1 mL) was added to a solution of NaHCO3 (313.3 mg, 3.7 mmol, 6.0 eq) and morpholine (54.7 μL, 0.62 mmol, 1.0 eq) in water (10 mL) at 0° C. The resulting mixture was stirred at 25° C. for 16 h and monitored by TLC (Petroleum ether: EtOAc=1: 1). Upon completion, the reaction was quenched with water (5 mL) and extracted with ethyl acetate (3×5 mL). The combined organic layers were washed with brine (5 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuo. The resulting residue was purified by silica gel chromatography (Petroleum ether: EtOAc=5: 1) to give compound SI-24 (200.0 mg, 95%) as a white solid.


Step 4.

SnCl2.2H2O (400.0 mg, 1.77 mmol, 3.1 eq) was added to a mixture of intermediate SI-24 (190.0 mg, 0.56 mmol, 1.0 eq) and DMF (2.2 μL, 27.9 μmol, 0.05 eq) in EtOH (2.0 mL). The mixture was stirred at 78° C. for 16 h. Upon completion, the reaction was quenched by adjusting the pH to pH 9 with saturated aqueous NaHCO3 (10 mL) and the resulting mixture was extracted with ethyl acetate (3×5 mL). The combined organic layers were washed with brine (5 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuo to afford crude SI-25 (150.0 mg) as a yellow solid, which was used in the next step without further purification.


Step 5.

Acryloyl chloride (18.9 μL, 0.23 mmol, 1.0 eq) was added to a solution of compound SI-25 (70.0 mg, 0.23 mmol, 1.0 eq) and NEt3 (62.5 μL, 0.45 mmol, 2.0 eq) in anhydrous DCM (1 mL) at 0° C. and the mixture was stirred at 25° C. for 3 h. Upon completion, the reaction was concentrated in vacuo, the resulting residue was re-dissolved in CH3CN (2 mL) and water (3 mL) and purified by prep. HPLC (FA conditions) to give the title compound (26.0 mg, 32%) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.91 (s, 1H), 8.42-8.40 (m, 1H), 8.34 (t, J=1.8 Hz, 1H), 7.65-7.62 (m, 1H), 6.48-6.31 (m, 2H), 5.89 (dd, J=9.5, 2.4 Hz, 1H), 3.67-3.62 (m, 4H), 2.97-2.92 (m, 4H). HRMS electrospray (m/z): [M+H]+ calcd for C14H16F3N2O4S: 365.0777, found: 365.0776.


Example S-14: Synthesis of 2-chloro-N-(3-(N-phenylsulfamoyl)-5-(trifluoromethyl)phenyl)acetamide (BPK-14)



embedded image


Intermediate SI-23 was synthesized according to the procedure described above.


Step 1.

A solution of intermediate SI-23 (1.30 g, 4.49 mmol, 1.0 eq) in THF (7 mL) was added to a solution of NaHCO3 (2.26 g, 26.9 mmol, 6.0 eq) and aniline (410.0 μL, 4.49 mmol, 1.0 eq) in water (70 mL) at 0° C. The resulting mixture was stirred at 25° C. for 2 h and monitored by TLC (Petroleum ether: EtOAc=10: 1). Upon completion, the reaction was quenched with water (5 mL) and extracted with ethyl acetate (3×5 mL). The combined organic layers were washed with brine (5 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuo. The resulting residue was purified by silica gel chromatography (Petroleum ether: EtOAc=100: 1, then 10: 1) to give compound SI-24 (450 mg, 29%) as a white solid.


Step 2.

SnCl2.2H2O (929.6 mg, 4.12 mmol, 3.2 eq) was added to a solution of intermediate SI-24 (450.0 mg, 1.30 mmol, 1.0 eq) and DMF (5.1 μL, 65 μmol, 0.05 eq) in EtOH (5.0 mL). The mixture was stirred at 78° C. for 4 h. Upon completion, the reaction was quenched by adjusting the pH to pH 9 with saturated aqueous NaHCO3 (10 mL) and the resulting mixture was extracted with ethyl acetate (3×5 mL). The combined organic layers were washed with brine (5 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuo to afford crude SI-25 (200.0 mg) as a yellow oil, which was used in the next step without further purification.


Step 3.

DMAP (50.2 mg, 0.41 mmol, 1.0 eq) was added to a mixture of intermediate SI-27 (130.0 mg, 0.41 mmol, 1.0 eq), tert-butoxycarbonyl tert-butyl carbonate (94.4 μL, 0.41 mmol, 1.0 eq), and NEt3 (170.9 μL, 1.23 mmol, 3.0 eq) in DCM (3 mL) at 25° C. The mixture was stirred at 25° C. for 2 h. Upon completion, the reaction was concentrated in vacuo and the residue was re-dissolved in CH3CN (3 mL). The target product was purified by prep. HPLC (basic conditions) to afford SI-28 as a yellow solid.


Step 4.

2-chloroacetyl chloride (15.3 μL, 0.19 mmol, 2.0 eq) was added to a solution of SI-28 (40.0 mg, 96 μmol, 1.0 eq) and NEt3 (40.0 μL, 0.29 mmol, 3.0 eq) in DCM (1 mL) at 0° C. and the mixture was stirred at 25° C. for 1 h. Upon completion, the reaction was quenched with water (1 mL) and extracted with ethyl acetate (3×2 mL). The combined organic layers were washed with brine (2 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo to afford SI-29 (40.0 mg) as yellow oil, which was used in the next step without further purification.


Step 5.

TFA (200 μL, 2.70 mmol, 33.3 eq) was added to a solution of intermediate SI-29 (40.0 mg, 81 μmol, 1.0 eq) in DCM (2 mL) and the mixture was stirred at 25° C. for 1 h. Upon completion, the reaction was diluted with CH3CN (3 mL) and purified by prep. HPLC (FA conditions) to afford the title compound (20.0 mg, 63%) as a yellow solid. 1H NMR (DMSO-d6, 400 MHz) δ 10.95 (s, 1H), 8.29 (m, 1H), 8.16 (m, 1H), 7.67 (s, 1H), 7.26-7.20 (m, 2H), 7.08-7.01 (m, 3H), 4.30 (s, 2H). HRMS electrospray (m/z): [M+H]+ calcd for C15H13C1F3N2O3S: 393.0282, found: 393.0281.


Example S-15: Synthesis of N-(1H-benzo[d]imidazol-5-yl)-N-benzyl-2-chloroacetamide (BPK-15)



embedded image


Step 1.

Boc2O (2.82 mL, 12.7 mmol, 2.0 eq) was added to a mixture of 6-nitro-1H-benzimidazole (1.00 g, 6.13 mmol, 1.0 eq) and NEt3 (1.70 mL, 12.3 mmol, 2.0 eq) in DCM (10.0 mL). The mixture was stirred at 25° C. for 2 h and the reaction progress was monitored by TLC (DCM: MeOH=50: 1) and LCMS. Upon completion, the reaction mixture was concentrated in vacuo and purified by silica gel chromatography (Petroleum ether: EtOAc=50: 1, then 10: 1) to afford compound SI-30 (1.60 g, 99%) as a white solid.


Step 2.

Under an atmosphere of nitrogen, Pd/C (200.0 mg, 10%) was added to a solution of intermediate SI-30 (1.60 g, 6.08 mmol, 1.0 eq) in MeOH (50 mL). The mixture was degassed under vacuum and purged with H2 several times. The mixture was stirred under H2 (50 psi) at 25° C. for 16 h. Upon completion, the reaction mixture was filtered and concentrated to give SI-31 (1.40 g) as colorless oil which was used in step 3 without further purification.


Step 3.

Benzaldehyde (191 μL, 1.89 mmol, 1.1 eq) was added to a solution of compound SI-31 (400.0 mg, 1.71 mmol, 1.0 eq) in anhydrous MeOH (2 mL) and the reaction was stirred at 25° C. for 2 h. Subsequently, NaBH3CN (215.5 mg, 3.43 mmol, 2.0 eq) was added at 0° C. and the mixture was stirred at 25° C. for an additional 14 h. Upon completion, the reaction was quenched by the addition of saturated aqueous NaHCO3 (10 mL) and extracted with ethyl acetate (3×10 mL). The combined organic layers were washed with brine (5 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The solution was then purified by prep. HPLC (basic conditions) to afford intermediate SI-32 (300.0 mg, 54%) as colorless oil.


Step 4.

2-chloroacetyl chloride (74 μL, 0.93 mmol, 2.0 eq) was added dropwise to a solution of compound SI-32 (150.0 mg, 0.46 mmol, 1.0 eq) and NEt3 (257 μL, 1.86 mmol, 4.0 eq) in anhydrous DCM (2 mL) at 0° C. and the mixture was stirred at 25° C. for 2 h. Upon completion, the reaction was quenched by the addition of saturated aqueous NaHCO3 (2 mL) and then extracted with DCM (5 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated in vacuo to afford compound SI-33 (180.0 mg) as yellow oil, which was used in the next step without further purification.


Step 5.

TFA (800 μL, 10.8 mmol, 24 eq) was added dropwise to a solution of compound SI-33 (180.0 mg, 0.45 mmol, 1.0 eq) in DCM (4 mL) and the mixture was stirred at 25° C. for 16 h. Upon completion, the reaction was concentrated in vacuo and the residue was re-dissolved in CH3CN (2 mL). The target product was purified by prep. HPLC (basic conditions) to afford the title compound (25.0 mg, 19%) as a white solid. 1H NMR (CDCl3, 400 MHz) δ 8.12 (s, 1H), 7.62 (d, J=8.5 Hz, 1H), 7.34 (s, 1H), 7.25-7.16 (m, 5H), 6.94 (dd, J=8.5, 2.0 Hz, 1H), 4.96 (s, 2H), 3.89 (s, 2H). HRMS electrospray (m/z): [M+H]+ calcd for C16H15C1N3O: 300.0898, found: 300.0896.


Example S-16: Synthesis of N-benzyl-2-chloro-N-(4-oxo-3,4-dihydroquinazolin-6-yl)acetamide (BPK-16)



embedded image


Step 1.

NaBH3CN (117.0 mg, 1.86 mmol, 2.0 eq) was added to a solution of AcOH (53.3 μL, 0.93 mmol, 1.0 eq), benzaldehyde (108.7 mg, 1.02 mmol, 1.1 eq), and 6-aminoquinazolin-4(3H)-one (150.0 mg, 0.93 mmol, 1.0 eq) in anhydrous MeOH (1 mL) and the resulting mixture was stirred at 15° C. for 16 h. Upon completion, the reaction was quenched with saturated aqueous NaHCO3 (10 mL) and extracted with EtOAc (3×10 mL). The combined organic layers were washed with brine (5 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo to afford compound SI-34 (200.0 mg) as a white solid, which was used in the next step without additional purification.


Step 2.

NaH (101.9 mg, 2.55 mmol, 60% in oil, 4.0 eq) was added to a solution of compound SI-34 (160.0 mg, 0.64 mmol, 1.0 eq) in anhydrous DMF (1 mL) at 0° C. and the reaction was stirred at 0° C. for 30 min. 2-chloroacetyl chloride (101 μL, 1.27 mmol, 2.0 eq) was then added dropwise and the mixture was stirred at 0° C. for another 30 min. Upon completion, the reaction was concentrated in vacuo, the remaining residue was re-dissolved in CH3CN (2 mL) and water (1 mL) and purified by prep. HPLC (HCl conditions) to afford compound the title compound (10.0 mg, 5%) as a yellow solid. 1H NMR (DMSO-d6, 400 MHz) δ 8.50-8.37 (m, 1H), 7.96-7.91 (m, 1H), 7.78-7.68 (m, 2H), 7.33-7.13 (m, 5H), 5.00-4.87 (m, 2H), 4.20-4.03 (m, 2H). HRMS electrospray (m z): [M+H]+ calcd for C17H15C1N3O2: 328.0847, found: 328.0849.


Example S-17: Synthesis of N-(3-(morpholine-4-carbonyl)benzyl)-N-phenylacrylamide (BPK-17)



embedded image


Step 1.

A solution of DIEA (5.8 mL, 33.3 mmol, 5.0 eq), HATU (3.80 g, 10 mmol, 1.5 eq) and 3-formylbenzoic acid (1.0 g, 6.7 mmol, 1.0 eq) in DMF (10 mL) was stirred at 25° C. for 30 min. Morpholine (586 μL, 6.7 mmol, 1.0 eq) was then added and the reaction mixture was stirred for another 1.5 h. Upon completion, the reaction was quenched with water (20 mL) and extracted with DCM (3×10 mL). The combined organic layers were washed with brine (3×10 mL), dried over Na2SO4, filtered and concentrated under reduced pressure to give product compound SI-35 (1.20 g) as yellow oil.


Step 2.

Compound SI-36 was synthesized following the procedure detailed for compound SI-34. In particular, AcOH (0.98 mL, 17.1 mmol, 5.5 eq) was added to a solution of compound SI-35 (750 mg, 3.1 mmol, 1.0 eq) and aniline (312.3 μL, 3.42 mmol, 1.1 eq) in DCM (5 mL) at 25° C. After stirring for 30 min, NaBH3CN (430 mg, 6.8 mmol, 2.2 eq) was added to the mixture at 0° C. The mixture was then stirred at 25° C. for another 1.5 h. Upon completion, the reaction was quenched with water (10 mL) and extracted with DCM (3×5 mL). The combined organic layers were washed with brine (3×5 mL), dried over Na2SO4, filtered and concentrated in vacuo to afford compound SI-36 (880.0 mg) as yellow oil, which was used into the next step without further purification.


Step 3.

Acryloyl chloride (181 μL, 2.22 mmol, 2.0 eq) was added dropwise to a solution of compound SI-36 (330.0 mg, 1.11 mmol, 1.0 eq) and NEt3 (769 μL, 5.55 mmol, 5.0 eq) in DCM (1 mL) at 0° C. and the resulting mixture was stirred at 25° C. for 2 h. Upon completion, the reaction was quenched with water (3 mL) and extracted with DCM (3×1 mL). The combined organic layers were washed with brine (3×2 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The resulting residue was re-dissolved in CH3CN and water, and purified by prep. HPLC (TFA conditions) to give the title compound (92.0 mg, 20%) as yellow oil. 1H NMR (DMSO-d6, 400 MHz) δ 7.38-7.32 (m, 3H), 7.29 (t, J=8.1 Hz, 2H), 7.23 (d, J=7.4 Hz, 1H), 7.12-7.06 (m, 3H), 6.23 (dd, J=16.8, 2.2 Hz, 1H), 6.05-5.92 (m, 1H), 5.61 (dd, J=10.1, 2.2 Hz, 1H), 4.97 (s, 2H), 3.67-3.38 (m, 6H), 3.13 (s, 2H). HRMS electrospray (m/z): [M+H]+ calcd for C21H23N2O3: 351.1703, found: 351.1703.


Example S-18: Synthesis of N-benzyl-4-((2-chloro-N-phenylacetamido)methyl)benzamide (BPK-18)



embedded image


Step 1.

HATU (3.80 g, 10.0 mmol, 1.5 eq) and benzylamine (728 μL, 6.7 mmol, 1.0 eq) were added to a solution of DIEA (5.81 mL, 33.3 mmol, 5.0 eq) in DMF (10 mL) and the mixture was stirred at 25° C. for 30 min. 4-formylbenzoic acid (1.00 g, 6.7 mmol, 1.0 eq) was then added to the reaction and the resulting mixture was stirred for another 1.5 h. Upon completion, the reaction was quenched with water (20 mL) and extracted with DCM (3×10 mL). The combined organic layers were washed with brine (3×10 mL), dried over Na2SO4 filtered and concentrated under reduced pressure to afford compound SI-37 (800 mg) as yellow oil, which was used in the next step without additional purification.


Step 2.

AcOH (895 μL, 15.7 mmol, 5.1 eq) and aniline (286 μL, 3.1 mmol, 1.0 eq) were added to a solution of compound SI-37 (750 mg, 3.1 mmol, 1.0 eq) in DCM (5 mL) at 25° C. After stirring for 0.5 h, NaBH3CN (393 mg, 6.2 mmol, 2.0 eq) was added to the mixture at 0° C. The mixture was then stirred at 25° C. for another 1.5 h. Upon completion, the reaction was quenched with water (10 mL) and extracted with DCM (3×5 mL). The combined organic layers were washed with brine (3×5 mL), dried over Na2SO4, filtered and concentrated in vacuo to afford compound SI-38 (600 mg) as yellow oil, which was used in the next step without further purification.


Step 3.

2-chloroacetyl chloride (105 μL, 1.33 mmol, 2.0 eq) was added dropwise to a solution of compound SI-38 (210 mg, 0.66 mmol, 1.0 eq) and NEt3 (460 μL, 3.32 mmol, 5.0 eq) in DCM (1.0 mL) at 0° C. and the resulting mixture was stirred at 25° C. for 2 h. Upon completion, the reaction was quenched with water (3 mL) and extracted with DCM (3×1 mL). The combined organic layers were washed with brine (3×2 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The resulting residue was re-dissolved in CH3CN and water, and purified by prep. HPLC (HCl conditions) to give compound the title compound (27.0 mg, 10%) as yellow oil. 1H NMR (DMSO-d6, 400 MHz) δ 7.77 (d, J=8.3 Hz, 2H), 7.43-7.14 (m, 14H), 4.92 (s, 2H), 4.43 (s, 2H), 4.04 (s, 2H). HRMS electrospray (m/z): [M+H]+ calcd for C23H22C1N2O2: 393.1364, found: 393.1365.


Example S-19: Synthesis of 2-chloro-N-(3-fluorobenzyl)-N-(4-phenoxy-3-(trifluoromethyl)phenyl)acetamide (BPK-19)



embedded image


Step 1.

A mixture of 4-phenoxy-3-(trifluoromethyl)aniline (200.0 mg, 0.79 mmol, 1.0 eq), AcOH (54.2 μL, 0.95 mmol, 1.2 eq) and 3-fluorobenzaldehyde (91.4 μL, 0.86 mmol, 1.1 eq) in anhydrous MeOH (3 mL) was stirred at 63° C. for 16 h. NaBH3CN (148.9 mg, 2.37 mmol, 3.0 eq) was then added at 0° C. and the mixture was stirred at 25° C. for additional 4 h with the reaction progress monitored by TLC (Petroleum ether: EtOAc=10: 1). Upon completion, the mixture was concentrated in vacuo, the resulting residue was re-dissolved in saturated aqueous NaHCO3 (2 mL) and extracted with DCM (3×3 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo to give compound SI-39 (240.0 mg) as yellow oil, which was used in the next step without further purification.


Step 2.

2-chloroacetyl chloride (61.6 μL, 0.78 mmol, 2.0 eq) was added dropwise to a solution of compound SI-39 (140.0 mg, 0.39 mmol, 1.0 eq) and NEt3 (269 μL, 1.94 mmol, 5.0 eq) in anhydrous DCM (1.5 mL) at 0° C. and the resulting mixture was stirred at 25° C. for 2 h. Upon completion, the mixture was concentrated in vacuo and the remaining residue was re-dissolved in aqueous NaHCO3 (2 mL) and extracted with DCM (3×3 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. Purification by prep. HPLC (HCl conditions) afforded compound the title compound (30.0 mg, 18%) as colorless oil. 1H NMR (CDCl3, 400 MHz) δ 7.44 (t, J=7.9 Hz, 2H), 7.40 (d, J=2.2 Hz, 1H), 7.33-7.23 (m, 2H), 7.12-7.07 (m, 3H), 7.04-6.95 (m, 3H), 6.86 (d, J=8.8 Hz, 1H), 4.89 (s, 2H), 3.89 (s, 2H). HRMS electrospray (m/z): [M+H]+ calcd for C22H17ClF4NO2: 438.0878, found: 438.0877.


General Procedure for the synthesis of compounds Examples S-20-S-24



embedded image


General Procedure A.

A mixture of aldehyde (1.0 eq), AcOH (1.2 eq) and 4-phenoxy-3-(trifluoromethyl)aniline (1.0 eq) in anhydrous MeOH was stirred at 25° C. for 1 h. NaBH3CN (3.0 eq) was added at 0° C. and the reaction mixture was stirred at 25° C. for 2h. Upon completion, the mixture was concentrated in vacuo, the remaining residue was re-dissolved in saturated aqueous NaHCO3 (2 mL) and extracted with DCM (3×3 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo to afford the corresponding intermediate, which was used in the next step without further purification.


General Procedure B.

2-chloroacetylchloride (2.0 eq) was added dropwise to a solution of intermediate from procedure A (1.0 eq) and NEt3 (5.0 eq) in anhydrous DCM at 0° C. and the mixture was stirred at 25° C. for 2 h. Upon completion, the reaction mixture was concentrated in vacuo, the remaining residue was re-dissolved in saturated aqueous NaHCO3 and extracted with DCM. The combined organic layers were then dried over Na2SO4, filtered, concentrated in vacuo and purified by prep. HPLC to give the desired compound.


Example S-20: Synthesis of 2-chloro-N-(2,3-dichlorobenzyl)-N-(4-phenoxy-3-(trifluoromethyl)phenyl)acetamide (BPK-20)



embedded image


Step 1.

Compound SI-40 was synthesized according to general procedure A from 2,3-dichlorobenzaldehyde (206.5 g, 1.18 mol), AcOH (81 mL, 1.42 mol), 4-phenoxy-3-(trifluoromethyl)aniline (300.0 g, 1.18 mol, 1.0 eq), and NaBH3CN (222.5 g, 3.54 mol). Aqueous work up afforded SI-40 (450.0 g) as yellow oil, which was used in the next step without further purification.


Step 2a.

Compound BPK-20 was synthesized according to general procedure B from SI-40 (125.0 mg, 0.30 mmol), Et3N (210 μL, 1.52 mmol), and 2-chloroacetyl chloride (48.2 μL, 0.61 mmol). Aqueous extraction, followed by purification by prep. HPLC (HCl conditions) afforded the title compound (63.1 mg, 42%) as light yellow oil. 1H NMR (CDCl3, 400 MHz) δ 7.42-7.37 (m, 4H), 7.30 (d, J=7.8, 1H), 7.25-7.16 (m, 2H), 7.13 (dd, J=8.8, 2.7 Hz, 1H), 7.07-7.02 (m, 2H), 6.83 (d, J=8.8 Hz, 1H), 5.08 (s, 2H), 3.89 (s, 2H). HRMS electrospray (m/z): [M+H]+ calcd for C22H16C13F3NO2: 488.0193, found: 488.0192.


Example S-21: Synthesis of N-(2,3-dichlorobenzyl)-N-(4-phenoxy-3-(trifluoromethyl)phenyl)acrylamide (BPK-21)



embedded image


Step 2b.

NEt3 (210 μL, 1.52 mmol, 5.0 eq) and acryloyl chloride (49.5 μL, 0.61 mmol, 2.0 eq) were added to a solution of compound SI-40 (125.0 mg, 0.30 mmol, 1.0 eq) in anhydrous DCM (1.5 mL) at 0° C. and the mixture was stirred at 25° C. for 2 h. Upon completion, the mixture was concentrated in vacuo, the remaining residue was re-dissolved in saturated aqueous NaHCO3 (2 mL) and extracted with DCM (3×3 mL). The combined organic layers were dried over Na2SO4, filtered, concentrated in vacuo and purified by prep. HPLC (basic conditions) to give the title compound (82.0 mg, 57%) as light yellow oil. 1H NMR (CDCl3, 400 MHz) δ 7.42-7.36 (m, 4H), 7.30 (dd, J=7.8, 1.6 Hz, 1H), 7.23-7.16 (m, 2H), 7.11-7.07 (m, 1H), 7.06-7.02 (m, 2H), 6.83 (d, J=8.8 Hz, 1H), 6.48 (dd, J=16.7, 1.8 Hz, 1H), 6.09 (dd, J=16.7, 10.3 Hz, 1H), 5.67 (dd, J=10.3, 1.8 Hz, 1H), 5.13 (s, 2H). HRMS electrospray (m z): [M+H]+ calcd for C23H17C12F3NO2: 466.0583, found: 466.0582.


Example S-22: Synthesis of 2-chloro-N-(3-morpholinobenzyl)-N-(4-phenoxy-3-(trifluoromethyl)phenyl)acetamide (BPK-22)



embedded image


Step 1

Compound SI-41 was synthesized according to general procedure A from 3-morpholinobenzaldehyde (225.7 mg, 1.18 mmol), AcOH (81.0 μL, 1.42 mmol), 4-phenoxy-3-(trifluoromethyl)aniline (300.0 mg, 1.18 mmol), and NaBH3CN (222.5 mg, 3.54 mmol). Aqueous work up afforded Compound SI-41 (480.0 mg) as yellow oil, which was used in the next step without further purification.


Step 2.

Compound BPK-22 was synthesized according to general procedure K from Compound SI-41 (125.0 mg, 0.29 mmol), Et3N (202 μL, 1.46 mmol), and 2-chloroacetyl chloride (46.4 μL, 0.58 mmol). Aqueous work up, followed by purification by prep. HPLC (HCl conditions) afforded the title compound (104.9 mg, 65%) as light yellow oil. 1H NMR (CDCl3, 400 MHz) δ 7.41 (t, J=7.8 Hz, 2H), 7.34 (d, J=2.6 Hz, 1H), 7.23 (t, J=7.5 Hz, 1H), 7.18 (t, J=7.8 Hz, 1H), 7.08-7.03 (m, 3H), 6.84-6.79 (m, 2H), 6.77 (s, 1H), 6.64 (d, J=7.5 Hz, 1H), 4.82 (s, 2H), 3.87-3.80 (m, 6H), 3.13-3.07 (m, 4H). HRMS electrospray (m/z): [M+H]+ calcd for C26H25C1F3N2O3: 505.1500, found: 505.1500.


Example S-23: Synthesis of N-(3-(1H-1,2,4-triazol-1-yl)benzyl)-2-chloro-N-(4-phenoxy-3-(trifluoromethyl)phenyl)acetamide (BPK-23)



embedded image


Step 1.

Compound SI-42 was synthesized according to general procedure A from 4-(1H-1,2,4-triazol-1-yl)benzaldehyde (171.0 mg, 0.99 mmol), AcOH (67.8 μL, 1.18 mmol), 4-phenoxy-3-(trifluoromethyl)aniline (250.0 mg, 0.99 mmol), and NaBH3CN (186.1 mg, 2.96 mmol). Aqueous work up afforded compound SI-42 (240.0 mg) as yellow oil, which was used in the next step without further purification.


Step 2.

2-chloroacetyl chloride (15.5 μL, 0.19 mmol, 1.0 eq) was added to a solution of compound SI-42 (80.0 mg, 0.19 mmol, 1.0 eq) and NaH (9.4 mg, 0.39 mmol, 2.0 eq) at 0° C. and the reaction was stirred at 25° C. for 2h. Upon completion, the reaction mixture was concentrated in vacuo. The resulting residue was diluted with CH3CN (2 mL) and water (1 mL) and purified by prep. HPLC (HCl conditions) to afford the title compound (10.0 mg, 10%) as yellow oil. 1H NMR (CDCl3, 400 MHz) δ 8.78 (s, 1H), 8.02 (s, 1H), 7.54-7.47 (m, 2H), 7.32 (t, J=7.4 Hz, 1H), 7.30-7.21 (m, 3H), 7.15-7.05 (m, 3H), 6.99 (d, J=7.9 Hz, 1H), 6.92 (d, J=7.9 Hz, 2H), 6.69 (d, J=7.9 Hz, 1H), 4.81 (s, 2H), 3.75 (s, 2H). HRMS electrospray (m/z): [M+H]+ calcd for C24H19C1F3N4O2: 487.1143, found: 487.1143.


Example S-24: Synthesis of 2-chloro-N-((3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yl)methyl)-N-(4-phenoxy-3-(trifluoromethyl)phenyl)acetamide (BPK-24)



embedded image


Step 1.

Compound SI-43 was synthesized according to general procedure A from 3,4-dihydro-2H-benzo[b][1,4]dioxepine-7-carbaldehyde (175.9 mg, 0.99 mmol), AcOH (67.8 μL, 1.18 mmol), 4-phenoxy-3-(trifluoromethyl)aniline (250.0 mg, 0.99 mmol), and NaBH3CN (186.1 mg, 2.96 mmol). Aqueous work up afforded compound SI-43 (400.0 mg) as yellow oil, which was used in the next step without further purification.


Step 2.

Compound BPK-24 was synthesized according to general procedure B from compound SI-43 (200.0 mg, 0.48 mmol, 1.0 eq), Et3N (333.7 μL, 2.41 mmol, 5.0 eq), and 2-chloroacetyl chloride (76.6 μL, 0.96 mmol, 2.0 eq). Aqueous work up, followed by prep. HPLC (HCl conditions) afforded the title compound (105.0 mg, 44%) as light yellow oil. 1H NMR (CDCl3, 400 MHz) δ 7.38 (t, J=6.9 Hz, 2H), 7.27 (s, 1H), 7.19 (t, J=7.4 Hz, 1H), 7.03 (d, J=7.9 Hz, 3H), 6.89-6.67 (m, 4H), 4.73 (s, 2H), 4.19-4.08 (m, 4H), 3.80 (s, 2H), 2.13 (s, 2H). HRMS electrospray (m/z): [M+H]+ calcd for C25H22C1F3NO4: 492.1184, found: 492.1182.


Example S-25: Synthesis of 5-(N-((6-chloropyridin-2-yl)methyl)acrylamido)-N-phenylpicolinamide (BPK-25)



embedded image


Step 1.

NaBH3CN (408.4 mg, 6.50 mmol, 2.0 eq) was added to a solution of AcOH (185.85 μL, 3.25 mmol, 1.0 eq), 5-aminopicolinic acid (448.9 mg, 3.25 mmol, 1.0 eq) and 6-chloropyridine-2-carbaldehyde (460.0 mg, 3.25 mmol, 1.0 eq) in anhydrous MeOH (5.0 mL). The reaction was stirred at 25° C. for 16 h. Upon completion, the reaction was concentrated in vacuo to afford compound SI-44 (1.00 g) as a yellow solid.


Step 2.

DIEA (3.97 mL, 22.8 mmol, 3.0 eq) was added to a solution of aniline (1.39 mL, 15.2 mmol, 2.0 eq), HATU (3.46 g, 9.10 mmol, 1.2 eq), and compound SI-44 (2.00 g, 7.58 mmol, 1.0 eq) in DMF (15 mL) and the resulting mixture was stirred at 25° C. for 16 h. Upon completion, the reaction was quenched with water (20 mL) and extracted with ethyl acetate (3×10 mL). The combined organic layers were washed with brine (10 mL), dried with anhydrous Na2SO4, filtered and concentrated in vacuo. The resulting residue was purified by silica gel chromatography (Petroleum ether: EtOAc=10: 1, then 0: 1) to afford compound SI-45 (1.00 g) as yellow oil.


Step 3.

NaH (63.8 mg, 1.59 mmol, 60% in oil, 3.0 eq) was added to a solution of SI-45 (300.0 mg, 0.53 mmol, 1.0 eq, 60% pure) in anhydrous THF (2 mL) at 0° C. and the reaction was stirred at 0° C. for 2 h. Acryloyl chloride (86.6 μL, 1.06 mmol, 2.0 eq) was added at 0° C. and the reaction mixture was stirred at 25° C. for 14 h. Upon completion, the mixture was concentrated in vacuo, the resulting residue was re-dissolved in CH3CN (3 mL) and saturated aqueous NaHCO3 (1 mL) and purified by prep. HPLC (basic conditions) to afford the title compound (14.0 mg, 7% yield) as yellow oil. 1H NMR (DMSO-d6, 400 MHz) δ 10.63 (s, 1H), 8.69 (d, J=2.4 Hz, 1H), 8.20 (d, J=8.4 Hz, 1H), 8.06 (dd, J=8.4, 2.5 Hz, 1H), 7.90-7.80 (m, 3H), 7.44-7.32 (m, 4H), 7.12 (t, J=7.4 Hz, 1H), 6.30-6.24 (m, 2H), 5.76-5.71 (m, 1H), 5.13 (s, 2H). HRMS electrospray (m/z): [M+H]+ calcd for C21H18C1N4O2: 393.1113, found: 393.1114.


Example S-26: Synthesis of 2-chloro-N-(3-chloro-2-fluorobenzyl)-N-(6-chloropyridin-3-yl)acetamide (BPK-26)



embedded image


Step 1.

NaBH3CN (118.9 mg, 1.89 mmol, 2.0 eq) was added to a solution of AcOH (54.1 μL, 0.95 mmol, 1.0 eq), 5-chloropyridin-2-amine (121.6 mg, 0.95 mmol, 1.0 eq), and 3-chloro-2-fluorobenzaldehyde (150.0 mg, 0.95 mmol, 1.0 eq) in anhydrous MeOH (2 mL) and the reaction was stirred at 25° C. for 2 h. Upon completion, the reaction was quenched with saturated aqueous NaHCO3 (10 mL) and extracted with ethyl acetate (3×10 mL). The combined organic layers were washed with brine (5 mL), dried over anhydrous Na2SO4, filtered and concentrated in vacuo to afford compound SI-46 (250.0 mg) as yellow solid, which was used in the next step without additional purification.


Step 2.

2-chloroacetyl chloride (82.1 μL, 1.03 mmol, 2.0 eq) was added to a solution of NEt3 (358 μL, 2.58 mmol, 5.0 eq) and compound SI-46 (140.0 mg, 0.52 mmol, 1.0 eq) in anhydrous DCM (2 mL) at 0° C. and the reaction was stirred at 25° C. for 2 h. Upon completion, the reaction mixture was concentrated in vacuo. The resulting residue was re-dissolved in CH3CN (2 mL) and water (1 mL) and purified by prep. HPLC (HCl condition) to afford compound the title compound (28.0 mg, 14%) as colorless oil. 1H NMR (DMSO-d6, 400 MHz) δ 8.38 (d, J=2.7 Hz, 1H), 7.87 (d, J=8.6 Hz, 1H), 7.59 (d, J=8.5 Hz, 1H), 7.54-7.45 (m, 1H), 7.35-7.28 (m, 1H), 7.20-7.15 (m, 1H), 4.98 (s, 2H), 4.17 (s, 2H). HRMS electrospray (m/z): [M+H]+ calcd for C14H11Cl3FN2O: 346.9915, found: 346.9916.


Example S-27: Synthesis of N-(4-(benzyloxy)-3-methoxybenzyl)-N-(5-(tert-butyl)-2-methoxyphenyl)-2-chloroacetamide (BPK-27)



embedded image


Step 1.

AcOH (15.0 μL, 0.27 mmol, 1.2 eq) and NaBH(OAc)3 (52.8 mg, 0.25 mmol, 1.1 eq) were added to a solution of 5-(tert-butyl)-2-methoxyaniline (44.3 mg, 0.25 mmol, 1.1 eq) and 4-(benzyloxy)-3-methoxybenzaldehyde (53.6 mg, 0.22 mmol, 1.0 eq) in dicholoroethane (1.5 mL) and the mixture was stirred at 25° C. for 16 h. Upon completion, the reaction was concentrated under a stream of nitrogen and the resulting residue was re-dissolved in saturated aqueous NaHCO3 solution (2 mL) and extracted with ethyl acetate (3×2 mL). The combined organic layers were washed with brine (3 mL), dried over anhydrous Mg2SO4, filtered and concentrated under a stream of nitrogen. The resulting residue was re-dissolved in DCM and purified by silica gel chromatography (15-25% EtOAc/hexanes) to afford SI-47 (59.7 mg, 67%).


Step 2.

2-chloroacetyl chloride (35.2 μL 0.44 mmol, 3.0 eq) was added dropwise to a solution of SI-47 (59.7 mg, 0.15 mmol, 1.0 eq) and pyridine (55.5 μL, 0.77 mmol, 5.2 eq) at 0° C. and the resulting mixture was stirred at 25° C. for 16 h. Upon completion, the reaction mixture was concentrated under a stream of nitrogen. The residue was re-dissolved in saturated aqueous NaHCO3 solution (2 mL) and diethyl ether (2 mL), stirred for 20 min, and further extracted with diethyl ether (2×2 mL). The combined organic layers were dried over anhydrous MgSO4, filtered and concentrated under a stream of nitrogen. The resulting residue was re-dissolved in DCM and purified by silica gel chromatography (15-35% EtOAc/hexanes) to afford the title compound (42.6 mg, 60%) as light yellow oil. 1H NMR (CDCl3, 400 MHz) δ 7.40 (d, J=7.4 Hz, 2H), 7.34 (t, J=7.6 Hz, 2H), 7.30-7.26 (m, 2H), 6.83 (d, J=8.6 Hz, 1H), 6.77 (d, J=1.4 Hz, 1H), 6.73 (d, J=2.4 Hz, 1H), 6.71 (d, J=8.2 Hz, 1H), 6.56-6.53 (m, 1H), 5.25 (d, J=13.9 Hz, 1H), 5.11 (s, 2H), 4.19 (d, J=13.9 Hz, 1H), 3.82 (d, J=5.1 Hz, 2H), 3.80 (s, 3H), 3.70 (s, 3H), 1.14 (s, 9H). HRMS electrospray (m/z): [M+H]+ calcd for C28H33C1NO4: 482.2093, found: 482.2094.


Synthesis of Intermediate SI-50 as a Common Precursor for Compounds of Examples S-28-S-34



embedded image


Step 1.

AcOH (53.6 μL, 0.94 mmol, 2.0 eq) was added to a solution of tert-butyl 4-oxoazepane-1-carboxylate (100.0 mg, 0.47 mmol, 1.0 eq) and BnNH2 (61.5 μL, 0.56 mmol, 1.2 eq) in MeOH (5 mL) at 25° C. The reaction was stirred for 30 min, after which NaBH3CN (44.2 mg, 0.70 mmol, 1.5 eq) was added at 0° C. and the mixture was stirred at 25° C. for additional 1.5 h. Upon completion, the reaction was quenched by the addition of water (10 mL) and extracted with DCM (3×5 mL). The combined organic layers were dried over Na2SO4 and concentrated to give crude compound SI-48 (120.0 mg) as yellow oil, which was used in step 2 without further purification.


Step 2.

Under an atmosphere of nitrogen, 2-chloroacetyl chloride (1.55 mL, 19.7 mmol, 1.2 eq) was added dropwise to a solution of compound SI-48 (5.0 g, 16.4 mmol, 1.0 eq) and NEt3 (5.0 g, 49.3 mmol, 3.0 eq) in anhydrous DCM (2 mL) at 0° C. The resulting mixture was stirred at 15° C. for 2 h. Upon completion, the reaction was quenched by the addition of water (10 mL) at 15° C. and extracted with DCM (3×5 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated to give compound SI-49 as yellow oil (4.5 g), which was used in the next step without additional purification.


Step 3.

TFA (1.17 mL, 15.75 mmol, 5.0 eq) was added to a solution of compound SI-49 (1.20 g, 3.15 mmol, 1.0 eq) in DCM (10 mL) and the mixture was stirred at 25° C. for 1.5 h. Upon completion, the reaction was quenched by the addition of water (20 mL) and extracted with DCM (3×10 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated to give compound SI-50 (800.0 mg) as yellow oil, which was used as an intermediate in the synthesis of compounds E94 in the next step without additional purification.


Example S-28: Synthesis of N-benzyl-2-chloro-N-(1-(2-methylbenzoyl)azepan-4-yl)acetamide (BPK-28)



embedded image


A solution of compound SI-50 (150.0 mg, 0.53 mmol, 1.0 eq), NEt3 (370 μL, 2.67 mmol, 5.0 eq), and 2-methylbenzoic acid (82 μL, 0.64 mmol, 1.2 eq) in DCM (0.5 mL) was stirred at 0° C. for 30 min. MsCl (82.7 μL, 1.07 mmol, 2.0 eq) was then added and the mixture was stirred at 25° C. for additional 1.5 h. Upon completion, the reaction was quenched with water (5 mL) and extracted with DCM (3×5 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated. The residue was purified by prep. HPLC (FA conditions) to give the title compound (58.0 mg, 27%) as a white solid. 1H NMR (CDCl3, 400 MHz) δ 7.44-6.97 (m, 9H), 4.77-4.41 (m, 2H), 4.40-3.76 (m, 4H), 3.44-2.94 (m, 3H), 2.34-2.21 (m, 3H), 2.16-1.89 (m, 2H), 1.87-1.48 (m, 4H). HRMS electrospray (m z): [M+H]+ calcd for C23H28C1N2O2: 399.1834, found: 399.1835.


Example S-29: Synthesis of N-benzyl-2-chloro-N-(1-(4-morpholinobenzoyl)azepan-4-yl)acetamide (BPK-29)



embedded image


HATU (196.5 mg, 0.52 mmol, 1.2 eq) and DIEA (166.9 mg, 1.29 mmol, 3.0 eq) were added to a suspension of 4-morpholinobenzoic acid (98.2 mg, 0.47 mmol, 1.1 eq) in DMF (2.0 mL), followed by intermediate SI-50 (170.0 mg, 0.43 mmol, 1.0 eq, TFA salt). The reaction mixture was stirred at 0° C. for 1 h. Upon completion, the reaction was poured onto ice-water (3 mL) and extracted with ethyl acetate (3×3 mL). The combined organic layers were washed with brine (3 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by prep. HPLC (HCl conditions) to afford the title compound (44.5 mg, 19%) as a white solid. 1H NMR (CDCl3, 400 MHz) δ 7.87 (br, 2H), 7.58-7.25 (m, 5H), 7.24-7.13 (m, 2H), 4.68-4.42 (m, 2H), 4.41-4.09 (m, 5H), 4.02-3.76 (m, 3H), 3.53 (br, 4H), 3.46-3.08 (m, 3H), 2.16-1.47 (m, 6H). HRMS electrospray (m/z): [M+H]+ calcd for C26H33ClN3O3: 470.2205, found: 470.2202.


Example S-30: Synthesis of N-benzyl-2-chloro-N-(1-(4-phenoxybenzoyl)azepan-4-yl)acetamide (BPK-30)



embedded image


A solution of intermediate SI-50 (150.0 mg, 0.53 mmol, 1.0 eq), NEt3 (370 μL, 2.67 mmol, 5.0 eq), and MsCl (82.7 μL, 1.1 mmol, 2.1 eq) in DCM (0.5 mL) was stirred at 0° C. for 30 min. 4-phenoxybenzoic acid (137.3 mg, 0.64 mmol, 1.2 eq) was then added and the mixture was stirred at 25° C. for another 1.5 h. Upon completion, the reaction was quenched with water (5 mL) and extracted with DCM (3×5 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated. The residue was purified by prep. HPLC (FA conditions) to give the title compound (23.0 mg, 9%) as a white solid. 1H NMR (CDCl3, 400 MHz) δ 7.58-7.10 (m, 10H), 7.10-6.83 (m, 4H), 4.76-3.71 (m, 6H), 3.67-3.20 (m, 3H), 2.12-1.54 (m, 6H). HRMS electrospray (m/z): [M+H]+ calcd for C28H30ClN2O3: 477.1939, found: 477.1940.


Example S-31: Synthesis of N-benzyl-2-chloro-N-(1-(1-phenylpiperidine-4-carbonyl)azepan-4-yl)acetamide (BPK-31)



embedded image


MsCl (74.2 μL, 0.96 mmol, 2.0 eq) was added to a solution of 1-phenylpiperidine-4-carboxylic acid (100.0 mg, 0.49 mmol, 1.0 eq) and intermediate SI-50 (164.2 mg, 0.58 mmol, 1.2 eq) in CH3CN (2.0 mL) at 0° C. Subsequently, 3-methylpyridine (141.8 μL, 1.46 mmol, 3.0 eq) was added and the reaction mixture was stirred at 25° C. for 16 h. Upon completion, the reaction was quenched with water (2 mL) and concentrated. The residue was purified by prep. HPLC (HCl conditions) to give the title compound (8.0 mg, 4%) as a white solid. 1H NMR (Methanol-d4, 400 MHz) δ 7.69-7.50 (m, 5H), 7.43-7.18 (m, 5H), 4.74-4.53 (m, 2H), 4.50-4.34 (m, 1H), 4.17 (d, J=8.9 Hz, 1H), 4.00 (s, 1H), 3.85-3.35 (m, 8H), 3.25-3.03 (m, 1H), 2.31-1.53 (m, 10H). HRMS electrospray (m/z): [M+H]+ calcd for C27H35C1N3O2: 468.2412, found: 468.2411.


Example S-32: Synthesis of N-(1-(1H-benzo[d]imidazole-2-carbonyl)azepan-4-yl)-N-benzyl-2-chloroacetamide (BPK-32)



embedded image


A solution of 1H-benzimidazole-2-carboxylic acid (104.0 mg, 0.64 mmol, 1.2 eq), NEt3 (370 μL, 2.67 mmol, 5.0 eq), and MsCl (82.7 μL, 1.1 mmol, 2.1 eq) in DCM (0.5 mL) was stirred at 0° C. for 30 min. Intermediate SI-50 (150.0 mg, 0.53 mmol, 1.0 eq) was then added and the mixture was stirred at 25° C. for another 1.5 h. Upon completion, the reaction was quenched with water (5 mL) and extracted with DCM (3×5 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated. The residue was purified by prep. HPLC (HCl conditions) to give the title compound (31.0 mg, 13%) as a white solid. 1H NMR (CDCl3, 400 MHz) δ 7.75-7.64 (m, 2H), 7.40-7.14 (m, 7H), 4.89-4.44 (m, 3H), 4.44-4.13 (m, 2H), 4.09-3.90 (m, 2H), 3.90-3.27 (m, 2H), 2.21-1.70 (m, 6H). HRMS electrospray (m/z): [M+H]+ calcd for C23H26C1N4O2: 425.1739, found: 425.1736.


Example S-33: Synthesis of N-(1-(1-naphthoyl)azepan-4-yl)-N-benzyl-2-chloroacetamide (BPK-33)



embedded image


A solution of intermediate SI-50 (50.0 mg, 0.18 mmol, 1.0 eq), NEt3 (74.1 μL, 0.53 mmol, 3.0 eq), and naphthalene-1-carbonylchloride (26.7 μL, 0.18 mmol, 1.0 eq) in DCM (1.0 mL) was stirred at 25° C. for 2 h. Upon completion, the reaction was quenched with water (5 mL) and extracted with DCM (3×5 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated. The residue was purified by prep. HPLC (basic conditions) to give the title compound (9.0 mg, 11%) as a white solid. 1H NMR (DMSO-d6, 400 MHz) δ 8.03-7.91 (m, 2H), 7.79-7.08 (m, 10H), 4.73-4.16 (m, 4H), 4.14-3.78 (m, 2H), 3.26-2.80 (m, 3H), 2.12-1.87 (m, 2H), 1.88-1.63 (m, 2H), 1.62-1.42 (m, 2H). HRMS electrospray (m/z): [M+H]+ calcd for C26H28C1N2O2: 435.1834, found: 435.1836.


Example S-34: Synthesis of N-(1-acetylazepan-4-yl)-N-benzyl-2-chloroacetamide (BPK-34)



embedded image


A solution of acetyl chloride (38.1 μL, 0.53 mmol, 1.5 eq), SI-50 (100.0 mg, 0.36 mmol, 1.0 eq), and NEt3 (148.1 μL 1.07 mmol, 3.0 eq) in DCM (2.0 mL) was stirred at 25° C. for 2 h. Upon completion, the reaction was quenched with water (10 mL) and extracted with DCM (3×5 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated. The residue was purified by prep. HPLC (basic conditions) to afford the title compound (7.0 mg, 6%) as colorless oil. 1H NMR (DMSO-d6, 400 MHz) δ 7.38 (t, J=7.7 Hz, 1H), 7.32-7.22 (m, 2H), 7.23-7.14 (m, 2H), 4.63-4.41 (m, 3H), 4.25-3.55 (m, 2H), 3.54-3.36 (m, 2H), 3.33-3.02 (m, 2H), 2.01-1.90 (m, 3H), 1.86-1.52 (m, 6H). HRMS electrospray (m z): [M+H]+ calcd for C17H24C1N2O2: 323.1521, found: 323.1523.


Example S-35: Synthesis of 2-chloro-N-(3-ethynylbenzyl)-N-(1-(4-morpholinobenzoyl)azepan-4-yl)acetamide (BPK-29-yne)



embedded image


embedded image


Step 1.

AcOH (229 μL, 4 mmol, 2.0 eq) was added to a solution of tert-butyl 4-aminoazepane-1-carboxylate (428.6 mg, 2 mmol, 1.0 eq) and 3-ethynylbenzaldehyde (260.4 mg, 2.0 mmol, 1.0 eq) in MeOH (40 mL) at 25° C. The reaction was stirred for 30 min, cooled down to 0° C. after which NaBH3CN (188.5 mg, 3.0 mmol, 1.5 eq) was added and the mixture was stirred at 25° C. for additional 1.5 h. Upon completion, the reaction was quenched by the addition of water (50 mL) and extracted with DCM (3×50 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated to give crude compound SI-51 (654.1 mg) as pale yellow oil, which was used in step 2 without further purification.


Step 2.

2-chloroacetyl chloride (200 μL, 2.5 mmol, 1.25 eq) was added dropwise to a solution of SI-51 (654.1 mg, 2 mmol, 1.0 eq) and NEt3 (693.5 μL, 5 mmol, 2.5 eq) in anhydrous DCM (10 mL) at 0° C. The resulting mixture was stirred at room temperature for 1 h. Upon completion, the reaction was quenched by the addition of water (50 mL) and extracted with DCM (3×50 mL). The combined organic layers were dried over Na2SO4, filtered and concentrated to give compound SI-52 as pale yellow oil (875.8 mg, crude), which was used in the next step without additional purification.


Step 3.

Methanolic HCl (7.8 mL, 6.2 mmol, 3.1 eq, 1.25 M) was added to a solution of compound SI-52 (857.8 mg, crude from 2 mmol scale reaction, 1.0 eq) and the mixture was stirred at 25° C. overnight. Upon completion, methanol was removed and the title compound was passed through a silica gel plug (0-10% MeOH/CH2Cl2) to afford SI-53 (504.4 mg) as an off-white solid, which was used in the next step without additional purification.


Step 4.

HATU (66.1 mg, 0.18 mmol, 1.25 eq) and DIEA (24.4 μL, 0.14 mmol, 1.0 eq) were added to a suspension of 4-morpholinobenzoic acid (29.0 mg, 0.14 mmol, 1.0 eq) in DMF (1.0 mL) and the reaction was stirred for 5 min at ambient temperature. A solution of SI-53 (50.0 mg, 0.15 mmol, 1.1 eq) and DIEA (48.4 μL, 0.28 mmol, 2.0 eq) was then added dropwise and the reaction mixture was stirred for an additional 1 h. Upon completion, the reaction was quenched by the addition of water (5 mL) and extracted with ethyl acetate (3×5 mL). The combined organic layers were washed with brine (3 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by prep. TLC (EtOAc), followed by trituration with cold Et2O to afford the title compound (21.6 mg, 31%) as a white solid. 1H NMR (D2O, 400 MHz) δ 7.47-7.14 (m, 6H), 6.97 (br, 2H), 4.74-4.32 (m, 3H), 4.17 (s, 1H), 4.13-3.91 (m, 1H), 3.91-3.72 (m, 5H), 3.74-3.33 (m, 4H), 3.21 (br, 4H), 2.18-1.65 (m, 6H). HRMS electrospray (m/z): [M+H]+ calcd for C28H32C1N3O3: 494.2204, found: 494.2211.


While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.










LENGTHY TABLES




The patent application contains a lengthy table section. A copy of the table is available in electronic form from the USPTO web site (). An electronic copy of the table will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).





Claims
  • 1. A protein-probe adduct wherein the probe binds to a cysteine residue illustrated in Tables 1A, 2, 3A, and 4; wherein the probe has a structure represented by Formula (I):
  • 2. The protein-probe adduct of claim 1, wherein the protein is ubiquitin carboxyl-terminal hydrolase 7 (USP7) and the cysteine residue is C223, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier Q93009.
  • 3. The protein-probe adduct of claim 1, wherein the protein is B-cell lymphoma/leukemia 10 (BCL10) and the cysteine residue is C119 or C122, wherein the numberings of the amino acid positions correspond to the amino acid positions with the UniProt Identifier O95999.
  • 4. The protein-probe adduct of claim 1, wherein the protein is RAF proto-oncogene serine/threonine-protein kinase (RAF1) and the cysteine residue is C637, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P04049.
  • 5. The protein-probe adduct of claim 1, wherein the protein is nuclear receptor subfamily 2 group F member 6 (NR2F6) and the cysteine residue is C203 or C316, wherein the numberings of the amino acid positions correspond to the amino acid positions with the UniProt Identifier P10588.
  • 6. The protein-probe adduct of claim 1, wherein the protein is DNA-binding protein inhibitor ID-1 (ID1) and the cysteine residue is C17, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P41134.
  • 7. The protein-probe adduct of claim 1, wherein the protein is Fragile X mental retardation syndrome-related protein 1 (FXR1) and the cysteine residue is C99, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P51114.
  • 8. The protein-probe adduct of claim 1, wherein the protein is Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) and the cysteine residue is C883, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier O95819.
  • 9. The protein-probe adduct of claim 1, wherein the protein is Cathepsin B (CTSB) and the cysteine residue is C105 or C108, wherein the numberings of the amino acid positions correspond to the amino acid positions with the UniProt Identifier P07858.
  • 10. The protein-probe adduct of claim 1, wherein the protein is integrin beta-4 (ITGB4) and the cysteine residue is C245 or C288, wherein the numberings of the amino acid positions correspond to the amino acid positions with the UniProt Identifier P16144.
  • 11. The protein-probe adduct of claim 1, wherein the protein is TFIIH basal transcription factor complex helicase (ERCC2) and the cysteine residue is C663, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P18074.
  • 12. The protein-probe adduct of claim 1, wherein the protein is nuclear receptor subfamily 4 group A member 1 (NR4A1) and the cysteine residue is C551, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P22736.
  • 13. The protein-probe adduct of claim 1, wherein the protein is cytidine deaminase (CDA) and the cysteine residue is C8, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P32320.
  • 14. The protein-probe adduct of claim 1, wherein the protein is sterol O-acyltransferase 1 (SOAT1) and the cysteine residue is C92, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P35610.
  • 15. The protein-probe adduct of claim 1, wherein the protein is DNA mismatch repair protein Msh6 (MSH6) and the cysteine residue is C615, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P52701.
  • 16. The protein-probe adduct of claim 1, wherein the protein is telomeric repeat-binding factor 1 (TERF1) and the cysteine residue is C118, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P54274.
  • 17. The protein-probe adduct of claim 1, wherein the protein is NEDD8-conjugating enzyme Ubc12 (UBE2M) and the cysteine residue is C47, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier P61081.
  • 18. The protein-probe adduct of claim 1, wherein the protein is E3 ubiquitin-protein ligase TRIP12 (TRIP12) and the cysteine residue is C535, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier Q14669.
  • 19. The protein-probe adduct of claim 1, wherein the protein is ubiquitin carboxyl-terminal hydrolase 10 (USP10) and the cysteine residue is C94, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier Q14694.
  • 20. The protein-probe adduct of claim 1, wherein the protein is ubiquitin carboxyl-terminal hydrolase 30 (USP30) and the cysteine residue is C142, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier Q70CQ3.
  • 21. The protein-probe adduct of claim 1, wherein the protein is nucleus accumbens-associated protein 1 (NACC1) and the cysteine residue is C301, wherein the numbering of the amino acid position corresponds to the amino acid position with the UniProt Identifier Q96RE7.
  • 22. The protein-probe adduct of claim 1, wherein the protein is lymphoid-specific helicase (HELLS) and the cysteine residue is C277 or C836, wherein the numberings of the amino acid positions correspond to the amino acid positions with the UniProt Identifier Q9NRZ9.
  • 23. The protein-probe adduct of claim 1, wherein n is 3.
  • 24. A synthetic ligand that inhibits a covalent interaction between a protein and a probe, wherein in the absence of the synthetic ligand, the probe binds to a cysteine residue illustrated in Tables 1A, 2, 3A, and 4; and wherein the probe has a structure represented by Formula (I):
CROSS-REFERENCE

This application claims the benefit of U.S. Provisional Application No. 62/564,223, filed Sep. 27, 2017, which application is incorporated herein by reference in its entirety.

STATEMENT AS TO FEDERALLY SPONSORED RESEARCH

The invention disclosed herein was made, at least in part, with the support of the United States government under Grant No. CA132630, by the National Institutes of Health. Accordingly, the U.S. Government has certain rights in this invention.

PCT Information
Filing Document Filing Date Country Kind
PCT/US2018/053157 9/27/2018 WO 00
Provisional Applications (1)
Number Date Country
62564223 Sep 2017 US